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Abstract 
 
Structural study of the C-terminal domain of non-structural protein 1 
and capsid protein from Japanese encephalitis virus 
Thanalai Poonsiri 
 
Japanese encephalitis virus (JEV) is a mosquito-transmitted Flavivirus that is closely 
related to other emerging viral pathogens including dengue (DENV), West Nile (WNV) 
and Zika viruses (ZIKV). JEV infection can result in meningitis and encephalitis, which 
in severe cases cause permanent brain damage and death. JEV occurs predominantly 
in rural areas throughout South East Asia, the Pacific islands, and the Far East, causing 
around 68,000 cases worldwide each year. There is no specific treatment for JEV. This 
study aims to determine the molecular structure of new potential drug targets for 
JEV. 
In this study, the JEV non-structural protein 1 C-terminal β-ladder domain (C-NS1) is 
presented at 2.1 Å resolution. The crystal structure of C-JEVNS1 shares a conserved 
fold with flavivirus C-NS1 domains. The surface charge distribution of C-JEVNS1 is 
similar to WNV and ZIKV but is significantly different from DENV. Analysis of the C-
JEVNS1 structure, in silico molecular dynamics simulations and experimental solution 
small angle X-ray scattering, indicate extensive loop flexibility on the exterior of the 
protein. It is proposed that this together with charge distribution on the exterior of 
the protein influence NS1-host protein interaction specificity which may impact on 
pathogenicity. These factors may also affect the interaction with the monoclonal 
antibody, 22NS1, which is protective against WNV infection. Liposome and heparin 
binding assays indicate that only the N-terminal region of NS1 participates in the 
interaction with lipidic membranes and that sulphate binding sites are not the 
glycosaminoglycans binding interfaces. 
For the first time, the crystal structure of the JEV capsid protein at 1.98 Å is also 
reported and compared to the existing flavivirus capsid protein. JEV capsid shows 
helical secondary structure (α helixes 1-4) and protein folding similar to DENV and 
WNV capsid proteins. It forms a homodimer by antiparallel pairing with another 
subunit (‘), α helix 1-1’, 2-2’, and 4-4’. The capsid dimer is believed to be the building 
block of the nucleocapsid. The flexibility of the N-terminal α helix 1 of the capsid could 
be important for its function. This dimer model agrees with a previous suggestion 
that the capsid protein interacts with RNA via the basic rich C-terminal, α4-α4’, and 
associates with lipid bilayers at the opposite hydrophobic, α2-α2’.  
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 1 
 
Chapter 1 Introduction to Japanese Encephalitis 
Virus 
 
Japanese encephalitis virus (JEV) is a mosquito-transmitted member of the genus 
Flavivirus, family Flaviviridae that is closely related to other emerging viral pathogens 
including DENV, WNV, and ZIKV (Figure 1.1). JEV infection can result in meningitis and 
encephalitis, which in severe cases causes permanent brain damage or death. JEV 
occurs predominantly in rural areas throughout Southeast Asia, the Pacific islands 
and the Far East causing around 68,000 cases worldwide each year, despite extensive 
vaccination. The true number is probably much higher because many cases are still 
unreported. Moreover, only supportive treatment is available to cure flavivirus 
infection. To better manage flavivirus diseases, apart from vaccination, vector 
control, and personal protection, development of an anti-viral agent is needed. 
 
Figure 1.1 Flavivirus classification. 
The phylogenetic tree was generated from NS5 genes. Evolutionary distance is not 
shown. (taken from (Mukhopadhyay et al., 2005). Licence permission no. 
4236680904226). 
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1.1. Japanese encephalitis virus 
1.1.1 Distribution and transmission cycle 
JEV is believed to evolve from a flavivirus ancestor in the Indonesia-Malaysia area 
(Schuh et al., 2013, Solomon et al., 2003b). Based on the envelope protein gene 
(some studies use membrane-envelope or membrane-capsid protein genes), the 
virus is divided into 5 genotypes (Solomon et al., 2003b). Genotype IV and V are the 
oldest lineages and are retained in the Indonesia-Malaysia region, whereas the rest 
have spread wider. Genotype III and Ib (newly emerged) circulate in temperate Asia, 
while genotype II and Ia circulate in tropical Asia (Schuh et al., 2013). In the temperate 
zone, large JEV epidemics occur in the summer months but it is endemic year-round 
in the tropical zone. Japanese encephalitis (JE) was first described in Japan in the 
1870s, but the first isolation was from the human brain in 1935 and from mosquitoes, 
Culex tritaeniorhynchus, in 1938 (Ishikawa and Konishi, 2015). In the first reported 
outbreaks from Japan, both adult and children were affected indicating no pre-
existing immunity in the population and suggesting the virus had recently arrived in 
Japan (Solomon et al., 2003b). It seems that the distribution of JEV comes from 
Indonesia-Malaysia region to the north, west, and east. JEV was first detected in 
Saipan in 1990, Pakistan in 1992, Torres Strait Islands in 1995, and Australian 
mainland (Cape York) in 1998 (van den Hurk et al., 2006, Schuh et al., 2013, Knope et 
al., 2014). Now the risk area of JEV is throughout Asia (Figure 1.2). 
In the past few decades, displacement of genotype III, which was dominant since the 
1970s, with genotype I has been observed in China, India, Japan, South Korea, 
Taiwan, Thailand, and Vietnam (Han et al., 2014). However, the majority of human 
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cases in this region are still genotype III. Replacement of genotype II with genotype I 
has been observed in Australia (van den Hurk et al., 2006). Moreover, genotype V, 
which had never been found beyond the Indonesia-Malaysia region, was more 
recently reported in China in 2009 and South Korea in 2010, both from mosquito 
samples (Li et al., 2011, Takhampunya et al., 2011). JEV circulation is dynamic and will 
possibly continue to spread to new areas, even though there has not been any 
reported JEV detection outside these areas since the arrival of JEV on the Australian 
mainland (CDC, 2015). The last human case in the Australian mainland was in 1998 
(Knope et al., 2014) and a human case of genotype V in re-emerging areas have not 
been observed yet. The reasons why JEV cannot establish are unclear. It may be 
because the virus has not entered the zoonotic cycle in these areas. JEV probably has 
to compete with other flaviviruses that have already filled the ecological niche. 
Figure 1.2 Geographic distribution of Japanese encephalitis virus 
(The Centers for Disease Control and Prevention (CDC), 2015) 
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The natural transmission cycle of JEV involves the mosquito vector and wading birds 
(Figure 1.3). JEV was isolated from several species of mosquito including in genus 
Culex, Aedes, and Anopheles, but Cx. tritaeniorhynchus is the principal vector 
(Sucharit et al., 1989, van den Hurk et al., 2009). Detection of JEV or antibodies 
against it were demonstrated in more than 90 species of different avian families 
including chicken, pigeon, duck, sparrow and especially egret and heron, which have 
high viremia and recognized as the primary hosts. JEV was also detected in many 
mammal species such as dog, rat, goat, and cattle. Pig in particular, which has high 
and prolonged viremia, serve as an amplifying host. Disease symptoms in the animals 
are rare, but it can cause abortion in pigs (van den Hurk et al., 2009). Human and 
horse infections develop serious encephalitis, but both are accidental and dead-end 
hosts. Unlike in pigs or wading birds, JEV usually does not develop the high level of 
Figure 1.3 Japanese encephalitis virus transmission cycle 
Modified from(Pfeffer and Dobler, 2010).  
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viremia in human and horse which is therefore unlikely to result in transfer to 
mosquitoes. 
Rice and irrigated crop fields are associated and contribute to the JEV natural 
transmission cycle. It is the place where wading birds meet Culex spp. mosquitoes 
that initiate transmission. Pig farming plays an important role in transmission to 
humans and animals nearby. Detection of JEV antibodies in pigs was found to be 
synchronous with a significantly increased number of human cases (Konno et al., 
1966). The rapid spread of JEV may due to several reasons including a rising of the 
human population, increased farming, changing agricultural practices, migrating of 
reservoir hosts (birds), globalization, climate change, and wind patterns might explain 
dispersal to islands. 
1.1.2 Virion structure and viral protein functions 
JEV is a positive-sense single strand RNA virus. It has a genome of around 11 kb, which 
is translated into a polyprotein consisting of three structural proteins: capsid (C), 
membrane (prM/M), and envelope protein (E), and seven non-structural proteins 
(NS): NS1, NS2A, NS2B, NS3, NS4, NS4B, and NS5 (Figure 1.4). The E and M proteins 
are the main components inserting into the lipid bilayer to form the external shell of 
the virus (Figure 1.5) (Mukhopadhyay et al., 2005, Kuhn et al., 2002, Perera and Kuhn, 
2008, Wang et al., 2017). Binding of viral E protein to cell’s receptor plays a role in 
the host cell attachment and entry step, and fusion to the endosomal membrane to 
release nucleocapsid into the cytoplasm (Figure 1.6). JEV attachment factors and 
attachment receptors were identified in different cell types, for example, heparan 
sulphate proteoglycans, heat-shock protein 70, and laminin receptor. Flaviviruses use 
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different endocytic pathways to enter host cells depending on the cell type. Few 
candidates of JEV entry receptors have been suggested, however, the entry receptors 
still remain ambiguous. (Liu et al., 2017, Nain et al., 2016, Yamauchi and Helenius, 
2013) The nucleocapsid is composed of multiple copies of the capsid protein 
enclosing the single-stranded RNA genome. Dissociation of the capsid releases the 
viral RNA, which serves as mRNA for viral protein translation using the host cell 
machinery. The signal sequence in the genome translocates E, prM and NS1 proteins 
to the endoplasmic reticulum (ER) lumen while C, NS3, and NS5 remain in the 
cytoplasm (Figure 1.4a). The NS2A/B and NS4A/B are transmembrane proteins. The 
polyprotein is cleaved into individual proteins by both host and virus enzymes 
(NS2B/NS3 harbours serine protease activity). The newly synthesized NS proteins 
form the replication complex in the vesicle packets generated from ER (Welsch et al., 
2009). RNA synthesis involves the helicase domain of NS3 and RNA-dependent RNA 
polymerase domain of NS5, which also bears the methyltransferase domain at N-
terminus. Once the viral RNA is synthesized, it is enclosed in the capsid and buds into 
the ER to obtain the host cell lipid bilayer together with the E and prM proteins 
(Figure 1.6). Cleaving of prM to M protein in Golgi body by the enzyme furin produces 
the mature virion ready to be released from the cell and start a new infection cycle. 
However, the molecular details of each step such as dissociation and assembly of 
capsid and RNA replication are still unclear. 
DENV is the most well-studied flavivirus. All of the proteins coded by its genome have 
been structurally characterized except for NS2A and NS4A/B. Although NS2B is a 
small transmembrane protein, the structure was determined by co-crystallization 
with its co-factor, NS3. 
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Figure 1.4 JEV polyprotein. 
(a) Protein topology diagram created by PROTTER (OMASITS ET AL., 2014) (b) Flavivirus genome organization and protein functions. 
ER membrane 
prM          E                              NS1 
C                                                                                                      NS3                                                                    NS5 
a 
b 
cytoplasm 
Cytoplasm 
ER lumen 
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Figure 1.5 JEV cryo-EM structure reconstruction 
Taken from (Wang et al., 2017) 
Figure 1.6 JEV replication cycle. 
Taken from (Yun and Lee, 2014) 
(1) Binding of virus particles to the attachment and cell entry receptors locates 
viruses on the cell membrane and initiates endocytic pathways. (2-3) Low pH in 
endosome causes the E protein to change its conformation and consequently triggers 
the membrane fusion step to release the viral genomic RNA, (4) which is translated 
and processed into mature viral proteins. (5) Replication of the viral RNA occurs inside 
the ER-derived vesicle. (6) The viral genomic RNA enclosed in neuclocapsid buds into 
the ER lumen to obtain the lipid bilayers together with the prM and E proteins. These 
immature virions are transported to the Golgi secretory pathway. (7) Cleaving of prM 
to M protein in Golgi body by the enzyme furin produces the mature virions. (8) 
Finally, the mature virions are released by exocytosis from the cell. 
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Capsid protein 
Capsid protein is not only involved with nucleocapsid dissociation and assembly. 
Many studies have revealed the crucial functions of the capsid protein in the virus life 
cycle (Oliveira et al., 2017, Byk and Gamarnik, 2016). RNA secondary structure of 5’ 
DENV capsid coding region has been found to function as the RNA cis-regulatory 
element involved in both RNA synthesis and cyclization (Clyde et al., 2008, Liu et al., 
2013, Villordo and Gamarnik, 2009). Mutation of N-terminal residues also 
demonstrated impairment in virus particle formation (Samsa et al., 2012). The capsid 
proteins of DENV and WNV were shown to act as RNA chaperones (Pong et al., 2011, 
Ivanyi-Nagy et al., 2008), and the RNA binding sites were mapped to positively 
charged residues at the WNV C protein N and C terminus (Khromykh and Westaway, 
1996). The capsid–prM junction is processed by NS2B/NS3 protease. Failure to cleave 
and produce mature C protein leads to a defective in viral particle assembly and 
release (Amberg and Rice, 1999). The capsid protein is found localized in the 
cytoplasm of the infected cell in ER and lipid droplets (LDs) and also in nucleoli in the 
nucleus (Wang et al., 2002, Bulich and Aaskov, 1992). The rationale of these 
subcellular distributions is unclear. Interaction with LDs was suggested to be a viral 
replication regulation process (Samsa et al., 2009) and it may affect cell lipid 
metabolism (Byk and Gamarnik, 2016). Mutagenesis studies identified a hydrophobic 
patch in the helix 2 region to play an important role in viral replication (Schlick et al., 
2009). The function was recovered by reverting the mutation to restore the 
hydrophobic property of the protein indicating the importance of the residues 
properties rather than the residue position (Byk and Gamarnik, 2016, Schlick et al., 
2009). While small mutation based deletions affect the protein function greatly, the 
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protein can tolerate the deletion of up to 16 residues in tick-borne encephalitis virus 
(TBEV) (Kofler et al., 2002) and 36 residues in WNV (Schlick et al., 2010). However, 
attenuation was observed in those large deletion viruses (Kofler et al., 2002, Schlick 
et al., 2010). Moreover, the capsid protein was reported to interact with several host 
proteins, for example, Death-associated protein 6 (DAXX) which may induce 
apoptosis and core histones that may mediate transcription through nucleosome 
disruption (Byk and Gamarnik, 2016). 
The 3D structure of DENV (Ma et al., 2004) and WNV (Dokland et al., 2004) have been 
solved and show similar protein folds with the sequence identity of 36 %. (Figure 1.7 
and Figure 1.8) The monomer is composed of 4 α helices. Both studies demonstrated 
the dimeric state of the capsid. Helix 2 and 4 are an antiparallel pair together with 
positively charged residues at the helix 4 C-terminus. The basic rich region was 
suggested to interact with the viral RNA, while the opposite side of the dimer contains 
an apolar cleft created by the α2-α2’ region, which may bind to lipid bilayer or LDs. 
Helix 1 shows a distinct conformation between DENV and WNV indicating its 
flexibility. The tetrameric form was observed only in WNV capsid structure and the 
capsid protein assembly to form nucleocapsid is proposed to be poorly ordered, 
different from the icosahedral external shell (Kuhn et al., 2002). 
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Figure 1.8 Capsid protein ribbon diagrams 
(a) WNV capsid diagram protein taken from (Dokland et al., 2004) (b) DENV capsid 
protein diagram taken from (Ma et al., 2004) 
Figure 1.7 Multiple sequence alignment of flavivirus capsid protein 
The alignment was produced from Clustral Omega (Sievers et al., 2011). An asterisk 
indicates fully conserved residue. A colon indicates conservation between groups of 
strongly similar properties. A period indicates conservation between groups of 
weakly similar properties. Spiral above sequence indicates the α helix positions. 
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NS1 and NS1’ proteins 
NS1 is a multifunctional glycoprotein that has drawn significant attention because of 
its importance in viral replication, immune modulation, and immune evasion. 
Mutagenesis and trans-complementation assays have established that NS1 is 
essential for RNA replication (Lindenbach and Rice, 1997, Mackenzie et al., 1996, 
Muylaert et al., 1996, Youn et al., 2013, Fan et al., 2014). It co-localizes with the 
replication complex (Mackenzie et al., 1996), and interacts genetically and physically 
with NS4A (Lindenbach and Rice, 1999) and NS4B (Youn et al., 2012), respectively. 
DENV NS1 was previously described as a complement fixing antigen found in patient 
serum and binds to complement pathway components: C1s, C4, C4b (Avirutnan et al., 
2011, Avirutnan et al., 2010). WNV NS1 can also interact with factor H, complement 
control protein, which protects cells from complement-dependent clearance (Chung 
et al., 2006a). In addition, NS1 has been suggested to interfere with the dsRNA 
sensors. NS1 inhibits Toll-like receptor 3 (TLR-3) (Morrison and Scholle, 2014, Wilson 
et al., 2008) to escape host detection mechanisms. 
Secreted NS1 is used as a diagnostic marker for infection as it is found in the blood at 
an early stage, typically before antibodies appear (Li et al., 2012, Amorim et al., 2014). 
Alternatively, detection of anti-NS1 antibodies, IgM and IgG, can also be used 
(Amorim et al., 2014, Solomon et al., 1998, Chao et al., 2015). NS-antibody complexes 
can trigger several inflammatory processes involving both innate and adaptive 
immune responses (Muller and Young, 2013, Amorim et al., 2014). Immunization of 
NS1 in mice or passively acquiring anti-NS1 antibodies can confer protective effects 
against challenge with yellow fever virus or WNV (Chung et al., 2006b, Schlesinger et 
al., 1986, Schlesinger et al., 1993). However, in DENV, anti-NS1 antibodies may have 
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auto-reactivity and reportedly bind to host extracellular matrix components, 
platelets, and endothelial cells (Muller and Young, 2013, Krishna et al., 2009). This 
cross-reactivity can induce damage to the host cells that enhance disease impact. 
A signal sequence at the C-terminus of E protein translocates NS1 to the endoplasmic 
reticulum (ER) where it undergoes cleavage and posttranslational modification 
(Muller and Young, 2013). Structures of WNV (Edeling et al., 2014, Akey et al., 2014), 
DENV (Akey et al., 2014), and ZIKV NS1 (Xu et al., 2016, Brown et al., 2016) full-length 
proteins have been reported. NS1 proteins contain 6 conserved disulphide bonds and 
conserved N-linked glycosylation sites at Asn130 and Asn207. The JE serogroup 
(Figure 1.1) NS1 proteins have an additional glycosylation site at Asn175 linked to 
high-mannose carbohydrate, but this is not present in JEV NS1 itself (Muller and 
Young, 2013, Blitvich et al., 2001, Mandl et al., 1989). The NS1 monomer contains 3 
domains: β-roll (amino acid residues 1-29), wing (38-151), and β-ladder domains 
(181-352) (Akey et al., 2014, Xu et al., 2016) (Figure 1.9). There are two characterized 
forms of NS1: a membrane-associated dimer (~49 kDa per monomer), found on the 
cell and ER surface, and a secreted hexamer (52- 55 kDa per monomer) (Muller and 
Young, 2013). The mass of the two NS1 forms is different due to differential 
glycosylation. NS1 forms a homodimer by extending the β-ladder domain and forms 
a cross shape (Figure 1.9). The hydrophobic surface of the β-roll and wing domains 
may mediate the interaction with the cell membrane via a number of amino acid 
residues including 28, 115, 118, 123, and 160-163 (Xu et al., 2016, Brown et al., 2016) 
(Figure 1.9). The opposite side to the β-barrel is composed of loops linking the surface 
β-strands of the ladder domain. This region is a potential protein binding surface to 
host immune components due to its hydrophilicity and glycosylation. NS1 dimer 
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attachment on the infected cell surface may occur via a glycosylphosphatidylinositol 
(GPI) anchor, for which a hydrophobic carboxy-terminal GPI-addition signal peptide 
at the N-terminus of NS2A is required (Jacobs et al., 2000, Noisakran et al., 2008, 
Noisakran et al., 2007). NS1 also binds to uninfected cell membranes via 
glycosaminoglycans (GAGs) binding, primarily heparan sulphate and chondroitin 
sulphate E (Avirutnan et al., 2007). Three NS1 dimers can assemble to form a 
hexameric pore, which lipid is found inside (PDB ID 4O6B for DENV2 NS1 and 4O6C 
for WNV NS1) (Akey et al., 2014). 
Most knowledge of JEV NS1 functions has been inferred from studies of DENV and 
WNV NS1, but how it accomplishes those functions is not exactly known. Although 
the protein sequences are highly conserved (Figure 1.10) and the DENV, WNV, and 
ZIKV NS1 structures display the same protein fold, there are structural and non-
structural evidence indicate the important differences. For example, structures of 
flavivirus NS1 demonstrate distinct surface charge especially DENV (Song et al., 
2016). Polyclonal antibodies raised against DENV NS1 in mice were shown to cross-
react with protein on the epithelial cell. The cross-reactivity epitope was mapped to 
amino acid residues 311-330 on NS1 (Cheng et al., 2009) (Figure 1.10). Although JEV 
NS1 shares these conserved epitopes, antibodies against JEV NS1 showed no 
reactivity to any of these host cell targets. As another example, WNV NS1 bound the 
alternative complement pathway regulator, factor H, whereas JEV NS1 did not 
(Krishna et al., 2009). 
NS1’ is specific only to JE serogroup viruses. NS1’ is longer than NS1 by 52 extra amino 
acids at the NS2A N-terminus due to the formation of a pseudoknot by the conserved 
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sequences at the NS2A 5’ end. It pauses translation and shifts the reading frame back 
1 base, also called a classical -1 ribosomal frameshift motif (Melian et al., 2010). The 
frame-shift motif creates an alternative stop codon in NS2A sequence and terminates 
protein translation. NS1’ was found in dimeric form (monomer molecular mass 
around 58 kDa) and detected in both cell lysate and culture media (Mason, 1989, 
Young et al., 2013). NS1’ was suggested to play a role in neurovirulence and 
neuroinvasiveness as lack of function reduces mortality in mice (Melian et al., 2010, 
Ye et al., 2012). NS1’ was found co-localized with NS1 and RNA replication complex, 
and could substitute for NS1 in virus replication (Young et al., 2013). However, there 
is a discrepancy between the results of in vitro and in vivo studies. WNV NS1’ provides 
an advantage only in in vivo studies (Melian et al., 2014). There is also variation of 
NS1’ involvement in replication among different viruses. Whereas WNV NS1’ does 
not contribute to viral replication in vitro, JEV NS1’ mutants have less infectivity in a 
cell model (Melian et al., 2014, Takamatsu et al., 2014). Therefore, the role of NS1’ in 
the JEV life cycle and pathogenesis remains unclear. 
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Figure 1.9 ZIKV NS1 full length 
Taken from (Xu et al., 2016) (a) Cross-shaped homodimer NS1. One subunit is 
coloured in grey and another is coloured by domain. β-roll domain is coloured in 
green, wing domain in orange, and β-ladder domains in blue. (b) Side view of NS1 
dimer. Connecter subdomain (close to β-roll) is indicated in magenta. The intertwine 
loop of wing domain shown in yellow is disordered and not visible in DENV (PDB ID 
4O6B) and WNV (4O6C), but they are visible in ZIKV (PDB IDs 5GS6 and 5K6K). 
 17 
 
 
Figure 1.10 Multiple sequence alignment of flavivirus NS1 full length proteins 
The alignment was produced by ClustalW (Larkin et al., 2007). An asterisk indicates 
fully conserved residue. A colon indicates conservation between groups of strongly 
similar properties. A period indicates conservation between groups of weakly similar 
properties. The 22NS1 light chain epitopes are highlighted in red and heavy chain 
epitopes are in black squares The amino acid sequences used are related to the X-ray 
crystal structure studies: DENV1 U88535 for PDB ID 4OIG, DENV2 M84727 for 4O6B, 
WNV 196835 for 4O6C and 4OIE, ZIKV KU365779 for 5IY3, and ZIKV AY632535 for 
5K6K and 5GS6.
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1.1.3 Disease symptoms and pathogenesis 
Human JEV infection is usually asymptomatic. The ratio of unapparent and apparent 
JEV infections was less than 1% in endemic area (Scheld et al., 2008). The ratio in non-
endemic areas was reported higher (Ishikawa and Konishi, 2015). JE occurs primarily 
in children <15 years old and adult usually has pre-existing immunity. However, when 
the virus arrives in new areas it can affect those both adults and children (Scheld et 
al., 2008, Solomon et al., 2003b). In addition, in childhood JE vaccinated areas, the 
number of cases could be similar between the two age groups. The death rate is 20-
30% and 30-50% of the cases survive with permanent brain damage. After the 5-15 
days of the incubation period, JEV infection begins with common cold-like febrile 
illness and may include shivering and diarrhoea for a few days. These could be the 
only manifestations or in severe cases, acute encephalitis syndrome can develop. 
Headache, vomiting, a reduction of consciousness, and seizure are observed. Other 
manifestations resulted from different parts of central nervous system (CNS) damage 
are observed, for example, flaccid paralysis, meningitis, Parkinsonian syndrome with 
mask-like face, and movement disorders. Enlargement of spleen and liver have been 
reported. Heart and lung complications have also been observed (Unni et al., 2011). 
JEV is introduced to humans by a mosquito bite. First inoculation may occur in blood 
circulation or skin. However, the virus load in blood circulation is usually low and the 
early transmission events within the skin are not well described. DENV infected 
human skin explant tissue experiments demonstrated detection of DENV in the 
epidermis layer particularly in the basal epidermis cells, but not in the dermis, 
together with NS1 protein detection in the epidermis indicating viral replication 
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activity (Limon-Flores et al., 2005). This may be applicable to JEV, but no experiment 
has confirmed it. In addition, human dendritic cells and Langerhans cells were very 
permissive for DENV infection (Wu et al., 2000). In mouse models, JEV was detected 
in peritoneal macrophages early after JEV peritoneal inoculation (Mathur et al., 
1988). Later, the virus was detected in splenic macrophages, splenic T-lymphocytes 
(but not B-lymphocyte). It is probable that the replication might occur in the 
epidermis and infected tissue macrophages migrate to the local lymph nodes. Virus 
clearance at this stage by an immune response is very important. The first line 
defence is committed by the pattern recognition receptors (PRRs). Detecting viral 
RNA and proteins by PRRs are the upstream regulation of inflammatory respond 
genes transcription, for example, gene codes for type I interferons (IFNs). IFNs are 
signalling molecules secreted by host cells to initiate the defence mechanism, which 
is a principal defence against viral infection. Many of JEV immune invasion strategies 
have been demonstrated. JEV interferes with the pattern recognition viral dsRNA-
sensing that activates IFNs production by delaying the exposure of dsRNA in porcine 
kidney cells (Espada-Murao and Morita, 2011) and JEV NS1 was shown to inhibit TLR-
3 (Wilson et al., 2008). In the downstream cascade of dsRNA IFNs activation, short 
fragmented RNAs of the 3’UTR blocks the phosphorylation of IFN regulatory factor-3 
(Chang et al., 2013) and the JEV NS2A was observed to antagonize the IFN-induced 
dsRNA-activated protein kinase (PKR) (Tu et al., 2012). IFNs signalling regulates the 
expression of several antiviral genes via JAK/STAT signal transduction pathway. 
Inhibition of STAT1 and STAT2 phosphorylation by JEV NS4A was reported (Lin et al., 
2008) and the JEV NS5 also blocks the phosphorylation of TYK2 and STAT1 (Lin et al., 
2006). Moreover, a few different events were observed in JEV infected cells, including 
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depletion of cell maturation surface markers in dendritic cells (DCs), impaired DCs 
maturation (Cao et al., 2011) and reduction in the ability to present antigen through 
major histocompatibility complex class I (MHC-1) pathway to suppress the activation 
of T cells (Aleyas et al., 2010). T lymphocytes and neutralizing antibodies (IgM and 
IgG) play a major role in the adaptive immune response. Virus infected cells are 
eliminated by CD8+ cytotoxic T cells, which may occur via recognition of NS3 protein. 
The cell free viruses are neutralized by antiviral antibodies, which E protein is the 
main target (Unni et al., 2011). If the virus titre is high enough, viruses can enter the 
bloodstream and progress to the CNS infection. JEV reaches the brain via the blood 
but how the virus crosses the blood brain barrier (BBB) is not clear. The JEV antigen 
was detected in the vascular endothelium, but this has not proved the permissiveness 
of the cells. Astrocyte is a component of the BBB and was shown to be infected by 
JEV (Suri and Banerjee, 1995). Infection of astrocyte and/or vascular endothelial may 
bring the virus into the CNS. Rupture of the BBB was also suggested, but this tends to 
occur after encephalitis. Thus, it might not be the main reason for CNS introduction. 
Infiltration of infected white blood cells may also possible (Trojan horse) (Sapkal et 
al., 2007). Once the virus enters the brain, neurons are the principal target and ER 
stress in the cell leads to apoptosis (Su et al., 2002). Neuronal death then activates 
astrocytes and microglia which release proinflammatory cytokines which contribute 
to infiltration of monocytes and leukocytes. Moreover, the release of reactive oxygen 
species, nitric oxide, and other cytokines like tumour necrosis factor α (TNFα) causes 
neuron apoptosis (Ghosh and Basu, 2009). Mouse microglial cells were highly 
permissive to JEV along with a long persistence of the virus suggesting that microglia 
may serve as a viral reservoir (Thongtan et al., 2010). In conclusion, neuronal death 
 21 
 
is directly caused by JEV infection itself and indirect massive immune responses. The 
later may be the result of gradually reducing anti-inflammatory cytokine IL-10 after 
JEV infection (Swarup et al., 2007). JEV infection of neuron progenitor stem cells 
(NPCs) was reported, which could prevent NPC proliferation and consequently impair 
the neuron recovery. This may relate to permanent brain damage in JE survivor (Das 
and Basu, 2008). 
1.1.4 Diagnosis and treatments 
The early stages of JE are difficult to differentiate from other febrile illness and even 
with neurologic symptoms, JE is still not easily defined from other encephalitis 
diseases (Impoinvil et al., 2013). Neutrophilia is commonly found in peripheral blood 
tests. Laboratory testing is typically performed by using serum or cerebrospinal fluid 
(CSF) to detect JEV IgM specific antibodies. The test might need to be repeated as the 
initial test may be negative. IgM positive samples can be confirmed with neutralizing 
antibody testing if needed (CDC, 2015). Detection of the virus nucleic acid is 
sometimes also attempted. JEV nucleic acid is usually rarely detected by reverse 
transcription polymerase chain reaction (RT-PCR) (Sapkal et al., 2007) and also not 
detected in urine (Zhao et al., 2013). However, prolong detection of JEV in urine and 
whole blood was reported in a recent JE fatal case (Huang et al., 2017). Isolation of 
JEV from blood clots (white blood cells) was developed to improve the diagnosis, but 
a low genomic copy is still a limiting factor (Sapkal et al., 2007). Magnetic resonance 
imaging (MRI) of brain lesion can also help to describe flavivirus encephalitis (Kalita 
et al., 2016) but it should be considered with other evidence. 
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There is no anti-viral treatment for JE available. JE can cause several deadly 
complications, which only be treated by supportive care. The increase of intracranial 
pressure is related to seizures. Fluids or steroid may be given to maintaining body 
fluid balance, and sedation could help relieve the symptom. In unconscious cases, 
basic life support such as respiratory system and blood circulation support is 
required. Patients who recovered but with permanent brain damage still need an 
appropriate nursing care from their family. 
1.1.5 Vaccines 
Vaccination is a very effective way to prevent JE in humans. However, it is difficult to 
completely eliminate JEV, because humans are dead-end hosts and the virus is 
maintained in its natural cycle. Vaccines for domestic pigs are also available, but the 
high turnover in pig populations is a major drawback (Solomon, 2006). 
Following the discovery of JEV, the first mouse-brain-derived inactivated vaccine was 
developed and it was used worldwide (Table 1.1). Later, it was replaced by Vero-cell-
derived inactivated vaccines as recommended by World Health Organization (WHO) 
in 2006 and 2015 due to the risk of adverse effect from mouse brain derived 
substances and animal ethical issues. The primary hamster kidney-cell-derived 
inactivated vaccine was previously used, but later was also replaced by the Vero-cell-
derived inactivated vaccine and a live-attenuated vaccine. The live-attenuated 
vaccine, also called the second-generation vaccine, has been used previously in China 
(from 1988). Now it is approved in many Asian countries and prequalified to use in 
children by WHO. Another current vaccine is a live-attenuated chimeric vaccine. The 
vaccine is based on yellow fever virus strain 17D inserted with JEV prM and E genes 
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(Ishikawa and Konishi, 2015). The vaccines are administered by intramuscular 
injection. 
 
Table 1.1 List of vaccines against JEV 
No. Vaccine JEV strain 
1 mouse-brain-derived inactivated vaccine Nagayama 
2 primary hamster kidney-cell-derived inactivated vaccine Beijing 
3 
Vero-cell-derived inactivated vaccines 
SA14-14-2/ 
Beijing 
4 live-attenuated vaccine SA14-14-2 
5 live-attenuated chimeric vaccine SA14-14-2 
 
1.1.6 Drug developments 
The antiviral drug is aimed to inhibit any virus activities that facilitate replication. 
Every single step in the virus life cycle could be a target including the viral immune 
invasion mechanism. Understanding of disease pathogenesis and molecular 
mechanism of virus life cycle could inform on how to prevent virus replication. As 
mentioned above, part of the disease outcome is thought to be due to the immune 
response, so many therapeutic candidates are antagonistic molecules such as 
antioxidants that reduce reactive oxygen species production (Table 1.2). Some of 
them are immune modulators, for example, IFNs, which is a common antiviral 
response that is blocked by the virus. Direct RNA intervention also shows anti-viral 
effect. E, NS3, and NS5 are well described in structure and function. They are the 
main targets for drug development. Several NS3 protease inhibitors for hepatitis C 
virus have been recently approved by the Food and Drug Administration (FDA) for 
clinical use (Salam and Akimitsu, 2013). Straightforwardly, targeting E protein aims to 
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block virus entry, while NS3 and NS5 interfere with RNA replication. Moreover, the 
virus hijacks several parts of the host machinery to survive. Targeting those necessary 
host proteins, for example, glucosidase and hydroxymethylglutaryl-coenzyme A 
(HMG-CoA) reductase (cholesterol synthesis), demonstrates protection in vitro and 
in vivo, respectively (Table 1.2). However, none of the anti-viral agent candidates 
have succeeded at the clinical level. In many of the in vitro and in vivo studies, 
candidates were given before, simultaneously, or immediately after inoculation such 
as Lovastatin that offered success only prior to infection not after, which are not 
practical as patients are treated after diagnosed (usually after disease onset). In 
theory, products to apply on the skin that contains the candidates might interfere 
with replication cycle in the skin cells and helps to block the virus to enter lymph and 
blood circulation. The brain is a particular target for JEV, so measurement that 
delivers drugs into CNS is very important. Moreover, a combination of the candidates 
may create a synergistic effect that is better than given on its own. 
.
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Table 1.2 Anti-Japanese encephalitis drugs reviewed  
Adapted from (Ishikawa and Konishi, 2015) 
Category Antiviral drugs Target/mechanism Experiment Drug administration 
Nonspecific broad spectrum IFN IFN-stimulated gene 
Human clinical 
trial 
After onset/ diagnosis confirm for 7 
days (Solomon et al., 2003a) 
 Ribavirin 
Inosine monophosphate 
dehydrogenase, etc. 
Human clinical 
trial 
After onset/ diagnosis confirm for 7 
days (Kumar et al., 2009) 
 Minocycline Antioxidant In vivo 1 dpi/ after onset 
 Arctigenin Antioxidant In vivo 1 dpi 
 Fenofibrate Antioxidant In vivo 4 dbi 
 Curcumin Antioxidant In vitro Immediately after infection 
 Pentoxifylline Assembly or Release In vivo Immediately after infection 
 Nitazoxanide Early/mid-replication cycle In vivo 1 dpi 
Nucleic acid-based siRNA C, M, E, NS1, NS3, NS4B, NS5 In vivo 
Simultaneous or before infection 
directly to the viral replicating cells. 
 Peptide nucleic acid UTR In vitro  
 Morpholino oligomer UTR In vivo 
Before or immediately after 
infection 
Virus replication cycle-
based 
Heparan sulphate Receptor binding In vivo Before infection 
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Category Antiviral drugs Target/mechanism Experiment Drug administration 
 E-binding peptide Receptor binding In vitro 
Incubated with virus before 
infection 
 
Nanoscale silicate 
platelet 
Attachment In vivo Immediately after infection 
 Indirubin Attachment In vivo 
Immediately after infection intra 
cranial 
 Bovine lactoferrin Receptor binding In vitro Before infection 
 Griffithsin Receptor binding In vivo Before infection 
 Recombinant E Receptor binding In vivo Before infection 
 MCPIP1 RNA replication In vitro Before infection 
 Kaempferol RNA replication In vitro Before and after infection 
 FGIN-1-27 RNA replication In vitro Before infection 
 Pokeweed RNA replication In vivo Before and after infection 
 SCH16 Translation In vivo Before and after infection 
In silico modelling-based Ivermectin NS3 In vitro (helicase inhibition assay) 
 4-hydroxypanduratin A NS2B/NS3 - - 
Intravenous 
immunoglobulin (IVIG) 
intravenous 
immunoglobulin (IVIG) 
Neutralizing antibodies, anti-
inflammatory 
Human clinical 
trial 
Day 6 of hospitalization 
Other potential drug targets 
(other flaviviruses ) 
NITD-451 Translation In vivo Immediately after challenging 
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Category Antiviral drugs Target/mechanism Experiment Drug administration 
 Lovastatin 
Cholesterol synthesis, 
Isoprenoid synthesis, 
Dolichol synthesis 
In vivo Before infection 
 Iminosugar derivative 
Inhibit glucosidase 
(glycosylation) 
In vitro Before infection 
 Celgosivir 
α-glucosidase inhibitor, 
interfere N-glycosylation 
Human clinical 
trial 
>48 hr after diagnosis 
 ST-148 
Inhibit capsid assembly and 
disassembly 
In vivo Immediately after challenging 
 
Note: Dpi = days post infection, MCPIP1 = monocyte chemoattractant protein 1-induced protein 1, siRNA = small-interfering RNA, UTR = 
untranslated region, FGIN-1-27 = N, N-di-n-hexyl 2-(4-fluorophenyl)indole-3-acetamide, SCH16 = N-methylisatin β-thiosemicarbazone derivative
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1.2. Dengue virus 
DENV infection presents in the tropical and subtropical region including more than 
100 countries (Figure 1.11) (Guzman and Harris, 2015) and affects infant, children, 
and adult. The estimated number is around 390 million infections, of which 96 million 
develop disease symptoms (Bhatt et al., 2013). The clinical features of dengue fever 
are flu-like symptoms but may include nausea, rash, and swollen lymph glands. In 
some cases, the disease may progress to dengue haemorrhagic fever (DHF) and 
dengue shock syndrome (DSS) which are deadly. Severe dengue infection causes by 
plasma leakage leading to severe bleeding, fluid imbalance, circulatory failure, and 
organ failure. Dengue viruses are transmitted by Aedes mosquitoes, primarily Aedes 
aegypti. DENV is originally a monkey virus circulated in sylvatic (primate) transmission 
cycle (Holmes and Twiddy, 2003). Dengue in human causes by four serotypes of 
dengue viruses (DENV1-4). The E protein substitution rate suggested that the four 
serotypes emerged (split) around 1000 years ago and the cross-species to human 
transmission happened just in a few hundred years (Twiddy et al., 2003). Severe 
dengue is suspected to associate with sequential infection of different dengue 
serotype. Lifelong antibodies produced from the primary infection are able to cross-
interact with the other three serotype viruses, but cannot neutralize the virus. The 
virus-antibody complexes are endocytosed into cells such as macrophages, 
monocytes, and dendritic cells, but are not destroyed. Instead, it increases the 
infected cell population and so the presence of viruses in the blood. There is no 
specific treatment for dengue. Dengue vaccine (CYD-TDV, a live attenuated 
tetravalent yellow fever 17D backbone) was recently available in 2015 and has been 
licensed in some endemic countries(WHO, 2016). 
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1.3. West Nile virus 
WNV is closely related to JEV (Figure 1.1) and has a similar life cycle. WNV is 
transmitted by Culex mosquitoes. The main vector is Culex pipiens. The natural 
transmission cycle is between mosquitoes and birds such as domestic birds. In North 
America, more than 50 species of mosquitoes and 280 species of birds were found 
infected with WNV. Some mammals (e.g. squirrels) and reptiles (e.g. alligators) may 
act as the amplifying host. Human and horse are the dead-end hosts as they usually 
develop low viraemia. WNV is present in Western hemisphere throughout Canada to 
Venezuela, Africa, parts of Europe, Middle East, West Asia, and Australia. It was 
originally isolated from patient in West Nile district of Uganda, 1937. WNV was 
introduced to New York, the United States of America in 1999 and caused a large 
outbreak which later spread to all over the continent. There are 5 lineages of WNV, 
which lineage 1 found in all distribution area. Lineage 2-5 are geographically 
distributed. Lineage 2 present in Africa and Europe. Lineage 3 was isolated in Europe 
Figure 1.11 Global presence of dengue 
Taken from (Guzman and Harris, 2015). License permission no. 4235380130183. 
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(Austria), but only from mosquitoes. Lineage 4 is circulating in Russia and lineage 5 is 
restricted in India. Majority of infection around 80% is asymptomatic. Approximately 
20% of infected people develop symptoms including flu-like symptoms, diarrhea, rash 
(on the torso), and swollen lymph glands. In severe cases, around 1 in 150 infections, 
patients may develop encephalitis or meningitis which symptoms include neck 
stiffness, disorientation, tremors, seizure, and paralysis. There is no specific 
treatment for West Nile virus infection. Even horse vaccine is available, currently, 
there is no vaccine available for human treatment. 
1.4. Zika virus 
Zika virus (ZIKV) is drawing the world’s attention by its ability to spread very quickly 
and has affected millions of people (only in Brazil, 2015, between 440,000 and 1.3 
million cases were estimated to occurred)(Slavov et al., 2016). ZIKV was first isolated 
from a monkey during research in the Zika Forest of Uganda in 1947 (Figure 1.12). 
The first human cases were reported in Uganda and the United Republic of Tanzania 
in 1952 (Smithburn, 1952) and Indonesia in 1977 (Olson et al., 1981), which was 11 
years after ZIKV was isolated from mosquitoes in Malaysia in 1966. Despite the 
intermittent human infection, other nonspecific methods studied on human serum 
suggested that ZIKV circulates in both Africa and Asia (Weaver et al., 2016). Five 
positive human sera tests were reported in Gabon in 2007 and in the same year, an 
outbreak occurred in Yap Island with 49 confirmed cases (Duffy et al., 2009). In 2013, 
a large outbreak in French Polynesia causing approximately 28,000 cases was 
reported (Musso et al., 2014). In late 2014, large numbers of skin rash cases were 
reported in North-eastern Brazil. Almost 7,000 cases were reported but ZIKV was not 
suspected to be the cause. Until around May, 2015, laboratory confirmed the 
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circulation of ZIKV in Brazil and ZIKV was announced as associated with the outbreak 
(Campos et al., 2015) (WHO, 2015). ZIKV rapidly spread to South and Central 
American countries. 
Typically, symptoms of Zika virus infection are mild including fever, skin rash, muscle 
and joint pain, and headache. There is, however, a proposed relationship between 
Zika infection and Guillain-Barré syndrome and microcephaly, which later was proved 
by detection of ZIKV in blood and tissue samples of babies with microcephaly (Marrs 
et al., 2016). Moreover, studies in a mouse experimental model confirmed the 
disruption of neural progenitor development by ZIKV (Cugola et al., 2016, Li et al., 
2016). ZIKV is transmitted by several Aedes spp. mosquitoes including Aedes aegypti, 
which is widespread globally. Even though case reports are declining, ZIKV has high 
potential to spread to new areas where Aedes spp. mosquitoes are present. Similar 
to other flaviviruses, there is no specific treatment. In addition, there is currently no 
vaccine available. Base on the NS5 gene, ZIKV is very closely related to DENV, so it is 
believed to share many characteristics with other flaviviruses. However, it is obvious 
that ZIKV has a distinct disease mechanism. It is interesting therefore to see the 
protein structures and compare to other flaviviruses with the aim to determine any 
differences that may cause these conserved proteins to function differently. 
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Figure 1.12 ZIKV distribution map 
Uganda is indicated with yellow star. Taken from (Weaver et al., 2016). License 
permission no. 4171011417242. 
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1.5. Scope of this thesis 
JEV is the major cause of viral encephalitis in Asia with no specific treatment. 
Flavivirus diseases management can be improved by a combination of vaccination, 
vector control, personal protection, and development of an anti-viral agent. 
Understanding virus biology is a fundamental key for us to manage the virus. 
Similarly, defining the molecular structure of related proteins will help us to 
understand how they function. With mounting evidence suggesting significant roles 
for C and NS1 protein in the virus life cycle, these multifunctional proteins are targets 
for new antiviral development as none of the current anti-viral candidates has 
succeeded in clinical testing. Moreover, all the protein structures in the genome of 
DENV, the most well-studied flavivirus, have been solved except for the 
transmembrane proteins: NS2A and NS4A/B. Structural characterisation of JEV is still 
lacking the information on both C and NS1 proteins. Therefore, the thesis sets out to 
determine the following: 
1. Molecular structures of the two important multifunctional drug target 
potential proteins, C and NS1 (and its frameshift NS1’), using X-ray 
crystallography. 
2. The molecular structure of NS1 protein of the related virus, Zika virus, to 
compare to JEV NS1 by using X-ray crystallography. 
3. JEV NS1 protein function via protein interaction studies. 
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Chapter 2 Introduction to protein structural 
study 
 
Protein structure determination is usually performed by the experimental methods 
including X-ray crystallography, electron microscopy, nuclear magnetic resonance 
(NMR), and small-angle X-ray (SAX) and neutron scattering. There are advantages and 
disadvantages in each of these techniques. For example, X-ray crystallography can 
give a very high-resolution structure but not all proteins can be crystallised and the 
protein dynamics is restricted. NMR technique can show protein dynamics and 
applied to proteins in solution, but it gives lower resolution than X-ray crystallography 
and protein molecular weight is limited to below 50,000 Da. These techniques can be 
used in combination to obtain data on different aspects of the research questions. 
Homology modeling is also useful and more accurate if the template has high degree 
sequence identity with the target protein. Many successful homology models have 
been reported especially for small proteins (Zhang and Skolnick, 2004). In addition, 
partial structural information, for example, molecular mass and post-translational 
modification can be obtained from various spectrometry methods. In this study, X-
ray crystallography and SAXS were used. 
2.1 Protein expression 
Similar to other protein experiments, pure and functional proteins are required for 
structural determination, but in larger quantity. Crystallization experiment may 
require a different amount of protein depending on the success of crystallization 
screening. Usually, at least several milligrams of protein are required. Unless a large 
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amount of protein is isolated from the natural source, the protein sample is usually 
produced using bacterial, insect cell or mammalian protein expression systems 
(Gomes et al., 2016). 
2.1.1 Bacterial expression 
With its simplicity, good value for money, high yield, well known genetics, and various 
molecular implements available, Escherichia coli is a typical host for recombinant 
protein expression (Baneyx, 1999). Usually, sufficient amount of active soluble 
protein could be achieved from E.coli expression (functional tests are required to 
confirm). Occasionally protein overexpression in E. coli might cause partially folded 
or misfolded protein to accumulate together in inclusion bodies, which could be 
caused by insufficiency of folding machinery. Importantly, there are differences in cell 
environment and posttranslational modifications compared to the eukaryotic cell. E. 
coli cytoplasm has reduced environment, so disulphide bond formation is not allowed 
(Singh and Panda, 2005, Sorensen and Mortensen, 2005). N-linked and O-linked 
glycosylation have been observed in several bacteria, and the properties have 
succeeded to transfer to E. coli. However, glycoengineered E. coli is still in 
development (Nothaft and Szymanski, 2010). Lack of posttranslational modifications 
may result in misfolding and non-functional protein. Thus, expression of a eukaryotic 
glycoprotein may not suitable for the bacterial expression system. However, there 
are many strategies both with and without engineering of the target protein to 
improve the soluble protein production (Figure 2.1) (Sorensen and Mortensen, 2005). 
If none of the strategies are able to produce soluble protein, refolding from inclusion 
bodies may be the method of choice. 
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Figure 2.1 Diagram showing soluble protein production strategies used in 
recombinant E. coli expression. 
taken from (Sorensen and Mortensen, 2005) 
 
2.1.2 Eukaryotic cell expression 
In many cases, glycosylation and disulphide bond formation are crucial for protein 
folding and functioning. In these cases the use of eukaryotic cell expression system is 
needed. Three eukaryotic expression systems including yeast, insect cell, and 
mammalian cells are mentioned in this chapter. 
Yeasts are similar to E. coli for its ease of handling, low cost and scalability. However, 
yeasts have different glycosylation than mammalian cells. Mammalian protein 
expressed in yeast may induce immune response in human use (Ahmad et al., 2014). 
This is not a concern for structural study, but it may matter for protein-protein 
complex structure. 
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Insect and mammalian cells are suitable to produce functional protein due to cell 
environment and machinery. Mammalian cells are ideal for mammalian protein 
production, but the complex oligosaccharide chains generated in mammalian cells 
are heterogeneous and could hinder crystallization. Insect cells have similar protein 
glycosylation to mammalian cells, but it is more homogeneous. However, 
glycosylation mutant cell lines, glycosylation inhibitors, and endoglycosidase 
enzymes are able to manipulate and trim to produce uniform glycan chain. Glycan 
chain is usually flexible, so electron density of the whole chain may not be visible. 
Typically, only a first few residues are observed in X-ray structures (Nattleship, 2012). 
In addition, protein expression in insect and mammalian cells is demanding, 
expensive and time-consuming. Preferential choice of cells expression system 
depends on posttranslational modification needed and specific applications of the 
target protein. 
2.2 Protein purification 
The level of purity depends upon the purpose of use. For the structural study, the 
sample must not contain other protein species in the amount that interfere the 
structure investigation. 
Usually, in order to keep the biological activity throughout the process, protein 
purification is conducted at low temperature (on ice or 4°C containment), using of 
strong buffer such as very acidic or basic buffer should be avoided. Additionally, 
purification steps have to be minimized due to the loss of protein yield in every extra 
step. Purification process should start with low-resolution methods like affinity 
chromatography followed by refining methods with higher resolution like gel 
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filtration. One advantage of the recombinant protein expression is a large amount of 
the expressed target protein compared to the native host expression, which makes it 
easier to isolate from the mixture. 
Proteins differ from one another by their properties like solubility, charge, size, 
specific binding, and other special properties which can be exploited for protein 
purification. Required purification steps depend on the protein properties. What has 
been done previously with the close related protein might be a good starting point 
(Cutler, 2004). 
Histidine is known to bind divalent metal ions. To utilize it for protein purification, 
polyhistidine (6xHis or His6) is added to the target protein and the tagged protein will 
selectively bind to Ni2+ or Co2+ ions. A column packed with agarose beads media which 
conjugated with a chelating agent, e.g. nitrilotriacetic acid (NTA), and charged with 
metal ions, e.g. nickel ion (Ni2+) is commonly used for purification. This is called 
immobilized metal-ion affinity chromatography (IMAC). The target protein is eluted 
with buffer containing imidazole, which binds strongly to metal ions and competes 
with histidine-tagged protein. Protein can be directly purified with IMAC from cell 
lysate suspension. 
Size exclusion chromatography (SEC) separates proteins by their sizes using small 
porous resins with a variety of pore sizes, which different pore size material gives 
different separation range. Difference sizes of protein are separated by their elution 
time from the column. Very large proteins, out of the pore size separation range, will 
be eluted first in the void volume so as aggregated protein. Large molecules are not 
able to enter the pores and pass through the column faster. Small molecules get into 
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the pores and take a longer time to travel along the column. Different proteins can 
be similar in size causing gel filtration to be a weak resolving tool. However, it very 
benefits for homogeneity of the sample to apply size separation chromatography as 
the late purification step. SEC is also used for interactional studies when the size of 
the protein changes due to complex formation. 
In the case when protein is expressed as inclusion bodies, protein needs to undergo 
refolding as the first step of purification. Inclusion bodies, which have a higher density 
than other cell elements, are easy to separate by centrifugation after cell lysis. 
Traditionally, protein inclusion bodies are denatured with a high concentration (6-8 
M) of chaotropic reagents such as guanidine hydrochloride and urea. Then the 
denaturant is removed and exchanged with refolding buffer which contains protein 
folding additives such as L-arginine, detergent, and glycerol. Moreover, oxidizing and 
reducing agents are required in refolding buffer in order to create redox shuffle for a 
protein containing disulphide bonds to properly form disulphide bonds. Several 
refolding strategies can be used, for example, dialysis, dilution, and chromatographic 
refolding. There is no universal recipe that works for every protein (Singh and Panda, 
2005). 
2.3 X-ray crystallography 
To observe an object, the experimented object has to diffract light and its size has to 
be larger than the wavelength (λ) of the light. To distinguish between atoms in a 
molecule which are 0.1 -0.3 nm apart, X-ray with shorter wavelength (~0.1 nm) than 
visible light (400-700 nm) is required. Diffracted X-rays from one molecule are not 
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strong enough to detect. It is necessary to get crystals, which have millions of orderly 
oriented molecules, to obtain strong X-ray diffraction. 
2.3.1 Obtaining crystal and crystal quality 
Crystallization of inorganic molecules such as salts is well-known. A substance will 
solidify to form crystals in its supersaturation state, so sample purity and 
concentration are very important. For protein crystallization, the precipitant is added 
to separate protein from solution and reach its saturation. Hanging drop (Figure 2.2a) 
and sitting drop methods are commonly used. In each well is filled with reservoir 
solution which contains precipitant. In the crystallization drop, purified protein is 
mixed with reservoir solution. At the starting point, the concentration of precipitant 
in the drop is lower than in the reservoir. Evaporation of water from the drop will 
increase both protein and precipitant concentration until the concentration of the 
precipitant in the drop equilibrates with the precipitant concentration in the 
reservoir. 
When the concentration of protein increases and reaches the nucleation zone (Figure 
2.2b, grey area), nucleation can occur. Once the nucleation occurs, protein crystal 
growing will decrease the protein concentration to the growth zone (Figure 2.2b, 
orange area). At very high supersaturation beyond the nucleation region, protein will 
precipitate. However, crystals might also form after precipitation as the protein 
concentration decrease to the nucleation zone. During the process, besides forming 
crystals and precipitation, the protein might form a very dense liquid phase like gel 
or oil which is also in a supersaturated state that crystal may grow. Usually, various 
conditions are screened for crystallization. The conditions that give crystals or 
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promising are further optimized. Different pH, precipitant concentration, protein 
concentration, and additives could improve the crystal quality. The same protein may 
crystallise in more than one crystal form. Crystallization might take minutes, days, or 
months. 
The crystal quality is not judged by the perfection of the crystal (beautiful crystal 
might not diffract at all) but by its X-ray diffraction properties. Salts (precipitants) 
might crystallise instead of protein. Several protein crystal properties can be tested 
to distinguish between protein and salt crystal, for example, protein crystal is easy to 
crush (see 2.3.2) and will shrink when dehydrated. Protein crystal can absorb small 
dye molecule through it large solvent channel, while salt cannot, and protein can be 
detected when washed and dissolved protein crystal is run on SDS-PAGE and stained 
with Coomassie dye. Besides that, experimental control can be set up alongside by 
mixing sample buffer and reservoir solution at the same ratio as the experiment in 
the new drop. (Rhodes, 2006) 
Figure 2.2 Hanging drop method crystallization and crystallization phase diagram 
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2.3.2 Crystal Packing 
In the crystal, millions of motif with one identical orientation (or sometimes a few) 
are packed together in a periodical order. This motif can be an atom, molecule, 
protein, or protein complex. A unit cell is a term described the smallest volume in the 
crystal that can translate to fill in the volume of the entire crystal. One may think of 
a crystal as a lot of unit cells that stack beside and over each other (Figure 2.3). The 
unit cell 3-dimensional axes are specified by 𝑥, 𝑦, and 𝑧. The lengths of 3 edges are a, 
b, and c and 3 angles are α, β, and γ (Figure 2.3b). Difference edge lengths and angles 
create 7 possible crystal systems (different shapes of unit cells): cubic, tetragonal, 
orthorhombic, rhombohedral, hexagonal, monoclinic, and triclinic. An asymmetric 
unit is a term described the smallest volume that could multiply in the unit cell 
(generating different alignment copies filling in the unit cell) by symmetry operations 
called point group symmetry operations: rotation axes, inversion axes, and mirror 
planes. 
Figure 2.3 Unit cells in a crystal. 
(a) Unit cell duplicates itself by stacking on top and alongside each other in every 
direction through the crystal. (b) Unit cell axes, edge lengths, and angles specification. 
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The repeated order arrangement of motif forms a pattern in the crystal, which the 
outline of the patterns is called lattices. Points, where the lines intersect, are called 
lattice points, which are the sites where atoms can be placed but not necessary. Four 
types of lattices: primitive, face centered, body centered, and base centered, 
together with 7 crystal systems give 14 Bravais lattices, which can translate and 
represent the crystal. Combination of point group symmetry operations, translational 
symmetry operations (screw axes and glide planes), and Bravais lattices allows 230 
combinations in total, the 230 space groups, which describe the unit cell and atoms 
arrangement within the unit cell. However, inversion axes, mirror plane, and glide 
planes are not applicable to proteins, which are chiral molecules, making the possible 
point group symmetry operations and space groups reduce to 11 and 65, 
respectively. 
Each protein molecule in a crystal is held together by the network of hydrogen bonds 
with water molecules within and between the protein molecules, so protein crystal 
is fragile and considered to be in an aqueous state. Many studies have shown that 
crystal structure is the same as its solution state, and protein still retains its function. 
However, crystal packing could affect the conformation of the structure when 
molecule lies very close to a neighbouring molecule. Flexible regions such as loop and 
terminal ends might not visible in the crystal structure.
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2.3.3 X-ray diffraction 
X-rays are scattered at specific angles (θ) by the electron cloud of the atoms in the 
crystal. These angles depend on the crystal symmetry, protein structure, and X-ray 
wavelength (λ). 
When incoming X-ray interacts to electrons, electrons absorb energy, vibrate at the 
same frequency, and then emit wave at the same frequency in random directions. 
According to Bragg’s law, the diffraction takes place when the path length difference 
of the two scattered beams is an integer of the wavelength (nλ, where 𝑛 is an integral 
number), so they are in-phase with each other and interact constructively, while out-
of-phase waves interact destructively (Figure 2.4 and Figure 2.5). The X-rays are 
scattered from the set of lattice planes with the interplanar distance d with specific 
angle θ. The distance d also specifies the resolution of the structure. The total path 
difference between the two X-ray beams (Figure 2.5, orange line) is 2𝑑 sin 𝜃, which 
in the condition of constructive interference, it equals to 𝑛𝜆 (Figure 2.5, Bragg’s 
equation). Each diffracted X-ray is the contribution of all atoms in the unit cell, and 
summation of the scattered waves reach and creates one reflection on the detector. 
 
Figure 2.4 Constructive and destructive combining of waves 
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Suppose that molecules in the crystal are the arrays of spheres, the diffraction 
pattern of it also shows as a regular array (Figure 2.6). However, there is a 
proportional inverse relationship between the interval of real spheres and interval of 
reflections in the diffraction pattern. Because of this relationship, the dimensions of 
the unit cell in the crystalline lattice could be calculated from the diffraction pattern. 
For example, if a real unit cell has one of the edge lengths equal to a, a reciprocal unit 
cell has co-linear axis length of a*:𝑎∗ = 1 𝑎⁄ . The 3-D imaginary space where the 
reflections inhabit is called reciprocal space.
Figure 2.6 Crystalline lattice and reciprocal lattice inverse relationship. 
(a) When spheres are close together only vertically, (b) the reciprocal lattice 
(diffraction pattern) expands only vertically. (c) When spheres are close together only 
horizontally, (d) the reciprocal lattice expands only horizontally. 
Figure 2.5 Bragg’s law. 
The 2 scatter beams will be in-phase if the beam distance different is equal to 𝑛𝜆, 
where 𝑛 is an integral number, 𝜆 is X-ray wavelength, 𝑑 is crystal plane spacing, 
and 𝜃 is scattering angle.  
 
 46 
 
2.3.4 Data collection 
X-ray diffraction data are usually collected at cryogenic temperatures to improve 
diffraction by increasing molecular order and reducing radiation damage from X-ray 
beam. Crystals are held in a small loop and soaked in reservoir solution supplemented 
with cryoprotectant prior to the data collection. Crystal is picked up, flash frozen in 
liquid nitrogen, and stored in liquid nitrogen until the data collection (Rhodes, 2006). 
Crystal is rotated over a small range angle (0.1-0.2 degrees at the synchrotron source 
and 1 degree in-house) to collect reflections from different lattice points. Total 
rotation angle depends on crystal symmetry. Higher crystal symmetry needs the 
smaller overall rotation to collect all unique reflections. 
Modern X-ray detectors convert X-ray photons into an electrical signal by 
photoelectric effect of silicon in complementary metal-oxide-semiconductor (CMOS). 
Information is read out from chips in each pixel in the detector. Intensity and position 
of each reflection are recorded (Figure 2.7). The phases of x-rays are not directly 
observed, so the phase information is lost during the measurement. 
Figure 2.7 One frame of diffraction data detected from C-JEVNS1 protein crystal. 
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2.3.5 From diffraction data to electron density 
There is no lens to collect X-ray beams to accurately reconstruct an image. The 
refractive index of all mediums is very close to the refractive index of a vacuum for X-
rays. With a weak refraction, X-ray lenses are impracticable. Thus, all the processes 
to reconstruct the image are done by calculation. 
From data frames, unit cell dimension, symmetry of the crystal, detector parameters, 
reflection indices (ℎ, 𝑘, 𝑙)  and their intensities (𝐼ℎ𝑘𝑙)  are extracted ( ℎ, 𝑘, 𝑙 is a 3-
dimensional coordinate used to specify a position in reciprocal space). Set of data is 
integrated and a single output file is produced. This process is called data reduction. 
As the crystal is rotated, reflections might be partially recorded in one frame and fully 
recorded in another frame. The scaling process is performed to improve the 
consistency of raw intensity data. 
According to Fourier theory, a complex wave can be estimated by combining simple 
sine and cosine waves. Basic waveform is written as a complex number 
[𝑐𝑜𝑠2𝜋(ℎ𝑥) + 𝑖 𝑠𝑖𝑛2𝜋(ℎ𝑥)]  (equation 1, Eq.1) and can also be expressed as an 
exponential 𝑒𝑖 2𝜋 (ℎ𝑥)(Eq. 2). 𝐹 specifies the amplitude, ℎ specifies frequency, and 𝛼 
specifies phase, which is not directly stated. The sums of 𝑛 terms are as follow: 
𝑓(𝑥) =  ∑ 𝐹ℎ
𝑛
ℎ=0
[𝑐𝑜𝑠2𝜋(ℎ𝑥) + 𝑖 𝑠𝑖𝑛2𝜋(ℎ𝑥)]                             (1) 
or 
𝑓(𝑥) =  ∑ 𝐹ℎ
𝑛
ℎ=0
𝑒2𝜋𝑖(ℎ𝑥)                                              (2) 
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or as a 3-dimensional sum 
𝑓(𝑥, 𝑦, 𝑧) = ∑ ∑ ∑ 𝐹ℎ𝑘𝑙𝑒
2𝜋𝑖(ℎ𝑥+𝑘𝑦+𝑙𝑧)                              
𝑙𝑘
 (3)
ℎ
 
Diffracted X-ray, which is a summation of in-phase scattered waves, is a complex 
wave. Therefore, it can be written as a wave equation. The summation of the 
reflection ℎ𝑘𝑙 is called the structure factor 𝐹ℎ𝑘𝑙 . If a unit cell contains 𝑛 atoms, the 
structure factor 𝐹ℎ𝑘𝑙  is written as follow: 
𝐹ℎ𝑘𝑙 =  ∑ 𝑓𝑗
𝑛
𝑗=1
𝑒2𝜋𝑖(ℎ𝑥𝑗+𝑘𝑦𝑗+𝑙𝑧𝑗),                                         (4) 
where 𝑓𝑗 is the scattering factor of atom 𝑗. Coordinate of atom 𝑗 is indicated by 𝑥𝑗 , 𝑦𝑗, 
and 𝑧𝑗. The frequencies in 3 directions, 𝑥, 𝑦, and 𝑧, are the reflection indices, ℎ, 𝑘, and 
𝑙, respectively. 
The structure factor 𝐹ℎ𝑘𝑙  can also be written as the summation of small volumes of 
electron density in the unit cell. The 3-dimensional electron density is represented by 
𝜌(𝑥, 𝑦, 𝑧). To precisely get the average electron density, very small volume elements 
are integrated together where 𝑉 is the unit cell volume (Eq.5).  
𝐹ℎ𝑘𝑙 = ∫ 𝜌(𝑥, 𝑦, 𝑧)𝑒
2𝜋𝑖(ℎ𝑥+𝑘𝑦+𝑙𝑧)𝑑𝑉
𝑉
                                  (5) 
Fourier transform is a mathematical operation that changes the information in one 
domain to another, which still represent the same data, and the 2 domains are 
reciprocal to each other. Fourier transform is widely used to decompose a function 
of time into the frequencies (Eq.6).  𝑓(𝑥) is a function of time and 𝐹(ℎ) is a function 
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of frequency (1 (𝑡𝑖𝑚𝑒)⁄  is frequency). Fourier transform is reversible, so it can be 
written as in equation 7. 
𝐹(ℎ) = ∫ 𝑓(𝑥)𝑒2𝜋𝑖(ℎ𝑥)𝑑𝑥
+∞
−∞
                                              (6) 
𝑓(𝑥) = ∫ 𝐹(ℎ)𝑒−2𝜋𝑖(ℎ𝑥)
+∞
−∞
𝑑ℎ                                           (7) 
When compare equation 5 and equation 7, 𝐹ℎ𝑘𝑙  is, in fact, the Fourier transform of 
𝜌(𝑥, 𝑦, 𝑧). However, the electron density is the aim of the calculation revealing the 
structure of the target molecule. Thus, the inverse Fourier transform is as follow: 
𝜌(𝑥, 𝑦, 𝑧) =
1
𝑉
∑ ∑ ∑ 𝐹ℎ𝑘𝑙
𝑙
𝑒−2𝜋𝑖(ℎ𝑥+𝑘𝑦+𝑙𝑧)
𝑘
                              (8)
ℎ
 
Integral is not used and instead, the summation is used because the structure factor 
𝐹ℎ𝑘𝑙  is a set of the discrete function of reflections. Amplitude and phase are required 
to compute the structure factor 𝐹ℎ𝑘𝑙 . The amplitude of 𝐹ℎ𝑘𝑙  is proportional to the 
square root of the reflection intensity 𝐼ℎ𝑘𝑙 , so it can be obtained from measured 
reflection intensities. Only the phase information cannot be measured by a current 
diffraction experiment, because the instrument only detects the scattered energy in 
different directions. 
2.3.6 Phase problem 
There are techniques available to reconstruct the phases, unmeasurable information 
from diffraction experiment. Three main techniques for obtaining phases of protein 
structure are multiple isomorphous replacement, multiwavelength anomalous 
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dispersion, and molecular replacement. Only details of molecular replacement used 
in this study are presented in this chapter. 
Molecular replacement 
Molecular replacement is a phasing technique of obtaining the initial phases using 
the homological protein model. The template model is called a starting model. 
Nowadays, there are ~100,000 protein structures solved by X-ray crystallography in 
the protein data bank (PDB). Among these, more than 70% were solved by molecular 
replacement. This method is very useful if homologue structure is available. 
Homologue structure usually belongs to the same protein family. The starting model 
typically needs at least 35% sequence identity, cover at least 50% of the whole 
molecule, and has 𝐶∝ r.m.s.d. when superimposing with the final model less than 2 Å 
(Abergel, 2013). Below these criteria, the success rate is decreased. 
The structure of the starting model is rotated and translated to match the unknown 
target structure. The search of all possible orientations and locations is computed by 
2 distinct steps. First, the search for the best orientation. Second, the search for the 
best position. Orientation search is conducted by comparing the Patterson function 
(Eq.9) of the starting model and the unknown target structure, which does not need 
phase and could be calculated directly from experimental data. 
𝑃(𝑢, 𝑣. 𝑤) =
1
𝑉
∑ ∑ ∑|𝐹ℎ𝑘𝑙|
2
𝑙
𝑒−2𝜋𝑖(ℎ𝑢+𝑘𝑣+𝑙𝑤)
𝑘
                              (9)
ℎ
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Patterson function reports Patterson map which represents the positional vectors 
between each pair of atoms in the structure (Figure 2.8).
 
Patterson map of the starting model is superimposed and rotated against the 
Patterson map of the unknown target structure. The top solutions of the rotation 
search that give a good match to the model are then used for location search. The 
location search is performed by translating the selected interatomic Patterson map 
over that of the unknown structure to find the best match. The structure factors of 
each new model are calculated. Agreement of the 2 models is accessed by R-factor, 
the comparing the amplitude (Eq.10) where |𝐹𝑜𝑏𝑠|  is amplitude derived from 
diffraction experiment and |𝐹𝑐𝑎𝑙𝑐| is amplitude calculated from the structure factor 
of the new orientated and position model. 
𝑅 =
∑||𝐹𝑜𝑏𝑠| − |𝐹𝑐𝑎𝑙𝑐||
∑|𝐹𝑜𝑏𝑠|
                                                   (10) 
Figure 2.8 Patterson map of a three atoms structure. 
The interatomic vectors between atoms in the structure including the symmetry 
related molecules are plotted and moved to the origin of the unit cell of the Patterson 
space (identical to the crystal unit cell). 
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The model with the highest correlation coefficient, small R value, to the unknown 
target structure would give the best estimation of the target phase. Perfect match R 
is zero and the worse match is one. Phases obtained from molecular replacement are 
only the initial estimated phases, which require an improvement before interpreting 
into a final electron density map. R-value >0.5 indicates poor agreement and may not 
possible to improve (near 0.59 is a random model) (Karplus and Diederichs, 2012) and 
R-value <0.4 is more amenable to improve by refinement. 
2.3.7 Molecular modelling and validation 
Electron density map is a contour map of 𝜌(𝑥, 𝑦, 𝑧) (Figure 2.9). The first map is 
calculated from the observed amplitude and estimated phases. However, when the 
electron density map is purely calculated by phases from the model and amplitudes 
from experimentally measured data, it is possible to introduce bias from the model 
to the electron density map. To reduce the bias, the amplitude of each term of the 
electron density map is calculated by subtraction of the calculated amplitude from 
some multiple (𝑛) of the observed amplitude (|𝑛|𝐹𝑜𝑏𝑠| − |𝐹𝑐𝑎𝑙𝑐||) (Eq.11). A map 
from this calculation is a different map called 𝑛𝐹𝑜 − 𝐹𝑐  map where 𝐹𝑜 𝑎𝑛𝑑 𝐹𝑐  
represent 𝐹𝑜𝑏𝑠 𝑎𝑛𝑑 𝐹𝑐𝑎𝑙𝑐, respectively. The difference map with n = 2 with weighting 
terms is immensely used (2𝑚𝐹𝑜 − 𝐷𝐹𝑐  where m is the figure of merit and D is the 
Sigma-A weighting factor). 
𝜌(𝑥, 𝑦, 𝑧) =
1
𝑉
∑ ∑ ∑(𝑛|𝐹𝑜𝑏𝑠| − |𝐹𝑐𝑎𝑙𝑐|)
𝑙
𝑒−2𝜋𝑖(ℎ𝑥+𝑘𝑦+𝑙𝑧−𝛼𝑐𝑎𝑙𝑐
′ )
𝑘
            (11)
ℎ
 
 53 
 
Target protein sequence is usually known, so the molecular model is built into the 
electron density map according to the known sequence by partially automate 
computer program. However, there are still areas on the map that need user 
intervention to identify specific molecular features and additional molecules from 
crystallization condition or bound cofactors and ions. 
In the different maps, electron density can be either positive or negative. Positive 
density, usually shows in green colour, indicates that Fobs are larger than Fcalc (Eq.11). 
Thus, this region in the real unit cell has more electron density than indicated by the 
model. The positive map is suggesting that there should be atoms in this region but 
data are not accounted in the model. The positive density is corrected by moving or 
filling atoms into the region. Negative density, on the other hand, indicates that the 
model shows more electron density than in the real unit cell and usually shows in red 
colour. Adding atoms in negative density should be avoided. After optimization, new 
structure factors are calculated from this new model and a new phase is obtained. 
Figure 2.9 Electron density map and molecular model built into it. 
The JEV capsid protein displayed by program COOT (Emsley et al., 2010). 
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New electron density map is calculated from the observed amplitudes and the new 
phase. These sequence of events, called refinement, is repeated multiple times. 
Stereochemical parameters and R-factor are monitored in each round of refinement. 
Bond length, bond angle, and side chain rotation should be chemically realistic. R-
factor should keep low, for example, a model at 2.5 Å resolution is expected to have 
R-factor of 0.2. Another parameter is introduced, Rfree, to make sure that the refined 
model is not over manipulated. The Rfree calculation is the same as R-factor but the 
Fobs is the ~5% of the reflection data that set aside from refinement. R and Rfree values 
should be close to each other. Rfree is usually higher but ideally not more than 5%. The 
refinement is considered finished when both R and Rfree reach stable values, and 
there is no interpretable density present. 
Structure Validation 
The final step is to confirm that the model is complete and thoroughly refined. 
Submission of the model to the online server validation, Molprobity (Chen et al., 
2010), gives details on each parameter quality for each amino acid residue (Figure 
2.10). Geometric analysis and all-atom contact analysis are conducted for structure 
validation. Bond length, bond angle, backbone conformation ( 𝜑, 𝑃ℎ𝑖 𝑎𝑛𝑑 𝜓, 𝑃𝑠𝑖 
torsional angles accessed by Ramachandran diagram) should be in chemical realistic 
range. The residue with poor parameter should be remodelled. However, some 
molecular features, which categorizes as an outlier but have strong electron density 
map, may be the model uniqueness. 
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Figure 2.10 Molprobity statistics summary. 
Following by uploading the protein coordinates file to Molprobity server, the program calculate several 
statistical parameters. Colour coding red, yellow, and green demonstrate bad, moderate, and good values, 
respectively. Percentile is compared across protein structures deposited in PDB at similar resolution. 
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2.4 Small angle X-ray scattering (SAXS) 
SAXS shares the principles of elastic X-ray scattering with X-ray crystallography. Data 
obtained from the experiments are similar in terms of intensity and diffraction angle 
measurements, but the data are sampled differently. While X-ray crystallography 
focuses on the data at high resolution, SAXS analyses sample at low resolution, e.g. 
20 Å. SAXS can be used to probe the structure of molecules in solid, liquid, or gaseous 
states. The liquid sample is focused in this study as it is useful for determination of 
the overall shape and conformation of the protein in solution. Particles in solution do 
not exhibit periodicity but move freely. Particles in solution, therefore, give isotropic 
scattering patterns spherically averaged around the beam center. While this data 
cannot provide atomic detail of molecule under investigation, it does provide 
information on average shape, size, and molecular weight (MW). A necessity of SAXS 
measurements is the acquisition of pure and functional protein. 
2.4.1 SAXS measurements and data analysis 
Elastic scattering refers to a stage of no net energy loss before and after the 
interaction with matter. Incoming and scattering X-rays can be written as momentum 
vectors 𝑘𝑖𝑛  and 𝑘𝑜𝑢𝑡 , respectively (Figure 2.11). Vector 𝑞 , momentum transfer, 
specifies the difference momentum of X-ray before and after the collision. Vector 𝑞 
is: 
𝑞 =
4𝜋 sin 𝜃
𝜆
,                                                     (12) 
where scattering angle is 2𝜃 and a momentum vector 𝑘 is 2𝜋 𝜆⁄ . 𝑞 is in reciprocal 
space and the unit is the inverse of length, nm-1 or Å-1.  
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Target molecules are surrounded by solvent. Incident X-rays are scattered by both 
target molecules and solvent. The useful information is the difference of electron 
density between the target molecules and solvent (∆𝜌) (Figure 2.12a). Signal contrast 
is obtained by measuring the buffer signal alone then subtract it from the total signal 
(Figure 2.12b). 
 
Figure 2.11 SAXS experiment diagram. 
X-ray beams are written as momentum vector 𝑘 . Scattered wave intensities are 
recorded. 
Figure 2.12 Signal contrast. 
Electron density difference of protein is around 10% above the background (a) and 
obtained by subtraction of the solvent (background) signal (b). 
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Summation of scattering waves is specified by the form factor of the particle 𝐹(𝑞), 
which contain intra-particle interaction information such as size and shape. The term 
structure factor 𝑆(𝑞) gives additional information from neighboring particles when 
they are packed (concentrated) or has interparticle interaction such as attraction and 
repulsion. The scattering intensity equation is: 
𝐼(𝑞) = 𝐹(𝑞) ∗ 𝑆(𝑞)                                             (13) 
Scattering intensity 𝐼(𝑞) is experimentally measured. In order to get size and shape 
information of the sample, which is obtained from 𝐹(𝑞),  𝑆(𝑞) is expected to equal 
to 1, meaning no interparticle interaction in the solution. The ideal sample for SAXS 
is monodisperse (identical size and shape) with molecules far away from each other 
Distance between particles is larger than the wavelength. If the sample is 
polydisperse (varied sizes), the form factor gives the average size from all particles. 
An inter-particle interaction contributes to the form factor and cause inaccurate 
measurement of parameters. Attractive interaction usually gives larger parameters 
than the actual, for example, particle size, volume, and molecular weight, while 
repulsive interaction will give too small parameters (Figure 2.13). Thus, good sample 
preparation is very important. Multiple techniques may be used such as size exclusion 
chromatography to characterize the sample and avoid polydispersity or aggregation. 
Another method to check data quality is Guinier method, which developed by Andre 
Guinier, 1939. At very low 𝑞 value (close to zero), the intensity is approximated as 
follow: 
𝐼(𝑞) = 𝐼0𝑒
−𝑞2𝑅𝑔
2 3⁄                                                 (14) 
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ln 𝐼(𝑞) = ln 𝐼0 −
𝑅𝑔
2
3
𝑞2                                            (15) 
Equation 15 is a linear relationship plotted of ln 𝐼(𝑞) against 𝑞2 . High-quality and 
reliable data should fit perfectly to the slope line (Figure 2.13). Attractive or 
aggregation interaction shows upward curve line, and repulsive interaction shows 
downward curve line. Poor fit data should not be further processed (Figure 2.13). 
 
The radius of gyration defined by SAXS measurements is the root mean square (rms) 
radius of electron scatterers 𝑅𝑔, which is a measure of mass distribution from the 
center of mass. It is determined from the slope of the Guinier plot. 
Figure 2.13 Scattering and Guinier plot examples of inter-particle interaction 
samples. 
Attractive interaction give increase intensity at low 𝑞 values of scattering plot, while 
repulsive interaction gives the opposite result indicated by black arrows. In addition, 
inter-particle interaction sample is poorly fit to the slope line in Guinier plot. 
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The forward scattering intensity 𝐼0 is determined from the 𝐼(𝑞) axis intercept at the 
intensity at 𝑞 = 0 and it is proportional to the number of electrons in particle. 𝐼0 is 
useful for molecular weight determination. However, the SAXS intensity is not 
measured on an absolute scale. The indirect method to obtain the absolute intensity 
is calibrating to the secondary standards such as lysozyme, glucose isomerase, or 
bovine serum albumin. Known concentration of both sample and standard protein, 
and partial specific volume of the protein are required for 𝐼0 based molecular weight 
estimation. Normalized to the concentrations, the partial specific volume values of 
the standard and protein sample are assumed identical, so the ratio of the molecular 
weights of the two proteins is equal to the ratio of the 𝐼0 (Eq.16). 
𝑀𝑊𝑒𝑥𝑝
𝐼0 𝑒𝑥𝑝
=
𝑀𝑊𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑
𝐼0 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑
                                                 (16) 
Molecular weight may be estimated from the particle volume as well (where the 
particle is assumed to have uniform density) called Porod volume (𝑉𝑝)  method 
(Petoukhov et al., 2012)(Eq.17). 
𝑉𝑝 ≃ 2𝜋
2𝐼0 / ∫ 𝑞
2𝐼(𝑞)𝑑𝑞                                       (17)
∞
0
  
The entire range of momentum vector 𝑞  is used. However, at high 𝑞  angles, the 
scattering intensity falls off and extrapolated by 𝐼(𝑞) ∝ 𝑞−4 relationship by Porod’s 
law. 
The particle volume 𝑉𝑝 is multiply by the ratio between molecular weight and Porod 
volume, which is averaged to 0.625, to get the estimate molecular weight (Eq.18). 
𝑀𝑊 = 𝑉𝑝 ∗ 0.625                                                      (18) 
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To extract more information from the data, scattering profile undergoes a Fourier 
transform to get the pair distribution function 𝑃(𝑟)  in real space. The 𝑃(𝑟) 
distribution function describes the distances between atoms within the protein 
molecule (Eq. 19, Figure 2.14). 
𝐼(𝑞) = ∫ 𝑃(𝑟)
sin(𝑞𝑟)
𝑞𝑟
𝑑𝑟,                                          (19) 
where 𝑟  specifies the spatial distance between scattering points and 𝐼  specifies 
intensity. 
 
The 𝑃(𝑟) represents the distribution of distances between pairs of points contained 
within a particle. The maximum distance or the maximum linear dimension 𝐷𝑚𝑎𝑥can 
be obtained. 𝑃(𝑟)  plot can demonstrate the rough particle shape, for example, 
globular shape particle shows normal distribution profile (Figure 2.14), while 
elongate particle shows left skew and hollow sphere shows right skew profile. 𝑅𝑔 can 
also be calculated from 𝑃(𝑟) as follows: 
𝑅𝑔
2 = ∫ 𝑟2𝑃(𝑟)𝑑𝑟/ ∫ 𝑃(𝑟)𝑑𝑟         
𝐷𝑚𝑎𝑥
0
                      (20)
𝐷𝑚𝑎𝑥
0
 
Figure 2.14 Pair distribution function. 
It is calculated from X-ray scattering data via Fourier transformation.  
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Different from Guinier method which uses the information only at low 𝑞 value, 𝑅𝑔 
from 𝑃(𝑟) uses the entire information, so it can be more accurate. 𝑅𝑔 values from 
both methods are reported for data quality check and they should agree with each 
other. 
Ab initio structural modeling is one of the methods to reconstruct a low-resolution 
model of the proteins, which is monodisperse and assumed to have uniform density. 
The method proceeds by filling up the protein volume with beads. Beads in the model 
are connected to resemble an amino acid chain. The scattering profile of the bead 
model is calculated to compare with experimental SAXS profile. The discrepancy is 
evaluated by 𝜒2 value. Searching for a model which fits the data well is an iterative 
process and does not yield a unique solution. Thus, even though the shape 
restoration program is run with the same data, differences in the reconstructed 
models will arise. In order to overcome this problem, many models given by ab initio 
modeling are averaged together to give a representative model of the protein shape. 
  
 63 
 
Chapter 3 Materials and Methods 
 
The general materials and methods used in this study are described in this chapter. 
The specific materials and methods are in its own chapter. 
3.1 Materials 
3.1.1 Bacterial strains 
For routine cloning, Escherichia coli strain TOP10 was used. For E. coli protein 
expression, three strains, which were BL21(DE3), BL21(DE3)pLysS, and SHuffle®T7, 
were tested for soluble protein production. The SHuffle®T7 cells were kindly provided 
by Dr. Dunhao Su. Bacterial strains and genotypes are indicated in Table 3.1. Cells 
were treated with calcium chloride to generate chemically competent cells (see 
3.2.3). 
Table 3.1 Bacterial strains and its genotype 
Name Strain Genotype 
TOP10 K12 
F- mcrA Δ( mrr-hsdRMS-mcrBC) Φ80lacZΔM15 Δ lacX74 
recA1 araD139 Δ(araleu)7697 galU galK rpsL (StrR) 
endA1 nupG 
BL21(DE3) B fhuA2 [lon] ompT gal (λ DE3) [dcm] ∆hsdS 
BL21(DE3)pLysS B 
F-, ompT, hsdSB (rB–, mB–), dcm, gal, λ(DE3), pLysS, 
Cmr. 
SHuffle® T7 K12 
F´lac, pro, lacIQ / Δ(ara-leu)7697 araD139 fhuA2 
lacZ::T7 gene1 Δ(phoA)PvuII phoR ahpC* galE (or U) 
galK λatt::pNEB3-r1-cDsbC (SpecR, lacIq) ΔtrxB 
rpsL150(StrR) Δgor Δ(malF)3 
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3.1.2 Culture medium 
For routine non-inducing bacterial growth, for example, plasmid amplification, 
transformation, starter culture, colonies selection, glycerol stock and competent cell 
preparation, Miller’s formulation Luria-Bertani (LB) medium was used (Novagen). 
Protein expression in E. coli was conducted using Isopropyl β-D-1-
thiogalactopyranoside (IPTG) induction in LB broth or autoinduction terrific broth 
media without trace elements (AIMTB) (Formedium). The medium was prepared as 
in the product instructions. Homemade autoinduction media (ZYM5052) was 
prepared as following: 1% tryptone, 0.5% yeast extract, 25 mM Na2HPO4, 25 mM 
KH2PO4, 50 mM NH4Cl, 5 mM Na2SO4, 2 mM MgSO4, 0.2× trace elements, 0.5% 
glycerol, 0.05% glucose, 0.2% α-lactose) (Studier, 2014). The media was autoclaved 
at 121°C for 20 minutes before use. The appropriate amount of required antibiotics 
was added to the media for a selectable marker (see Table 3.2 and Table 3.3). 
Table 3.2 Antibiotic concentrations for bacterial selection. 
Antibiotic Working concentration 
Ampicillin 100 µg/ml 
(50 µg/ml, if 2 antibiotics were used in the same culture) 
Chloramphenicol 25 µg/ml 
(20 µg/ml, if 2 antibiotics were used in the same culture) 
Kanamycin 50 µg/ml 
 
3.1.3 DNAs 
Japanese encephalitis virus strain SA14 (accession: M55506) was used as a template 
for recombinant protein construction. Synthetic JEVNS1 DNA (nucleotide residues 
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2478-3533) optimized for E. coli was purchased from Life technologies and synthetic 
native JEVNS1 DNA was provided by OPPF-UK. NS1 gene fragments: N-JEVNS1 
(nucleotide residues 2478-3017), DII-III-JEVNS1 (2538-3533), and C-JEVNS1 (2991-
3533) (Figure 3.1), were generated by polymerase chain reaction (PCR) method using 
primer pairs shown in Table 3.4. Synthetic JEVNS1’ and capsid DNA (1-315) were 
purchased from GenScript (Piscataway, NJ, USA). NS1’ was the special case which the 
full length NS1’ was the NS1 sequence with 156 additional nucleotides. The 
frameshift sequence was manually added by insertion of thymine at position 3561 as 
a result of to -1 ribosomal frameshifting which creates new stop codon at 52 amino 
acids far from NS1 C-terminal (Figure 3.2). DII-III-JEVNS’1 (from residue 2538) and C-
JEVNS1’ (from 2991) (Figure 3.1) were generated from the synthetic JEVNS1’ by using 
PCR method. 
Zika virus (accession: KU365779) was the template for recombinant protein 
construction. Synthetic ZIKVNS1 DNA (residues 2476-3524) and C-ZIKVNS1 (residues 
2989-3524) optimized for E. coli were purchased from GenScript (Piscataway, NJ, 
USA). 
 
Figure 3.1 JEV NS1 gene diagram.  
The diagram shows β-roll, wing and β-ladder domains together with the amino acid 
position of each domain and nucleotide position for each truncation. 
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3.1.4 Vectors 
Synthetic sequences were cloned into expression vectors by the provider service 
(Table 3.3, shaded in gray). After that, if appropriate, the sequences were subcloned 
into new vectors to generate desired constructs. Different secretion signal 
sequences, fusion tags, and gene truncations were constructed as indicated in Table 
3.3. The pOPIN HBM, G, H, HBM-M, HA-M, Ac64-M, and G-M vectors, which used for 
mammalian and insect cell expression provided by OPPF-UK, were cloned with the 2 
version of target genes, none E. coli optimized and optimized JEVNS1. Chaperone 
plasmid set (Takara) for chaperone protein co-expression, which composes of pG-
KJE8, pGro7, pKJE7, pG-Tf2, and pTf16, was kindly provided by Dr. Cristina Yuntayanes 
and Piyapon Jirawatcharadech, Liverpool School of Tropical Medicine. 
Figure 3.2 The -1 ribosomal frameshifting. 
(a) Amino acid sequence of JEVNS1 C-terminal and JEVNS2A N-terminal are shown. 
Wildtype sequence is compared to frameshift sequence. Cleavage sites are indicated 
with arrows. Frameshifted sequences are in the dash box. (b) Repeated translation 
of amino acid thymine is indicated in red causes the translation frame to change and 
generates new amino acids. 
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3.1.5 Primers 
The oligonucleotides used with pOPIN vectors were designed for In-Fusion method, 
while with pET303 vector were designed for ligation method. Primer sequences are 
given in Table 3.4. Cloning site information is shown in Table 3.3. All of the 
oligonucleotides were purchased from Thermo Fisher Scientific except for the 
oligonucleotides used with pOPIN HBM-M, HA-M, Ac64-M, G-M, H, HBM, and G were 
provided by OPPF-UK. See Table 3.5 for cycling conditions used for each primer pair. 
3.1.6 Antibodies 
Peroxidase conjugated mouse anti-histidine monoclonal antibody (Roche, 
AB_840259) was used to detect recombinant histidine-tagged proteins. The 
experiments conducted at OPPF were routinely detected by the unconjugated mouse 
anti-histidine monoclonal antibody (R&D, AB_357353). Mouse monoclonal antibody 
against WNV NS1 (22NS1) was provided by Dr. Michael Diamond. Peroxidase 
conjugated goat anti-mouse IgG (Santa Cruz Biotechnology, AB_631738) provided by 
Sujitra Keadsanti was used to detect the 22NS1 antibody. 
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Table 3.3 Vector construction of the interested genes used in this study 
No. Vector  
Inserted 
gene 
Cloning 
sites 
SS/Tags 
Antibiotic 
resistance 
1 pRSET_A_A185 JEVNS1 BamHI/KpnI N-HIS amp 
2 pOPIN M JEVNS1 kpnI/HindIII N-HIS-MBP-3C amp 
3 pOPIN S JEVNS1 kpnI/HindIII N-HIS-SUMO-3C amp 
4 pOPIN J JEVNS1 kpnI/HindIII N-HIS-GST-3C amp 
5 pOPIN HBM JEVNS1a kpnI/HindIII HBM/C-HIS amp 
6 pOPIN G JEVNS1a kpnI/HindIII uPase/C-HIS amp 
7 pOPIN H JEVNS1a kpnI/HindIII uPase/N-HIS-3c amp 
8 pOPIN HBM-M JEVNS1a 
kpnI/HindIII 
HBM/N-HIS-
MBP-3C 
amp 
9 pOPIN HA-M JEVNS1a 
kpnI/HindIII 
HA/N-HIS-MBP-
3C 
amp 
10 pOPIN Ac64-M JEVNS1a 
kpnI/HindIII 
Ac64/N-HIS-
MBP-3C 
amp 
11 pOPIN G-M JEVNS1a 
kpnI/HindIII 
uPase/N-HIS-
MBP-3C 
amp 
12 pOPINTTGneo JEVNS1a  RPTPmu/C-HIS amp 
13 pET303 C-JEVNS1 XbaI/XhoI - amp 
14 pOPIN F C-JEVNS1 kpnI/HindIII N-HIS amp 
15 pET303 N-JEVNS1 XbaI/XhoI - amp 
16 
pET303 
DII-III-
JEVNS1 
XbaI/XhoI - amp 
17 pET-30a(+) JEVNS1’ NdeI/XhoI - kan 
18 pET303 C-JEVNS1’ XbaI/XhoI - amp 
19 
pET303 
DII-III-
JEVNS1’ 
XbaI/XhoI - amp 
20 pET-30a(+) JEVcapsid BamHI/XhoI N-HIS-S tag-E kan 
21 pET-15b ZIKVNS1 NdeI/BlpI N-HIS-TEV amp 
22 pET-15b C-ZIKVNS1 NdeI/BlpI N-HIS-TEV amp 
 
Notes: a = both of none E. coli optimized and E. coli optimized gene were tested with the 
plasmid. 
SS = signal sequence, N = N-terminal tag C = C-terminal tag, amp = ampicillin, kan = 
kanamycin, HIS = histidine tag, MBP = Maltose binding protein, GST = glutathione S-
transferase, HA = hemagglutinin, HBM = honeybee melittin, SUMO = small ubiquitin-like 
modifier, uPase = uridine phosphorylase, S tag = pancreatic ribonueclease A, Ac64 = 
Autographa californica evelope protein gp64, Cleavage sites: 3C = human rhinovirus (HRV) 3C 
Protease, TEV = tobacco etch virus protease, E = enterokinase, RPTPmu = receptor-like 
protein-tyrosine phosphatase
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Table 3.4 Primers used for subcloning of JEVNS1 N-terminal, C-terminal and domain 
II-III. 
Note: Lowercase characters indicate vector sequences and uppercase characters indicate 
gene sequences. 
PCR 
cycle 
Plasmid/ gene Sequence 
1 
pOPIN M, J, S 
optimized 
JEVNS1 
Fw 5’aagttctgtttcagggcccgGATACCGGTTGTGCCATTGAT 
ATT 
Rv 5’atggtctagaaagctttaTGCATCAACCTGGCTACGAACCAG 
2 
pOPIN HBM-M, HA-M, Ac64-M, G-M, H 
optimized 
JEVNS1 
Fw 
5’aagttctgtttcagggcccgGATACCGGTTGTGCCATTGATAT 
TACCCG 
Rv 5’atggtctagaaagctttaTGCATCAACCTGGCTACGAACCAG 
GG 
2 
pOPIN HBM 
optimized 
JEVNS1 
Fw 
5’tcttacatctatgcgGATACCGGTTGTGCCATTGATATTACC 
CG 
Rv 5’gtgatggtgatgtttTGCATCAACCTGGCTACGAACCAGGG 
Native JEVNS1 
Fw 
5’tcttacatctatgcgGACACTGGATGTGCCATTGACATCACA 
AG 
Rv 5’ 
gtgatggtgatgtttAGCATCAACCTGTGATCTGACGAGTGT TG 
2 
pOPIN G 
optimized 
JEVNS1 
Fw 5’gcgtagctgaaaccggcGATACCGGTTGTGCCATTGATATT 
ACCCG 
Rv 5’gtgatggtgatgtttTGCATCAACCTGGCTACGAACCAGGG 
Native JEVNS1 
Fw 
5’gcgtagctgaaaccggcGACACTGGATGTGCCATTGACATC 
ACAAG 
Rv 5’gtgatggtgatgtttAGCATCAACCTGTGATCTGACGAGTG 
TTG 
3 
pET303 
optimized C-
JEVNS1 
FW5’gctctagaatgCGTGAAGAAAGCACCGATGAATGTGAT 
RW5’ccgctcgagTTATGCATCAACCTGGCTACGAACCAG 
optimized N-
JEVNS1 
Fw5'gctctagaatgGATACCGGTTGTGCCATTGATATTACC 
Rw5'ccgctcgagttaATCACATTCATCGGTGCTTTCTTCACG 
optimized DII-
III JEVNS1 
Fw5'gctctagaatgGTGCATAATGATGTTGAAGCATGGGTG 
Rw5'ccgctcgagTTATGCATCAACCTGGCTACGAACCAG 
optimized C-
JEVNS1’ 
FW5’gctctagaatgCGTGAAGAAAGCACCGATGAATGTGAT 
Rw5'ccgctcgagTTAATGCAGATGATAACCCCATGCATctg 
 optimized DII-
III JEVNS1’ 
Fw5'gctctagaatgGTGCATAATGATGTTGAAGCATGGGTG 
 Rw5'ccgctcgagTTAATGCAGATGATAACCCCATGCATctg 
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3.2 Methods 
3.2.1 Polymerase chain reaction (PCR) 
Replication of DNA template was performed by using KOD Hot Start DNA polymerase 
(Merck Millipore) or CloneAmp HiFi PCR Premix (Clontech). The reaction was set up 
following the product instructions with the final concentration of template DNA ~10 
ng. Cycling conditions were set up as in Table 3.5 using Techne TC-PLUS thermal 
cyclers. See Table 3.5 to match the cycling conditions with the primers in Table 3.4. 
If appropriate, PCR products were purified using Wizard® SV Gel and PCR Clean-up 
System (Promega). 
Table 3.5 PCR reaction setup. 
Step 
PCR cycle 1 
KOD Hot Start 
PCR cycle 2 
KOD Hot Start 
PCR cycle 3 
CloneAmp HiFi 
1.Polymerase activation 95°C 2 min 95°C 2 min  
2.Denature 95°C 20 sec 95°C 20 sec 98°C 10 sec 
3.Annealing 65°C 10 sec 70°C 10 sec 55°C 15 sec 
4.Extension 70°C 40 sec 70°C 40 sec 72°C 5 sec 
5.Final extension 70°C 10 min 70°C 10 min  
Repeat steps 2-4 35 cycles 30 cycles 35 cycles 
 
3.2.2 Agarose gel electrophoresis 
DNA fragments were separated and analysed by agarose gel electrophoresis. Low 
melting point agarose was dissolved in 1x Tris-acetate-EDTA (TAE) buffer (40 mM Tris, 
20 mM acetic acid, 1 mM ethylenediaminetetraacetic acid (EDTA)), which prepared 
from 10x stock, to achieve 1% agarose gel with Midori green DNA stain (Bulldog Bio) 
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at the concentration of 6 µl/100 ml. DNA samples or 0.5 µg of 1 kb DNA ladder (New 
England Biolabs, N3232S) were mixed with 6x purple loading dye (New England 
Biolabs, B7025S) at 5:1 ratio DNA to dye. Electrophoresis was run in 1x TAE buffer at 
120 volts constant until the dye reached the bottom of the gel. 
3.2.3 Chemically competent cells 
To make chemically competent cells, each step was done with aseptic technique. 
Desire E. coli strain was recovered from glycerol stock by streaking on LB agar plate 
which contains appropriate antibiotics, if necessary, and incubating overnight at 37°C 
(12-16 hours). A colony was inoculated into 5 ml of LB broth with appropriate 
antibiotics and incubated at 37°C overnight to make an overnight culture. Cells were 
transferred to 500 ml LB broth with appropriate antibiotics and allowed to grow at 
37°C until OD600 reached 0.4. Cells were placed on ice for 20 minutes and kept cold 
throughout the procedure. Cells were pelleted at 3000xg for 10 min, resuspended in 
30 ml of cold 0.1 M CaCl2, and incubated on ice for 30 min. Cells were pelleted again 
and resuspended in 8 ml of cold 0.1 M CaCl2 and 15% glycerol. Cells were aliquot into 
1.5 ml tubes, freeze in liquid nitrogen and stored at -80°C. 
3.2.4 Plasmid extraction 
Five ml of overnight culture of E. coli that contain plasmid of interest was prepared. 
Plasmids were extracted by using Wizard® Plus SV Minipreps DNA Purification System 
(Promega) or Qiagen miniprep following the product instructions. 
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3.2.5 Cloning 
In-fusion cloning 
The primer used for infusion cloning was designed by the 5´ end was the 15 bases of 
one end of the vector sequences at the restriction site that the DNA fragment will be 
joined. Second part at 3´ end was the sequence which specific to target DNA, size 
about 18-25 bases, and contained 40-60% GC content. pOPIN vector was double 
digested using HindIII and KpnI restriction enzymes (New England Biolabs) at 37°C 
overnight. Cloning steps were followed the In-fusion HD Enzyme Premix protocol 
(Clontech Laboratories). Briefly, in 10 µl reaction, In-fusion enzyme (1x), linearized 
vector (~50 ng), DNA fragment PCR product (~50 ng), and deionized water were 
mixed together and incubated at 50°C for 15 min. Then the reaction was placed on 
ice and continued to the transformation experiment. 
Ligation cloning 
The primer used for ligation cloning was designed to contain restriction site at their 
5’ end. pET303 vector and DNA fragment PCR product were double-digested with 
XbaI and XhoI restriction enzymes (New England Biolabs) to create sticky ends at 37°C 
overnight and heat inactivated at 65°C for 20 min. Phosphorylated end of the cut 
vector was removed by incubated at 37°C for 15 minutes with Antarctic phosphatase 
(New England Biolabs) at 1 u/µg DNA and heat inactivated at 70°C for 5 min. The cut 
vector was purified with Wizard® SV Gel and PCR Clean-up System (Promega). The 
ligation reaction was set up by mixing of 1:3 vector to insert (usually 0.02:0.06 pmol) 
with T4 DNA ligase at the concentration of 20 u/ul (New England Biolabs). The 
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reaction was incubated overnight at 4°C and heat inactivated at 65°C for 10 min. Then 
the reaction was placed on ice and continued to the transformation experiment. 
3.2.6 Bacterial transformation 
Competent cells were thawed on ice. As soon as the cells were completely thawed, 2 
µl (~5 ng) of interested plasmid was added to each 50 µl reaction and mixed well by 
gently flicking the bottom of the tube a few times with a finger. After that, the mixture 
was incubated on ice for 20 minutes and heat shocked in 42°C water bath for 42 sec. 
Then the mixture was placed on ice for 5 minutes and 200 µl of LB media was added. 
Next, the cells were allowed to grow at 37°C for 45 min. All of the transformation 
reaction was plated onto 10 cm LB agar plate which contains appropriate antibiotics. 
Competent cells alone without plasmid were treated with the same procedure and 
used as negative control. Agar plates were incubated at 37°C for 12-16 hours. Plates 
containing colonies were kept at 4°C until use, but no longer than a month. 
3.2.7 DNA sequencing 
DNA sequencing experiments were performed by supreme Sanger sequencing 
service, GATC Biotech. The concentration of isolated plasmids from miniprep kit was 
measured using NanoDrop® ND-1000 (Thermo Scientific). The samples were 
prepared at concentration and volume according to supreme Sanger sequencing 
service requirements (30-100 ng/µl, 20 µl). Universal primers, T7 and pET RP, were 
used as sense and antisense primer, respectively. 
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3.2.8 Protein expression 
Bacterial expression 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) induction 
Five ml of E. coli overnight culture that contains interested plasmid was prepared and 
transferred to 500 ml of LB broth with appropriate antibiotics. After incubation at 
37°C for 2-3 hours or until OD600 reach ~0.5, IPTG was added at the concentration of 
0.5 M or 1 M and the temperature was changed to the appropriate temperature for 
protein expression. Cells were allowed to grow for 12-16 hour overnight and pelleted 
by centrifugation at 4500xg, 8°C for 20 min. 
Autoinduction 
Cells were prepared similarly to IPTG induction method. Instead of LB broth, cells 
were transferred to AIMTB or ZYM5052 with appropriate antibiotics. Cells were 
allowed to grow for 2-3 hours at 37°C and the temperature was changed to the 
appropriate temperature to express the protein for 12-16 hour overnight. Expression 
at 16°C and 18°C were conducted for 24 hr. No IPTG was added. 
3.2.9 Protein purification 
Lysis buffer screening 
After protein was expressed, 100 µl of the culture was aliquoted into 1.5 ml tube and 
centrifuged at 5000xg, 8°C for 10 min. Cell pellets were resuspended in 4 different 
initial lysis buffers as indicated in Table 3.6 (Perry, 2016) and incubated at room 
temperature for 30 min. Cells were briefly vertex before quickly frozen in liquid 
nitrogen and thawed in a water bath at 42°C. The freeze-thaw cycle was repeated for 
5 times. Cells were centrifuged at 16000xg, 8°C for 10 minutes to separate 
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supernatant, which contains soluble protein, and pellet, which contain insoluble 
protein. Supernatant and pellet were analysed separately by sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). The result was followed by 
another set of lysis buffer screen which could be pH, salt, urea, or detergents 
solubility screen depend on the result from the initial screen. In this study, only salt 
solubility screen was used (see Table 3.7). After the suitable buffer was found, the 
experiment was scaled up proportionally to the amount of pellet for routine protein 
purification (at least 1:4 pellet to buffer). 
Table 3.6 Lysis buffer screen. 
Name Buffer 
7.5N 50 mM Tris pH 7.5, 50 mM NaCl, 5 mM EDTA, 1 mg/ml lysozyme 
2S 50 mM Tris pH 7.5, 2 M NaCl, 5 mM EDTA, 1 mg/ml lysozyme 
0.5U 50 mM Tris pH 7.5, 50 mM NaCl, 5 mM EDTA, 0.5 M urea, 1 mg/ml 
lysozyme 
D 20 mM Tris pH 7.5, 50 mM NaCl, 0.2% NP 40, 1 mg/ml lysozyme 
 
Table 3.7 Salt solubility screen 
Name Buffer 
0.1S 50 mM Tris pH 7.5, 0.1 M NaCl, 5 mM EDTA, 1 mg/ml lysozyme 
0.5S 50 mM Tris pH 7.5, 0.5 M NaCl, 5 mM EDTA, 1 mg/ml lysozyme 
1S 50 mM Tris pH 7.5, 1 M NaCl, 5 mM EDTA, 1 mg/ml lysozyme 
0.1K 50 mM Tris pH 7.5, 0.1 M KCl, 5 mM EDTA, 1 mg/ml lysozyme 
1K 50 mM Tris pH 7.5, 1 M KCl, 5 mM EDTA, 1 mg/ml lysozyme 
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Protein isolation 
For routine protein purification, cells from 1 L culture were pelleted in appropriate 
lysis buffer (20mM Tris·HCl pH 7.4, 150 mM NaCl, and 1 mg/mL lysozyme). Cells were 
incubated at room temperature for 30 minutes before sonicated on ice with 9.5 mm 
probe at amplitude 10 for 30 seconds with 30 seconds interval on ice for 10 times. 
Then, cells were spun down at 17000xg, 4°C for 20 min. The supernatant and pellet 
fractions were analysed by SDS-PAGE and Coomassie staining. If target protein is 
insoluble, the pellet will further use for protein refolding or stored at-80°C until use. 
If protein is soluble, suspension fraction is further purified. 
JEV NS1 insoluble protein refolding, and purification 
Modified Edelling’s method 
Protein was expressed by auto-induction and insoluble protein pellet was isolated 
and resuspended in resolubilization buffer (7 M guanidine hydrochloride (Gnd·HCl), 
30 mM β-mercaptoethanol (β2ME)) for 1 hour at 37°C at 1:10 pellet to buffer. Then 
centrifuged at 16000xg for 10 minutes at 8°C to remove undissolved protein, and 
diluted with 50 mM sodium acetate pH 5.2 to reduce Gnd·HCl concentration to 2 M. 
The sample was filtered with 0.45 micron filter and refolded by adding 10 ml of 
denatured protein at 1 ml/hr to 1 L of 400 mM L-arginine, 100 mM Tris, pH 8.3, 2 mM 
EDTA, 0.5 mM oxidized glutathione (GSSH), 5 mM reduced glutathione (GSH), 0.2 mM 
phenylmethanesulfonyl fluoride (PMSF) at 4°C. After overnight incubation, the 
refolded protein was filtered with 0.2 µm filter and concentrated with Amicon stirred 
cell using PL-10 membrane and 10000 Da molecular weight cut-off (MWCO) 
centrifuge concentrator. NS1 protein was subjected to Superpose 6 10x300 mm or 
Superdex 200 10x300 mm size-exclusion chromatography column (GE Healthcare Life 
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Science) equilibrated with 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) pH 7.4, 150 mM NaCl. 
Protein quantification 
Protein concentration was determined by the bicinchoninic acid assay (BCA assay) 
following the product protocol (Pierce™ BCA Protein Assay Kit) or UV absorbance at 
280 nm by using NanoDrop® ND-1000 (Thermo Scientific). After obtained the 
absorbance value, protein concentration was calculated from Beer’s law: 
𝐴 = 𝜀 ∗ 𝑏 ∗ 𝑐, 
where A is the absorbance value, 𝜀 is extinction coefficient, b is container path length, 
and c is protein concentration in molarity. 
3.2.10 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE) 
Protein yield and purity were examined by SDS-PAGE in Laemmli buffer system. 
Protein was separated by 4% (stacking gel) and 12% polyacrylamide gel (resolving gel) 
at 0.75 or 1.0 mm thickness. See gel recipes in Table 3.8. Samples were mixed with 
4x sample buffer (277.8 mM Tris-HCl pH 6.5, 44.4% (v/v) glycerol, 4.4 % SDS, 0.02% 
(w/v) bromophenol blue) supplemented with 355 mM β2ME (100 µl in 900 µl 4x 
sample buffer) at 3:1 sample to buffer ratio and heated at 95°C for 5 min. Samples 
with a high concentration of Gnd·HCl were precipitated with ethanol prior mixing 
with sample buffer. Briefly, samples were mixed with chill absolute ethanol at 1:40 
ratio sample to ethanol and incubated at -80°C for 20 minutes to 1 hour. Then the 
samples were centrifuged at 16000xg for 5 minutes at 8°C to separate the 
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precipitated protein. Ethanol was discarded and protein pellet was air dried in the 
tube with the lid open for 10 minutes. The samples were then mixed with 50 µl of 1x 
sample buffer and heated normally. Protein standard (New England Biolabs, P7712 
or PageRuler, 26616) was used to determine the protein size. Electrophoresis was 
conducted at 200 volts constant in 1x electrode buffer (25 mM Tris-base, 200 mM 
glycine, 1% (w/v) SDS) until the dye reaches the bottom of the gel by using Mini-
PROTEAN®3 Cell electrophoresis system (BIO-RAD). The gel was subjected to Western 
blot or Coomassie staining. For Coomassie staining, the gel was stained in 0.1% (w/v) 
Coomassie Brilliant Blue R-250, 40 % (v/v) methanol and 10 % (v/v) glacial acetic acid 
for 20 minutes or until the gel was stained consistency blue and sample dye cannot 
be seen. Then gel was destained in 40 % (v/v) methanol 10 % (v/v) glacial acid solution 
until the background was clear. 
Table 3.8 Gel formulations (10 ml) 
12% Resolving gel  4% Stacking gel 
10% (w/v) SDS 100 µl 10% (w/v) SDS 100 µl 
Gel buffer (1.5 M Tris, pH 8.8) 2.5 ml Gel buffer (0.5 M Tris, pH 6.8) 2.5 ml 
Water 3.3 ml Water 6 ml 
30% Acrylamide/Bis 4 ml 30% Acrylamide/Bis 1.3 ml 
10% APS 100 µl 10% APS 100 µl 
TEMED 10 µl TEMED 10 µl 
3.2.11 Western blot 
After protein samples were resolved on polyacrylamide gels, the protein was 
transferred to Immobilon®-P membrane (Merck Millipore) by electro-tank transfer 
(Mini Trans-Blot® cell wet electroblotting systems, BIO-RAD) or dry transfer method 
 79 
 
by using iBlot® 2 Gel Transfer Device (Thermo Fisher Scientific). Protein was 
transferred according to transfer apparatus manufacturer’s instructions. For a tank 
transfer, gels were transferred in transfer buffer (25 mM Tris, pH 8.3, 192 mM glycine, 
20% methanol) at constant 400 mA for 1 hour with the cooling unit. For dry transfer, 
iBlot® 2 Transfer Stacks PVDF was used with P0 default method (7 min). After that, 
the membrane was incubated in blocking buffer (5% (w/v) non-fat dried milk, 20 mM 
Tris pH 7.6, 150 mM NaCl, 0.1% Tween 20) for 30 min. Next, the membrane was 
incubated with primary antibody (in blocking buffer) for 1.5 hours and washed with 
20 mM Tris pH 7.6, 150 mM NaCl, 0.1% Tween 20 for 5 minutes 3 times. After that, 
the membrane was repeated with the incubation and washing steps with secondary 
antibody (these steps were omitted if using peroxidase conjugated anti-histidine 
antibody). Amersham ECL start (GE Healthcare Life Science), a chemiluminescent 
detection reagent, was used and the result was analysed by ImageQuant LAS 4000 
(GE Healthcare Life Science). See antibodies used in this study in section 3.1.6. 
3.2.12 Crystallization and data collection 
The proteins were concentrated and screened using commercial crystallization 
screens. The SaltRx, PEGRx, and Natrix screens from Hampton research, and 
Structure, PACT premier, and JCSG screens from Molecular Dimension were used on 
crystallization robot (SCREENMAKER 96+8, Innovadyne/Gilson) by adding 200 nl of 
protein and 200 nl of reservoir solution to drop well of Intelli-Plate 96 sitting drop 
crystallization. All positive conditions are listed in Appendix 3. Successful conditions 
were optimized by hanging drop method in 24 (500 µl reservoir) or 48 wells plate 
(200 µl reservoir). 
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X-ray data were collected at a cryogenic temperature at beamline I24 or I02 at 
Diamond Light Source, UK and PROXIMA 1 at Soleil synchrotron, France. Data 
reduction was carried out by iMosflm (Battye et al., 2011) (C-JEVNS1), XDS (Kabsch, 
2010) (C-JEVNS1’) or Xia2 programs (Winter, 2010) (JEV capsid). The C-JEVNS1 and C-
JEVNS1’ protein structures were determined by molecular replacement using the 
structure of WNV NS1 C-terminal domain (PDB: 4OIE, >70% sequence identity) as a 
starting model by MOLREP (Vagin and Teplyakov, 2010) in the CCP4 program suite as 
well as capsid protein which WNV capsid protein (PDB: 1SFK, 68% sequence identity) 
was a starting model. For capsid protein, the automated model building was 
performed by Buccaneer (Cowtan, 2006). The structures were refined by REFMAC5 
(Murshudov et al., 2011) and built in COOT (Emsley et al., 2010) in CCP4. 
3.2.13 Small-angle X-ray scattering (SAXS) 
The purified C-JEVNS1 1st peak (2.4 mg/ml), C-JEVNS1 2st peak (3.4 mg/ml), C-JEVNS1’ 
1st peak (5 mg/ml), C-JEVNS1’ 2nd peak (5 mg/ml) (see Chapter 5), and C-JEVNS1-
22NS1 complex (3 mg/ml) (see chapter 6) in TBS buffer (20 mM Tris-HCl pH 7.4, 150 
mM NaCl) were analysed with SEC-SAXS on beamline SWING at Soleil synchrotron, 
France. Samples were load onto Agilent BioSEC-3 4.6x300 mm column at flow rate of 
0.25 ml/min, 15°C. Data were collected at a distance of 1.8 m and X-ray wavelength 
of 1 Å. Data were collected by Dr. Gareth Wright. Data processing was conducted in 
PRIMUS (Konarev et al., 2003). Comparison of scattering profile was done in FoXS 
(Schneidman-Duhovny et al., 2013). Ab initio model was the average from 10 (C-
JEVNS1 and C-JEVNS1’) or 20 (protein complex) independently model calculations 
with (protein complex) or without symmetry (C-JEVNS1 and C-JEVNS1’) using 
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DAMMIF (Franke and Svergun, 2009). The model was average with DAMAVER (Volkov 
and Svergun, 2003) and refine with DAMMIN (Svergun, 1999). The low resolution 
model surface representation was created in CHIMERA (Pettersen et al., 2004) using 
‘molmap’ command. The molecular mass was calculated from Porod volume 
(Petoukhov et al., 2012). 
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Chapter 4 JEV NS1 and NS1’ protein expression 
and purification trials 
 
Flavivirus NS1 protein has been studied for more than 30 years, but recombinant 
soluble protein has never been successfully produced from a bacterial expression 
system. The expression has been reported from insect and mammalian cells 
expression systems in the 1990s (Flamand et al., 1992, Falgout et al., 1989). Later 
with different vector constructions, expression of flavivirus NS1 protein in 
baculovirus and mammalian cell expression systems have been widely used in many 
studies to produce recombinant NS1 for protein characterization and functional 
study (Flamand et al., 1995, Brown et al., 2011, Falgout et al., 1989, Flamand et al., 
1992, Noisakran et al., 2008, Avirutnan et al., 2010, Avirutnan et al., 2011, Somnuke 
et al., 2011). In 2014, WNV and DENV full length NS1 protein X-ray structures were 
presented for the first time (Akey et al., 2014, Edeling et al., 2014). The proteins were 
produced by insect cells according to the previously described study of Brown, 2011 
(Brown et al., 2011). 
In this study, JEV NS1 expression was attempted in bacterial cells using both 
engineering and non-engineering of the gene strategies. Gene engineering strategies 
were including E. coli codon optimization, fusion tags, and expression of protein 
fragments. Non-engineering strategies were the testing of various culture 
temperature, medium, E. coli strains, and chaperone protein co-expression. 
Moreover, refolding from inclusion body was also tested. 
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Parallel to E. coli expression, JEV NS1 was expressed in mammalian and insect cell 
systems since the protein is glycosylated and both cells are the natural host of the 
virus. The protein produced from these systems should resemble natural NS1 and 
reveal its native characteristics and functions. The protein production trial was 
conducted at OPPF-UK. The vector construction for insect cell expression was 
designed followed Brown, 2011 study. 
4.1 Materials and methods 
4.1.1 Comparison of percentage identity of NS1 sequence 
Virus strain was chosen to use in this project by comparing of NS1 amino acid 
sequences of JEV genotype 1 to 5 and other flaviviruses taken from NCBI database. 
Five of genotype III, which are common and widely spreads strain, and 1 of each 
genotype II-V were used to represent each genotype. Percentage identity was 
obtained by using the local alignment search tool (BLAST), the National Center for 
Biotechnology Information (NCBI) with two strains aligned at a time. Moreover, JEV 
NS1 sequences were compared to WNV lineage 1, WNV lineage 2, Murray, Kunjin, St 
Louis, Usutu, Alfuy, DengueT1, DengueT2, DengueT3, DengueT4, TBE, YFV, and ZIKV. 
Percent identity was depicted in (Table 4.1). 
 
 84 
 
Table 4.1 Percentage identity of NS1 amino acid sequences compared within Flavivirus genus 
Flavivirus 
NCBI 
accession 
number 
JEV strain 
Genotype III 
Genotype 
IV 
Genotype 
I 
Genotype 
V 
Genotype 
II 
JEV SA 14-
14-2 
JEV SA 
14 
JEV 
P3 
JEV 
Nakayama 
JEV 
NC_001437 
JEV 
JKT6468 
JEV 
K94P05 
JEV 
MUAR 
JEV FU 
JEV SA 14-14-2 AF315119          
JEV SA 14 M55506 99%         
JEV Beijing L48961 98% 98%        
JEV P3 U47032 99% 99%        
JEV Nakayama EF571853 99% 99% 99%       
JEV NC_001437 NC_001437 99% 99% 100% 99%      
JEV JKT6468 AY184212 94% 95% 96% 95% 95%     
JEV K94P05 AF045551 95% 95% 95% 96% 96% 93%    
JEV MUAR HM596272 91% 91% 91% 92% 91% 92% 89%   
JEV FU AF217620 95% 96% 97% 96% 97% 92% 95% 91%  
WNV lineage 1 NC_009942 77% 77% 78% 78% 78% 77% 77% 78% 78% 
WNV lineage 2 NC_001563 76% 76% 77% 77% 77% 76% 76% 77% 77% 
Murray NC_000943 78% 78% 78% 78% 78% 79% 78% 81% 79% 
Kunjin AY274504 76% 76% 77% 76% 77% 75% 76% 76% 77% 
St Louis JF460774 64% 64% 65% 65% 65% 65% 64% 66% 64% 
Usutu NC_006551 76% 76% 76% 77% 76% 77% 75% 78% 77% 
Alfuy AY898809 78% 77% 78% 78% 78% 78% 76% 81% 78% 
DengueT1 U88535 51% 51% 51% 51% 51% 51% 50% 52% 51% 
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Flavivirus 
NCBI 
accession 
number 
JEV strain 
Genotype III 
Genotype 
IV 
Genotype 
I 
Genotype 
V 
Genotype 
II 
JEV SA 14-
14-2 
JEV SA 
14 
JEV 
P3 
JEV 
Nakayama 
JEV 
NC_001437 
JEV 
JKT6468 
JEV 
K94P05 
JEV 
MUAR 
JEV FU 
DengueT2 M29095 53% 53% 53% 53% 53% 54% 53% 54% 53% 
DengueT3 EF643017 51% 51% 51% 51% 51% 50% 51% 52% 52% 
DengueT4 AF326573 52% 52% 53% 53% 53% 51% 51% 53% 53% 
TBE NC_001672 44% 44% 44% 44% 44% 44% 44% 44% 44% 
YFV NC_002031 46% 46% 46% 46% 46% 46% 47% 47% 46% 
ZIKV KU365779 56% 56% 57% 57% 57% 56% 57% 57% 56% 
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4.1.2 Plasmid construction 
Synthetic JEVNS1 DNA optimized for E. coli in the pRSET_A_A185 vector was used for 
JEVNS1 full length expression. The JEVNS1 full length was subcloned into pOPIN M, J 
and S vectors to produce JEVNS1 with MBP, GST, and SUMO fusion tags, respectively. 
NS1 gene fragments, N-JEVNS1, DII-III-JEVNS1, and C-JEVNS1, were generated from 
the full length template by PCR method. 
Synthetic JEVNS1’ in pET-30a(+) was used for JEVNS1’ full length expression. DII-III-
JEVNS1’, and C-JEVNS1’ were generated from JEVNS1’ full length. All the truncated 
DNA fragments were cloned into a pET303 vector. 
For mammalian and insect cell expression, the experiments were divided into 2 sets 
by the inserted DNA. The first was the synthetic JEVNS1 DNA optimized for E. coli and 
the second was the synthetic native JEVNS1 DNA, which was provided by OPPF-UK. 
Both were cloned into pOPIN HBM, G, H, HBM-M, HA-M, Ac64-M, and G-M vectors. 
pOPINTTGneo was used later instead of pOPIN G for native DNA expression in 
mammalian cells expression for a better yield. The cloning step (except for 
pOPINTTGneo) was done in Liverpool with the guidance of Dr. Louise Bird, OPPF-UK.
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4.1.3 Protein expression and purification trials 
All of the trial conditions were summarised in Table 4.2. 
JEVNS1 full length with histidine tag 
JEVNS1 was expressed in E. coli BL21(DE3)PLysS by IPTG induction in LB media at 30°C 
and 18°C. The protein was also expressed in E. coli BL21(DE3) at 30°C and SHuffle® T7 
by autoinduction in AIMTB at 25°C, 30°C, and 37°C. Cells were pelleted and 
resuspended in lysis buffer. Protein was isolated. The supernatant and pellet fractions 
were analysed by SDS-PAGE and Coomassie staining. 
JEVNS1 full length with fusion tags 
The JEVNS1 with MBP, GST, and SUMO tags were expressed in E. coli BL21(DE3)PLysS 
at 30°C and 18°C by IPTG induction in LB media and SHuffle® T7 at 37°C by 
autoinduction in AIMTB. Protein was isolated and analysed by SDS-PAGE and 
Coomassie staining. 
Truncated JEVNS1, full length JEVNS1’ and its truncations 
C-JEVNS1 was expressed by autoinduction in AIMTB in E. coli BL21(DE3) at 16°C, 25°C, 
30°C, and 37°C and expressed in SHuffle® T7 at 25°C, 30°C, and 37°C. N-JEVNS1, DII-
III-JEVNS1, JEVNS1’, DII-III-JEVNS1’, and C-JEVNS1’ were expressed in E. coli 
BL21(DE3) by AIMTB at 18°C, 30°C, and 37°C. Protein was analysed by initial lysis 
buffer screening, SDS-PAGE, and Coomassie staining. 
Chaperone proteins co-expression 
Full length NS1 with different fusion proteins, MBP, SUMO, GST, and HIS, and NS1 C-
terminus were co-expressed with bacteria chaperone protein vectors, pG-KJE8, 
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pGro7, pKJE7, pTf16, and pG-Tf2 (TaKaRa chaperone plasmid set, cat.#3340). First, 
each chaperone protein vector that contains different chaperone proteins (see Table 
4.3) was transformed into E.coli BL21(DE3), and/or K12 Shuffle T7. The selection 
medium was supplemented with 20 µg/ml chloramphenicol as all of the vectors 
resistance to. Then the competent cells were prepared as explained in section 3.2.3. 
After that, the competent cells were retransform with the interested plasmids. Cells 
were grown in ZYM5052 media (Studier, 2014) containing appropriate induction 
compounds (see Table 4.3) at 16°C, 25°C, 30°C, and 37°C for protein expression. 
Protein was isolated and analysed by SDS-PAGE and Coomassie staining. 
Mammalian cell expression 
The experiment was conducted at OPPF-UK and followed OPPF-UK mammalian 
expression standard protocols. Human embryonic kidney cell line (HEK 239T) was 
used and cultured in Dulbecco's modified Eagle medium (DMEM) supplemented with 
non-essential amino acids, 2 mM L-glutamine, and fetal calf serum at required 
concentration. In brief, HEK 239T was transiently transfected by using GeneJuice® 
transfection reagent (Novagen) with 1 µl vector DNA (vector construct 5-11, Table 
3.3), which prepared by using PureLink® HiPure Plasmid Megaprep Kit (Invitrogen), 
at 2.66:1 ratio of GeneJuice to DNA (w/w) per 1 ml culture media. Transfection 
reaction was incubated for 3 days at 37°C. Kifunensine at concentration 1 mg/L was 
presented during protein expression. Cell supernatant (media) was collected, and 
cells were lysed by freeze-thaw method and were centrifuged to remove cell debris. 
Then cell supernatant and cells were analysed separately to indicate secreted 
products and intracellular soluble products, respectively, on SDS-PAGE. The 
expression was analysed by the anti-histidine Western blot. For large scale 
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purification, crude protein was purified by Ni-NTA column (His Trap FF, GE 
Healthcare) and followed with HiLoad Superdex 200 16x600 mm column (GE 
Healthcare). The experiments were conducted by Dr. Joanne Nattleship and Dr. Nahid 
Raman-huq. 
Insect cell expression 
The experiment was conducted at OPPF-UK and followed OPPF-UK Baculovirus 
expression standard protocols. Spodoptera frugiperda (Sf9) cells were cultured in Sf-
900™ II serum free medium (Invitrogen). Bacmid was prepared by using BacMax kit 
(Cambio) and linearized by Bsu36I restriction enzyme (New England Biolabs). Bacmid 
with target DNA (vector construct 5-11, Table 3.3) was transfected into Sf9 cells by 
using FuGENE® HD transfection reagent (Roche). Transfection reaction was incubated 
for 5-6 days at 27°C and then P0 viruses were harvested. Sf9 cells were infected with 
the P0 viruses to obtain P1 viruses. Protein expression screening was conducted by 
infection of the P1 viruses to Sf9 cells and incubated for 3 days at 27°C. Intracellular 
soluble protein was analysed by Ni-NTA affinity beads and followed by Western blot 
against histidine. The experiments were conducted by Dr. Joanne Nattleship and Dr. 
Nahid Raman-huq. 
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Table 4.2 Protein expression trial conditions. 
Protein construct Strain Induction Temperature (°C) 
N-HIS-JEVNS1 
BL21(DE3)PLysS IPTG 
30 
18 
BL21(DE3) IPTG 25, 30, 37 
SHuffle® T7 auto 25, 30, 37 
BL21(DE3) with 
chaperone plasmids 
auto 16, 25, 30, 37 
N-HIS-MBP-JEVNS1 
N-HIS-GST-JEVNS1 
N-HIS-SUMO-JEVNS1 
BL21(DE3)PLysS IPTG 18, 30 
SHuffle® T7 auto 37 
BL21(DE3) with 
chaperone plasmids 
auto 16, 37 
C-JEVNS1 
BL21(DE3) auto 16, 25, 30, 37 
SHuffle® T7 auto 25, 30, 37 
BL21(DE3) with 
chaperone plasmids 
auto 16, 25, 30, 37 
N-JEVNS1 
DII-III-JEVNS1 
JEVNS1’ 
DII-III-JEVNS1’ 
C-JEVNS1’ 
BL21(DE3) auto 18, 30, 37 
HBM/C-HIS-JEVNS1 
uPase/C-HIS-JEVNS1 
uPase/N-HIS-JEVNS1 
HBM/N-HIS-MBP-JEVNS1 
HA/N-HIS-MBP-JEVNS1 
Ac64/N-HIS-MBP-JEVNS1 
uPase/N-HIS-MBP-JEVNS1 
HEK239T - 37 
Sf9 - 27 
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Table 4.3 Chaperone protein vectors components. 
Protein 
vector 
Chaperone/MW 
(kDa) 
Antibiotic resistance 
Induction 
compound 
pG-KJE8 
dnaK/70-dnaJ/40-
grpE/22-groES/10-
groEL/60 
20 µg/ml of 
chloramphenicol 
0.5 mg/ml L-
arabinose, 
5 ng/ml tetracycline 
pGro7 groES/10-groEL/60 
20 µg/ml of 
chloramphenicol 
0.5 mg/ml L-
arabinose 
pKJE7 
dnaK/70-dnaJ/40-
grpE/22 
pTF16 
groES/10-groEL/60-
tig/56 
pG-Tf2 Tig/56 
20 µg/ml of 
chloramphenicol 
5 ng/ml tetracycline 
 
JEVNS1 protein refolding buffer screening 
The inclusion bodies from IPTG induction were resuspended in resolubilization 
buffer, TBS-Gnd·HCl containing 20 mM Imidazole (20 mM Tris-HCl pH 7.5, 150 mM 
NaCl, 6 M Guanidine hydrochloride (Gnd·HCl), 5 mM Dithiothreitol (DTT)), at wet 
weight concentration of 0.1 g/ml and incubated on roller at room temperature 
overnight. The protein was purified using 1 ml Ni-NTA column chromatography (GE 
Healthcare Life Science). The column was equilibrated with 5-10 ml re-solubilization 
buffer before the protein sample was loaded onto the column. The column was then 
washed with 30 ml of re-solubilization buffer and eluted by gradient steps of TBS-
Gnd·HCl with 50 increments of imidazole concentration from 50-500 mM (5 ml for 
each step) or a single step of 5-10 ml of TBS-Gnd·HCl contained 500 mM Imidazole. 
Protein concentration in the eluted fraction was quantified by using BCA assay 
(Pierce™ BCA Protein Assay Kit), and protein was refolded by dilution method to 
dilute out Gnd·HCl. The eluted NS1 was diluted 10 times in refolding buffer for 36-48 
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hours at room temperature. Totally 45 conditions of refolding buffer were screened 
to find the right buffer condition in 1 ml reaction by varying 3 factors, including pH 
(0.1 M of 2-(N-morpholino) ethanesulfonic acid (MES) pH 6, Tris-HCl pH 7.5, 8.5, 9, 
and 3-(Cyclohexylamino)-1-propanesulfonic acid (CAPS) pH 10), arginine 
concentration (0 M, 0.5 M and 1 M), and glutathione concentration (0 mM, 3 mM at 
2:1, and 5:1 reduced to oxidized) (Figure 4.1). The reactions were centrifuged at 
16000xg for 10 minutes or filtered with 0.45 µm filter to separate the aggregated 
protein. The supernatant was analysed by SDS-PAGE. The positive condition was 
chosen and expanded to large scale experiment. The selected refolding buffer from 
the screening result was further tested with different refolding methods. First, slow 
dilution refolding. After the denatured NS1 was purified from NiNTA column, the 
protein was 10 times diluted with either slowly added drop-by-drop of protein to 
refolding buffer (0.1 M MES pH 6, 0.85 M arginine, 3 mM at 2:1 reduced to oxidized 
glutathione) or the refolding buffer to protein. Second, refolding on the column. 
Denatured full length NS1 was prepared as mention above and applied to 5 ml Ni-
NTA column. 400 ml of refolding buffer (0.1 M MES pH 6, 0.85 M arginine, 3 mM at 
2:1 reduced to oxidized glutathione) was washed through the column and the protein 
was eluted with 30 ml of refolding buffer contained 500 mM imidazole. NS1 protein 
was subjected to Superdex 200 10x300 mm size-exclusion chromatography column 
equilibrated with TBS buffer. 
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Refolded JEVNS1 protein purification 
Refolded protein (10 times dilution method) was purified with different methods. 
First, the refolded protein was dialyzed against TBS without Gnd·HCl to remove the 
remaining Gnd·HCl. Second, the refolded protein was diluted to reduce the imidazole 
concentration to 20 mM and subjected to Ni-NTA column again and eluted with TBS 
buffer supplemented with 500 mM Imidazole. The protein was concentrated with 
3000 Da MWCO centrifugal concentrator and protein concentration was quantified 
by the scanning wavelength from 250 to 600 nm. The concentration was calculated 
using the Beer-Lambert’s law. Third, refolded NS1 protein was subjected to Ni-NTA 
column chromatography similar to the second method, but the protein was eluted 
from the column in 1 ml fractions for 50 ml to help concentrate the protein. Forth, 
concentration in refolding buffer. The NS1 full length was refolded in 2 different 
refolding buffers chosen from previous screening experiment (0.1 M MES pH 6 or 0.1 
Figure 4.1 Refolding buffer screen. 
Forty five buffer conditions were screened by varying of pH, arginine, and GSH: GSSH. 
The pH 6, 7.5, 8.5, 9, and 10 are labelled 6, 7, 8 ,9, and X, respectively. Arginine 
concentration of 0 M, 0.5 M, and 0.85 M are labelled 1, 2, and 3, respectively. No 
glutathione is labelled 1. Glutathione concentration of 3 mM at 2:1 molar ratio GSH 
to GSSH is labelled 2 and at 5:1 is labelled 3. Positive results was coloured in blue. 
 94 
 
M Tris pH 8 added with 0.85 M arginine, 3 mM at 2:1 reduced to oxidized) and 
concentrated by 10000 Da MWCO centrifuge concentrator. The Ni-NTA column 
chromatography after the refolding was omitted. NS1 protein was subjected to 
Superdex 200 10x300 mm size exclusion chromatography column equilibrated with 
TBS buffer. 
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4.2 Results 
4.2.1 Comparison of NS1 sequences 
Among the JEV strains from different genotypes, NS1 sequences are almost identical 
and the percent identity ranges from 89% to 100% (Table 4.1). When compared to 
viruses in the same serocomplex, which contain West Nile, Kunjin, Murray Valley 
encephalitis, and St Louis encephalitis virus, the protein sequences average about 
75% identity. The value reduces to 50% when aligned with other viruses in the same 
genus such as dengue, tick-borne encephalitis, Yellow fever, and Zika virus. With the 
high percent identity (89-100%), only one JEV strain can represent all genotypes, and 
comparable to the remaining in the genus (50-70%). JEV SA-14 was used as the 
template for this study. The advantage of the conserved sequence makes the findings 
applicable to all genotypes. 
4.2.2 Expression of JEVNS1 full length protein with histidine tag 
The soluble full length protein expressed in E. coli BL21(DE3)PLysS could only be 
detected at 30°C expression. No soluble protein expression was observed at 18°C 
analysed by SDS-PAGE (Figure 4.2a). However, the protein was isolated in pellet 
fraction indicating the insoluble protein expression. Expression of JEVNS1 in E. coli 
BL21(DE3) yield non-soluble protein from all the temperatures tested, 25°C, 30°C, 
and 37°C (Figure 4.2b). The best yield was obtained from expression at 37°C, which 
greater than expression in BL21(DE3)PLysS. A small amount of soluble protein was 
found in this E. coli strain expression (Figure 4.2b). E. coli SHuffle®T7 expression was 
also succeeded at 25°C, 30°C, and 37°C, and the best yield was at 30°C (Figure 4.2c). 
However, none of these conditions could produce soluble protein.
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Figure 4.2 SDS-PAGE analysis of JEVNS1 full length with histidine tag protein 
expression. 
(a) JEVNS1 expressed in BL21(DE3)PLysS at 18 and 30°C. Sample before induction is 
shown in 0 hr lane. (b) JEVNS1 expressed in BL21(DE3) at 25, 30, and 37°C. (c) JEVNS1 
expressed in SHuffle®T7 at 25, 30, and 37°C. Suspension fraction is labelled susp. NS1 
protein is indicated with red arrows. 
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4.2.3 Expression of JEVNS1 full length protein with fusion tags 
With fusion tags, the theoretical size of the target protein was increased to 81.9 kDa 
for MBP, 67 kDa for GST, and 52.9 kDa for SUMO. Bands at expected sized were 
observed only in the pellet fraction of BL21(DE3)PLysS at 30°C and SHuffle®T7 at 37°C. 
Protein not effectively expressed in BL21(DE3)PLysS at 18°C. No expected bands was 
observed analysed by SDS-PAGE (Figure 4.3). 
4.2.4 Expression of truncated JEVNS1, full length JEVNS1’ protein and its 
truncations 
The theoretical size of each protein constructs is 20.57 kDa for N-JEVNS1, 38 kDa for 
DII-III-JEVNS1, 20 kDa for C-JEVNS1, 45 kDa for JEVNS1’, 43 kDa for DII-III-JEVNS1’, 
and 26 kDa for C-JEVNS1’. Majority of C-JEVNS1 expressed in BL21(DE3) was in pellet 
fractions at all temperatures tested. Very small amounts of protein was found in 
supernatant fractions at 16°C and 25°C (Figure 4.4a). A similar result was found in the 
expression of C-JEVNS1 in SHuffle® T7 at 25°C and 30°C (Figure 4.4b). 
The growth of DII-III-JEVNS1 and CJEVNS1' at 18°C was very slow even after 24 hours 
expression. Thus, they were excluded from the lysis buffer screening experiment 
(Figure 4.4c). However, they grew normally at 30°C and 37°C. Analyse by SDS-PAGE 
indicates proteins were expressed as inclusion bodies. Overall, overexpression of the 
truncated protein obtained quite a low yield except for the C-JEVNS1. Tiny amounts 
of protein was found in suspension fractions of DII-III-JEVNS1’ expressed at 18°C in 
7.5N lysis buffer (Figure 4.4c), N-JEVNS1 and C-JEVNS1’ expressed at 30°C in 7.5N lysis 
buffer (Figure 4.5), C-JEVNS1’ expressed at 30°C in 0.5U lysis buffer, and JEVNS1’ 
 98 
 
expressed at 37°C in 7.5N lysis buffer (Figure 4.6). Protein solubilized in a buffer 
contained urea indicating that it may need to be refolded.
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Figure 4.3 SDS-PAGE analysis of JEVNS1 full length with fusion tags protein 
expression. 
(a) JEVNS1 expressed in BL21(DE3)PLysS at 30°C. (b) JEVNS1 expressed in 
BL21(DE3)PLysS at 18°C. (c) JEVNS1 expressed in SHuffle®T7 at 37°C. Fusion tag MBP, 
GST, and SUMO were labelled M, J, and S, respectively, according to the vector name. 
NS1 protein is indicated with red arrows. 
a b 
c 
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Figure 4.4 Truncated JEVNS1 expression trial. 
(a) C-JEVNS1 expression in E. coli BL21(DE3) at 16°C, 25°C, 30°C, and 37°C. (b) C-
JEVNS1 expression in E. coli SHuffle® T7 at 25°C, 30°C, and 37°C. (c) N-JEVNS1, 
JEVNS1’, and DII-III-JEVNS1’ expression in E. coli BL21(DE3) at 18°C. Protein solubility 
was analysed in 4 different buffer conditions. The buffer added with the following 
additives: no additive (7.5N), 2 M NaCl (2S), 0.5 M urea (0.5U), and 0.2% Triton X 100 
(D). Soluble protein is indicated with red arrow. 
a b 
c 
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Figure 4.5 Truncated JEVNS1 expression trial at 30°C. 
N-JEVNS1, DII-III-JEVNS1, JEVNS1’, C-JEVNS1’, and DII-III-JEVNS1’ expression in E. coli 
BL21(DE3). Protein solubility was analysed in 4 different buffer conditions, which 
added with the following additives: no additive (7.5N), 2 M NaCl (2S), 0.5 M urea 
(0.5U), and 0.2% Triton X 100 (D). Soluble protein is indicated with red arrow. 
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Figure 4.6 Truncated JEVNS1 expression trial at 37°C. 
N-JEVNS1, DII-III-JEVNS1, JEVNS1’, C-JEVNS1’, and DII-III-JEVNS1’ expression in E. coli 
BL21(DE3). Protein solubility was analysed in 4 different buffer conditions. Four lysis 
buffers were the buffer added with the following additives: no additive (7.5N), 2 M 
NaCl (2S), 0.5 M urea (0.5U), and 0.2% Triton X 100 (D). Soluble protein is indicated 
with red arrow. 
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4.2.5 Expression of JEVNS1 and C-JEVNS1 protein with chaperone proteins 
Multiple bands were observed because of the expression of chaperone proteins (see 
Table 4.3 for the molecular weight of each chaperone protein). JEVNS1 co-expression 
with chaperone plasmid pTF16 and pG-Tf2 grew slowly at 16°C (Figure 4.7a) and were 
eliminated from SDS-PAGE analysis. All cells containing chaperone plasmids grew 
normally at 25°C (Figure 4.7b), 30°C (Figure 4.7c), and 37°C (Figure 4.7d). Protein was 
isolated mainly in the pellet fraction and small bands of the same size were found in 
suspension fractions at 16°C, 25°C and 30°C expression (Figure 4.7c). 
The growth was again slow at 16°C expression of JEVNS1 with fusion tags and some 
of them were excluded out including MBP-JEVNS1 co-expressed with chaperone 
plasmid pGro7 and pTF16, GST-JEVNS1 with pTF16, and SUMO-JEVNS1 with pKJE7, 
pTF16, and pG-Tf2. Proteins were expressed as inclusion bodies (Figure 4.8a, b) 
except for SUMO-JEVNS1 with pG-KJE8 and pGro7 that shown large amounts of 
protein in suspension fractions. However, Western blot analysis demonstrated that 
the bands in suspension fractions were not the target protein (Figure 4.8a). 
C-JEVNS1 co-expressed well with chaperone proteins at 16°C (Figure 4.9a), 25°C 
(Figure 4.9b), 30°C (Figure 4.9c), and 37°C (Figure 4.9d). However, almost all of C-
JEVNS1 was in pellet fractions, and only small amounts were in suspension fractions 
especially at 16°C, 25°C and 30°C. 
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Figure 4.7 JEVNS1 chaperone proteins co-expression 
at (a) 16°C, (b) 25°C, (c) 30°C, and (d) 37°C. Chaperone plasmid pG-KJE8, pGro7, 
pKJE7, pTf16, and pG-Tf2 were labelled K8, O7, E7, Tf16, and Tf12, respectively. NS1 
full length size is indicate with red arrow. 
a b 
c d 
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Figure 4.8 JEVNS1 with fusion tags chaperone proteins co-expression 
at 16°C (a) and 37°C (b). Chaperone plasmid pG-KJE8, pGro7, pKJE7, pTF16, and pG-
Tf2 were labelled K8, O7, E7, Tf16, and Tf12, respectively. Expected band sizes are 
indicated with red arrows. 
a 
b 
58 
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Figure 4.9 C-JEVNS1 chaperone proteins co-expression 
at (a) 16°C, (b) 25°C, (c) 30°C, and (d) 37°C. Chaperone plasmid pG-KJE8, pGro7, 
pKJE7, pTf16, and pG-Tf2 were labelled K8, O7, E7, Tf16, and Tf12, respectively. NS1 
C-terminal domain size is indicated with red arrow. 
a b 
c d 
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4.2.6 Expression of JEVNS1 protein in mammalian cells 
E. coli codon optimized JEVNS1 with HBM/C-His, uPase/N-His and Ac64/N-His-MBP 
tags for mammalian cell expression were excluded because of the low sequencing 
quality check after cloning step. From Western blot analysis, native JEVNS1 with 
uPase/C-HIS was strongly expressed in both secreted and in-cell soluble protein 
(Table 4.4 and Figure 4.10, lane 2). There was a moderate expression of native 
JEVNS1 with HA/N-HIS-MBP, uPase/N-His-MBP (Figure 4.10, lane 3 and 15), and E. 
coli codon optimized JEVNS1 with uPase-N-His-MBP in media and cell lysis fractions 
(Figure 4.10, lane 19). Native JEVNS1 with HBM/C-HIS showed faint bands in both 
fractions (Figure 4.10, lane 8). Native JEVNS1 with HBM/N-HIS-MBP shown faint band 
only in secretion fraction (Figure 4.10, lane 20). JEVNS1 was subcloned into 
pOPINTTGneo vector. The pOPINTTGneo has a similar construct to pOPIN G (uPase/C-
HIS) and contains RPTPmu secretion signal (Table 3.3). This new vector was believed 
to give a better protein expression. The new protein construct was used for large 
scale protein expression (2 liters). After Ni-NTA purification and size exclusion 
chromatography, JEVNS1 displayed multiple bands and some background in SDS-
PAGE analysis (Figure 4.11, upper). Possibly due to too little or no protein expression 
that led to non-specific binding to the Ni-NTA column. Elution fraction B3-B10 was 
pooled together and concentrated to~1 ml. The concentration was ~5 mg/ml. 
Western blot analysis showed only faint bands in lane 9 (Figure 4.11, lower).
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Table 4.4 Secretion screen in HEK293-T Cells. 
Note: Dark green indicates strong expression. Light green indicates low expression. 
  
Gene Lane SS/Tags Secreted 
Soluble in 
the cell 
E. coli codon 
optimized 
1 uPase/N-HIS-3c   
Native 2 uPase/C-HIS   
Native 3 HA/N-HIS-MBP-3C   
E. coli codon 
optimized 
7 HBM/N-HIS-MBP-
3C 
  
Native 8 HBM/C-HIS   
Native 9 Ac64/N-HIS-MBP-
3C 
  
E. coli codon 
optimized 
13 HA/N-HIS-MBP-3C   
Native 14 uPase/N-HIS-3c   
Native 15 uPase/N-HIS-MBP-
3C 
  
E. coli codon 
optimized 
19 uPase/N-HIS-MBP-
3C 
  
Native 20 HBM/N-HIS-MBP-
3C 
 
Very faint 
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Figure 4.10 Western blot analysis of HEK239-T transient expression. 
Secreted protein is labelled media (upper) and soluble protein in the cell is labelled 
cells lysis (lower). Protein in each lane is indicated in table 4.4. 
2    3 
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Figure 4.11 HEK239-T scaled up transient transfection. 
HiLoad Superdex 200 16x600 mm column purification after Ni-NTA (upper). Western 
blot analysis. Native JEVNS1 was loaded in lane 9 indicated with red arrow. Positive 
control was loaded in lane 5 (lower). 
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4.2.7 Expression of JEVNS1 protein in insect cells 
E. coli codon optimized JEVNS1 with Ac64/N-His-MBP was excluded from the 
expression screening because of the low sequencing quality. Western blot analysis 
showed that E. coli codon optimized JEVNS1 and native JEVNS1 with uPase/C-HIS and 
native JEVNS1 with HBM/N-HIS-MBG demonstrated low protein expression (Table 
4.5 and Figure 4.12, lane B1, H1, and C2). Higher expression was observed in E. coli 
codon optimized and native JEVNS1 with uPase/N-His-MBP. However, the expression 
was not strong enough to continue to scale up compared to green fluorescent protein 
(GFP) positive control (Figure 4.12, lane H2). 
Table 4.5 Secretion screen in Sf9 cells. 
Gene Lane Vector Secreted 
E. coli codon optimized A1 HBM/C-HIS  
E. coli codon optimized B1 uPase/C-HIS Very faint 
E. coli codon optimized C1 uPase/N-HIS-3c  
E. coli codon optimized D1 HBM/N-HIS-MBP-3C  
E. coli codon optimized E1 HA/N-HIS-MBP-3C  
E. coli codon optimized F1 Ac64/N-HIS-MBP-3C  
E. coli codon optimized G1 uPase/N-HIS-MBP-3C  
Native H1 uPase/C-HIS Very faint 
Native A2 HBM/C-HIS  
Native B2 uPase/N-HIS-3c  
Native C2 HBM/N-HIS-MBP-3C Very faint 
Native D2 HA/N-HIS-MBP-3C  
Native E2 Ac64/N-HIS-MBP-3C  
Native F2 uPase/N-HIS-MBP-3C  
Blank G2   
GFP H2   
Note: Dark green indicates strong expression. Light green indicates low expression. 
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Figure 4.12 Western blot analysis of Sf9 expression. 
Protein in each lane is indicated in Table 4.5. The strongest expression is His-MBP-
tagged proteins in lane F2 and G1. H2 is the GFP positive control. 
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4.2.8 JEVNS1 protein refolding buffer screening 
From 45 conditions, 5 were succeed (Figure 4.1 and Figure 4.13) which were 
condition X13, 823, 632, 732, 832, and 932. The strongest band was acquired from 
condition 632 (0.1 M MES pH 6, 0.85 M arginine, and 3 mM glutathione at a 2:1 GSH 
to GSSH) and it was used for the large scale protein refolding and other refolding 
methods. Slow dilution (drop-by-drop) refolding did not give significant yield increase 
compared to one step dilution (data not shown). Refolding on column yielded a large 
amount of protein in elution fraction (Figure 4.14a). 
4.2.9 Refolded JEVNS1 protein purification 
Refolded JEVNS1 sample with buffer condition 632 appeared a weak band at the size 
of ~46 kDa (Figure 4.15a, lane 1). Followed by filtration and dialysis, the band 
disappeared (Figure 4.15a, lane 2). It is possible that the protein already aggregated 
and was eliminated via filtration. 
Ni-NTA purification after refolding step and elution with TBS buffer gave a clear band 
at 46 kDa (Figure 4.15b). However, it started to have some precipitation when stored 
at 4°C overnight and more debris was observed when the protein was concentrated 
to the volume about 1 ml. 
Small fraction elution. The elution fractions precipitated immediately especially in the 
fraction 8 which had a high concentration of protein (Figure 4.15c and d). 
Refolding on Ni-NTA column. A large amount of protein refolded on the column was 
eluted, but when elution profile of size exclusion chromatography was further 
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analysed, it become clear that protein eluted in a void volume of the column 
indicating protein aggregation (Figure 4.14b). 
Concentration in refolding buffer. Protein precipitation happened during the 
concentration step, but not in massive level. In both refolding conditions, pH 6 and 
pH 8, the majority of the protein was eluted from SEC in the void volume indicated 
protein aggregation (Figure 4.16a, b). Even though NS1 protein was eluted in a few 
fractions confirmed by Western blot, each peak was not separated well (Figure 4.16a, 
b) and multiple bands were observed make it difficult to obtain a pure and 
homogenous sample for crystallization. 
Even though the refolding buffer condition was found and several purification 
methods have been tried, none of these could give protein in quantity and purity for 
crystallization trials. 
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Figure 4.13 Protein refolding screen. 
Three digits code indicate pH, arginine concentration, and glutathione ratio, 
respectively. pH 6, 7.5, 8.5, 9, and 10 are labelled 6, 7, 8 ,9, and X, respectively. 
Arginine concentration of 0 M, 0.5 M, and 0.85 M are labelled 1, 2, and 3, 
respectively. No glutathione is labelled 1. Glutathione concentration of 3 mM at 2:1 
molar ratio GSH to GSSH is labelled 2 and at 5:1 is labelled 3. 
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Figure 4.14 JEVNS1 refolding on column. 
(a) Ni-NTA elution. Large amount of the protein was eluted by refolding buffer 
supplemented with 500 mM imidazole. (b) Refolding on column gel filtration profile. 
JEVNS1 protein was eluted in void volume of Superdex 200 10x300 mm column. 
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Figure 4.15 SDS-PAGE analysis of protein purification trials. 
(a) Dialysis after protein refolding. Refolded protein before dialysis shows in lane 1 
and after dialysis shows in lane 2. (b) Second Ni-NTA purification. Lane 1 is refolded 
protein. Lane 2 is flow-through fraction, lane 3 is washed fraction, and lane 4 is eluted 
fraction. (c) Small elution fraction. Protein was eluted with 500 mM Imidazole in TBS 
buffer for 50 ml (1 ml for each fraction). Elution fraction 3, 8, 13, 18, 23, 28, 33, 38, 
43, and 48 were analysed. (d) Fraction number 8. Protein precipitation was removed 
by centrifugation. Lane 1 is supernatant fraction and lane 2 is precipitant. 
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Figure 4.16 Size exclusion chromatography profiles of JEVNS1 after refolding 
After refolding in buffer pH 6 (a) and 8 (b) show poor resolution of separation. Elution 
fractions were analysed by SDS-PAGE and Western blot (a, b). 
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4.3 Discussion 
Protein expression in E. coli has advantages in that it is inexpensive and can give a 
good yield. However, the major drawback is the lack of post-translational 
modification found in more complex organisms. When heterologous proteins are 
expressed this can result in misfolding and failure to express the protein in the soluble 
fraction. Nowadays, there are many strategies to improve expression of the foreign 
protein in E. coli both engineering and non-engineering of the target protein. Some 
techniques are experimentally determined and there is no recipe that works for every 
protein such as fusion tag proteins and culture temperature. High throughput 
experiments would be more appropriate to test every possible method available. 
Thus, in this study, the methods were chosen based on the available materials and 
equipment. All the strategies used to modify protein expression in this study could 
not produce a satisfactory yield. This is not surprising as JEVNS1 protein carries 6 
disulphide bonds and also 2 glycosylation sites which are not supported in E. coli. 
Similar results were obtained from mammalian cell and insect cell expression 
systems. While the protein was expressed, the yield was too low and not worth 
scaling up. The conditions used in this study were developed from what has been 
reported to succeed (Brown et al., 2011). However, differences in small details could 
lead to different results such as signal sequence, vector construct, and culture 
techniques. Further modification of conditions to get a better protein yield might 
help and it is very promising. 
The strategy was, therefore, changed to refold protein from E. coli inclusion bodies. 
Even though the refolding buffer condition was found, JEVNS1 aggregated during the 
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purification process. It is possible that the protein was not properly refolded. 
Typically, dilution refolding is done in 100 fold dilution, but in this study, it was only 
10 fold dilution. Low dilution resulted in a moderate concentration of Gnd·HCl that 
may be too high for protein to refold and cause partial unfolding and keep the protein 
in the intermediate state which is prone to aggregation. Once the protein buffer was 
immediately changed, the aggregation might occur. 
In the future, people might develop new strategies to produce protein effectively in 
bacteria and also in higher expression systems. New technologies may prove more 
efficient in large-scale protein expression and purification. Besides that, if we 
understand more about protein folding, we may able to better design a method to 
express and purify the protein. 
4.4 Conclusion 
In this study, soluble JEVNS1, JEVNS1’, and the truncations of JEVNS1 and JEVNS1’ 
were attempted to produce in E. coli. Many strategies were examined to improve 
foreign protein expression. A great deal of protein was expressed as inclusion bodies. 
Only some conditions could express a soluble form of the proteins but the yield was 
too low. The protein was refolded from inclusion bodies instead. Our own refolding 
protocol was created, but a lot of protein aggregated during protein purification 
processes. In parallel, mammalian and insect cell expression screen were performed 
at OPPF-UK. Some vector constructs could produce JEVNS1. However, the yield was 
low hence not pursued further. 
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Chapter 5 Structural study of C-JEVNS1 and C-
JEVNS1’ 
 
Since the expression trials conducted in chapter 4 could not give the protein yield and 
purity required for crystallization, the strategy was changed to follow Edeling’s work 
published in 2014 (Edeling et al., 2014). Refolding of WNV NS1 truncations had 
previously been successful (Chung et al., 2006b), but it was used for structural study 
for the first time in Edeling’s publication. With highly conserved sequence, it is likely 
that the refolding method could work for JEVNS1 as well. The protein inclusion bodies 
were refolded by using the protocol modified from WNV NS1 and enterokinase 
refolding protocols (Edeling et al., 2014, Skala et al., 2013). Parts of the work reported 
in this chapter is now published (Poonsiri et al., 2018). 
5.1 Methods 
5.1.1 Plasmid construction 
Synthetic JEVNS1 DNA optimized for E. coli in pRSET_A_A185 vector and JEVNS1’ in 
pET-30a(+) were subcloned into pET303 to create C-JEVNS1 and C-JEVNS1’ without 
histidine tag by using the primers indicated in Table 3.4. 
5.1.2 Protein expression, refolding, and purification 
Protein was expressed in E. coli by autoinduction and refolded using a modified 
method previously described in Edeling et al, 2014. Briefly, inclusion bodies were 
denatured in 7 M Gnd·HCl, 30 mM β2ME and refolded by 100 times dilution in 400 
mM L-arginine, 100 mM Tris pH 8.3, 2 mM EDTA, 0.5 mM GSSH, 5 mM GSH, 0.2 mM 
PMSF. After refolding, the protein was purified once by size exclusion 
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chromatography column, Superose 6 10x300 mm or superdex 200 10x300 mm 
equilibrated with 20 mM HEPES pH 7.4, 150 mM NaCl. 
5.1.3 Protein oligomeric state analysis 
Agilent Bio SEC-3 4.6x300 mm HPLC column (300 Å pore structure) was equilibrated 
with 100 ml (20 column volumes) of a filtered-degassed buffer, 20 HEPES pH 7.4 and 
150 mM NaCl. The column was operated at a flow rate 0.25 ml/min, 35 °C. The 
purified C-JEVNS1 first peak, second peak, and total protein (80 µl each) at day 0, 3, 
6, 10, and 13 after the purification were loaded onto the column. Signals at the 
wavelength of 220, 260, and 280 nm were observed. 
5.1.4 Protein crystallization and data collection 
The protein was concentrated to ~6 mg/ml (C-JEVNS1) or ~7 mg/ml (C-JEVNS1’) and 
screened by using SaltRx, PEGRx, and Natrix screens from Hampton research, and 
Structure, PACT premier, and JCSG screens from Molecular Dimension. All the 
positive condition are given in Appendix 3. Needle crystals of C-JEVNS1 were 
produced from a range of salt concentrations, 0.7-1 M Ammonium sulphate or 1 M 
Li2SO4 and buffer pH, 0.1 M MES pH 5.5-6.7, while NS1’ C-terminus which also 
crystallised in needle form crystallised in 2 M Ammonium sulphate and 5% propanol. 
The crystals were flash frozen in reservoir solution added with 20-25% ethylene glycol 
or glycerol (Figure 5.1). 
X-ray data were collected at cryogenic temperature at 0.98 Å wavelength, at 
beamline PROXIMA 1 at Soleil synchrotron, France for C-NS1 protein and at beamline 
I02 at Diamond Light Source, UK for C-NS1’ protein. Data reduction was carried out 
 123 
 
by XDS programs for C-NS1 or iMosflm for C-NS1’. Scaling was performed by Scala or 
Aimless (Evans, 2011). Both protein structures were determined by molecular 
replacement using the structure of WNV NS1 C-terminal domain (PDB: 4OIE, 
sequence identity 73%) as a starting model by MOLREP in the CCP4 program package. 
The structure was refined by REFMAC5 and built in COOT. The C-NS1 data was 
collected twice from a single crystal at a time. The C-NS1 first model was refined with 
weight term of 0.01. The second data was refined against the first model with weight 
term of 0.2. The C-NS1’ models were built separately from C-NS1. The reflection data 
was refined against the C-NS1’ model with weight term of 0.15. Data collection and 
refinement statistics are shown in Table 5.1. Both of C-JEVNS1 and NS1’ have good 
protein geometry and those statistical parameters are in high quality compared to 
protein structures at similar resolution. The C-JEVNS1 refinement statistic of 
Ramachandran plot is 95.98% favoured and 0% outliers. The MolProbity score is 1.6. 
The JEV NS1’-C refinement statistic of Ramachandran plot is 94.89% favoured and 0% 
outliers. The MolProbity score is 1.84. 
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5.1.5 Structure analysis 
Assembly analysis was performed by program PISA (Krissinel and Henrick, 2007). 
Conservation scores of residues on protein structures were given by Consurf (Landau 
et al., 2005) using 21 homologous sequences (Appendix 4). Electrostatic surface 
maps were generated by using PDB2PQR (Dolinsky et al., 2007) and APBS (Baker et 
al., 2001) without pKa prediction. 
Figure 5.1 Protein crystallisation. 
C-JEVNS1 protein was crystallised under different crystallisation conditions and 
produced different shape crystals, for example, (a) needle shape in 0.1 M MES pH 
6.2, 0.8 M (NH4)2SO4, (b) short rod shape in 0.1 M MES pH 5.5, 1 M Li2SO4, and (c) 
sheet-like in 18% (v/v) 2-propanol, 0.1 M Sodium citrate tribasic dihydrate pH 5.5, 
20% (w/v) polyethylene glycol (PEG) 4000. (d) C-JEVNS1’ in 1.2 M (NH4)2SO4, 5% (v/v) 
Propanol. 
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5.1.6 Small angle X-ray scattering (SAXS) 
The purified C-JEVNS1 1st peak (2.4 mg/ml), C-JEVNS1 2st peak (3.4 mg/ml), C-JEVNS1’ 
1st peak (5 mg/ml), and C-JEVNS1’ 2nd peak (5 mg/ml) were analysed with SEC-SAXS 
(SEC-3 4.6x300 mm  HPLC column) on beamline SWING at Soleil synchrotron, France. 
The low resolution model surface representation was created and docked with C-
JEVNS1 or C-JEVNS1’ dimer. 
5.1.7 Molecular dynamics (MD) simulations 
Molecular dynamics (MD) simulations were performed by Dr. Gareth Wright using 
GROMACS 4.6.5 (Berendsen et al., 1995) and GROMOS96 54A7 (Scott et al., 1999) 
force field in a cubic box solvated with single point charge-E water molecules on C-
JEVNS1 dimers. A neutral charge was introduced at 150 mM NaCl. The distance 
between C-JEVNS1 dimers and the box edge was set to 10 Å. Long range interactions 
were defined using the particle mesh Ewald algorithm and other non-bonded 
interactions were restricted to 10 Å. An energy minimization was performed using 
the steepest descent algorithm followed by a 100 picosecond (ps) NVT ensemble (the 
number of particles N, the volume V, and the temperature T of the system are kept 
constant) at 310 K and a 200 ps NPT ensemble (the number of particles N, the 
pressure V, and the temperature T of the system are kept constant) at 310 K and 1 
bar. Production MD was performed at 310 K and 1 bar for 40 nanoseconds (ns). C 
displacement was calculated with the GROMACS RMSF function. Torsion angle MD 
was performed with crystallography and NMR System (CNS) at 100,000 K for 37.5 
picoseconds (ps) with sampling every 7.5 femtoseconds (fs) in eight separate 
simulations. The best structure was found with FoXS (Schneidman-Duhovny et al., 
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2013) using experimental data over data range 0.017<q<0.25 Å-1 and was the refined 
with another eight separate 7.5 ps simulations and energy minimization in GROMACS 
using the procedure described above. Models were again compared with FoXS. 
Freeing loop 214-243 gave a fit with experimental data of  1.66, however, expanding 
the flexible region to 218-272 allowed improvement of the fit to  1.48. 
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Table 5.1 X-ray data collection and refinement statistics 
*Values in parentheses are for highest-resolution shell.  
 C-JEVNS1 (1st) C-JEVNS1 (2nd) C-JEVNS1’ 
Data collection    
Space group I212121 I212121 I212121 
Cell dimensions    
a, b, c (Å) 
50.98, 77.48, 
164.28 
49.42, 78.24, 
163.18 
50.32, 77.94, 
163.49 
α, β, γ () 90, 90, 90 90, 90, 90 90, 90, 90 
Resolution (Å) 50-2.15 
47.3-2.10 (2.21-
2.10) 
81.75-2.6 (2.72-
2.6) 
Rmerge 
Rmeas 
Rpim 
- 
0.108(1.048) 
- 
0.103 (0.907) 
0.113(0.986) 
0.045 (0.383) 
0.2 (1.413) 
0.246(1.758) 
0.141 (1.030) 
I / σI 14.27 (1.76) 11.5 (2.3) 7.1 (2.1) 
CC half 0.999 (0.883) 0.998 (0.923) 0.981 (0.226) 
Completeness 
(%) 
Redundancy 
99.3 (96) 
- 
99.8 (99.6) 
6.3 (6.5) 
99.9 (99.9) 
5.3 (5.2) 
    
Refinement    
Resolution (Å) 44.43-2.13 47.3-2.10 81.75-2.6 
No. reflections 17335 17944 9719 
Rwork / Rfree 0.24/0.27 0.19/0.23 0.17/0.23 
No. atoms 
  Protein 
  Sulphate ion 
  Ligand 
  Water 
B-factors(Å) 
  Protein 
  Sulphate ions 
  Ligands 
  Water 
1472 
1411 
41 
- 
20 
 
38.15 
38.36 
- 
73.17 
1574 
1398 
60 
24 (MES) 
92 
 
41.52 
90.12 
86.74 (MES) 
50.19 
1573 
1418 
60 
4 (POL) 
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38.64 
85.15 
61.91 (POL) 
48.67 
R.m.s. deviations    
Bond lengths (Å) 0.007 0.016 0.016 
Bond angles () 1.144 1.785 1.741 
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5.2 Results 
5.2.1 Protein expression, refolding, and purification 
The theoretical molecular weight of C-JEVNS1 and C-JEVNS1’ are 20.54 kDa and 25.98 
kDa, but the SDS-PAGE appearance sizes are 23 kDa (Figure 5.2a-c) and 30 kDa (Figure 
5.2d), respectively. Conformational difference of the target proteins from the protein 
standards may cause the difference in size when analysed on polyacrylamide gel. 
Samples from each purification step were analysed by SDS-PAGE (Figure 5.2a, b). The 
protein pellets were successfully refolded and purified indicated by detection of 
protein in the soluble fraction. C-JEVNS1 was loaded onto a Superpose 6 10x300 mm 
column and the elution showed a single peak at a retention volume of 16.4 ml (Figure 
5.3a). C-JEVNS1’ also show a similar profile, but the peak was slightly separated at 
14.5 and 15.4 ml (Figure 5.3b). The C- JEVNS1 and C- JEVNS1’peak fractions were 
collected and used for crystallization. 
Figure 5.2. JEV NS1 and NS1’ C-terminus expression and purification. 
(a) C- JEVNS1 is mainly expressed as inclusion body. (b) After protein denaturation 
and refolding, sample suspensions were analysed and soluble protein was observed. 
(c) C- JEVNS1 peak 1 and peak 2 showed heat sensitivity when analysed by non-
denaturing SDS-PAGE. D indicate dimer. M indicate monomer. (d) C- JEVNS1’ 
purification by Superose 6 10x300 mm column. Peak 1 and peak 2 are in lane 6 and 
7, respectively. Target protein size is indicated with black arrow. 
a b c d 
D 
M 
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However, when both C- JEVNS1 and C- JEVNS1’ were purified with superdex 200 
10x300 mm column, the elution profiles showed 2 peaks (Figure 5.3b, c) that were 
not clearly separated. To further investigate the 2 populations of protein, C-JEVNS1 
was analysed by analytical SEC over a time-course which showed a time-dependent 
oligomerization between peak 1 and peak 2. Total protein which contains both peaks 
showed a small amount of peak 1 at day 0 (Figure 5.4a). The amount of peak 1 protein 
was gradually raised on day 3, 6, 10 and 13 samples, while the amount of peak 2 
protein was gradually reduced. Protein aggregation also increase which showed at 
the retention volume of ~2 ml. As the protein was not well separated, C- JEVNS1 peak 
1 fraction was contaminated with peak 2 protein. Both peaks were observed on day 
0 (Figure 5.4b), but peak 2 reduced on day 3 and could not detect on day 6. However, 
it was detected again on day 10 and 13. C- JEVNS1 peak 2 fraction alone did not shift 
to form peak 1 within 13 days (Figure 5.4c). 
Heat sensitivity is a characteristic of flavivirus NS1. The dimeric state will break down 
into monomer when heated, but is tolerant of reducing agents (Winkler et al., 1988) 
and detergent (Muller and Young, 2013). Both C- JEVNS1 peaks demonstrated heat 
sensitive property and showed the same oligomeric size at ~55 kDa (Figure 5.2c). 
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Figure 5.3 Size exclusion chromatography purification. 
C-JEVNS1 (a) and C-JEVNS1’ (b) elution profile purified from Superose 6 10x300 mm column. C-JEVNS1 protein purity is shown (right 
inset). (c) C-JEVNS1 and (d) C-JEVNS1’ elution profile purified from Superdex 200 10x300 mm column. 
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Figure 5.4 Protein dynamics analysis. 
(a) C-JEVNS1 total protein. (b) C-JEVNS1 peak 1. (c) C-JEVNS1 peak 2. Day 0, 3, 6, 10, and 13 sample are shown in black, orange, grey, 
yellow, and blue, respectively. 
a b c 
Retention volume (ml) 
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5.2.2 C-JEVNS1 and C-JEVNS1’ structure 
The crystal structure of the C-terminal part of JEVNS1 at 2.1 Å resolution is similar to 
all previously described NS1 structures. Measured from its widest point, monomeric 
C-JEVNS1 is 53 x 23 Å (Figure 5.5). Electron density is clearly seen from residues 177-
352, while the first 5 residues at the N-terminus are absent. One side of the monomer 
consists of 10 β-strands and another side are 4 helices and unstructured loops. β-
strands are connected by β-turns and short loops except for the β4 and β5 which are 
separated by a long unstructured loop (residues 218-273) (Figure 5.5a, b). The protein 
is held together by four conserved disulphide bonds (C179-C229, C280-C329, C291-
C312, and C313-C316) and hydrogen bonds between β-strands and loops. C-JEVNS1 
forms 20 β-strands head-to-head in the dimer similar to ZIKV, WNV, and DNEV NS1 
C-terminus with the dimer length of 96.5 Å at its widest point (Figure 5.5c). Twenty 
one residues from each monomer form the dimer interface with an average distance 
of 2.9 Å (Table 5.2). Among the interface residues, 8 of these are conserved compared 
to other flavivirus NS1 (Table 5.3, score 7-9). Twelve of hydrogen bonds are found at 
the dimer interface and there are 6 common residues which habitually have the same 
bond arrangement: Thr (JEV, ZIKV, WNV) / Ala (DENV) 186 – Val (JEV, ZIKV, WNV) / 
Ile (DENV) 188, Thr (JEV, WNV) / Ser (ZIKV, DENV) 228 - His254, and Thr230-Trp232 
(Table 5.4 and Figure 5.6) compared to ZIKV, WNV, and DENV NS1 C-terminus. 
The C-JEVNS1’ structure was determined at 2.6 Å resolution. The similar protein fold 
and identical disulphide bond orientations were revealed. The interface residues and 
hydrogen bond formation residues were identical (Table 5.5-5.6). C-JEVNS1’ dimer 
had the same orientation as NS1. However, the electron density for the C-terminus 
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created by the -1 frame-shift was not observed. Only 2 extra amino acids longer than 
the C-terminal domain of JEV NS1 were present (0.337 Å Cα root-mean-square 
deviation (RMSD)) (Figure 5.5d) indicating C-terminal is disordered. 
 
Figure 5.5 Structure of C-JEVNS1. 
(a) Ribbon model of C-JEVNS1 monomer. One side is built of 10 β-strands and the 
opposite is the non-structured loops. Disulphide bonds are shown in yellow. (b) 
Topology diagram of C-JEVNS1. Four disulphide bonds are indicated as white spheres. 
β represent the β-sheet and η represent 310 helix. (c) Superimposed ribbon diagram 
of C-NS1 of JEV (magenta), ZIKV (PDB: 5IY3, blue), WNV (PDB: 4OIE, green), and 
DENV1 (PDB: 4OIG, gold). (d) Superimposition of C-JEVNS1 (magenta) and C-JEVNS1’ 
(grey). 
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Table 5.2 Hydrogen bonds between C-JEVNS1 dimer interfacing residues and the 
distance 
 
1 Assembly analysis in the program PISA. 
2See histidine atoms nomenclature in Appendix 5. 
 
  
Number Structure 1 Distance (Å)1 Structure 2 
1 Gly190 [N] 2.93 Ile184 [O] 
2 Val188 [N] 2.86 Thr186 [O] 
3 Thr186 [N] 2.89 Val188 [O] 
4 His229 [NE2]2 2.83 Gly190 [O] 
5 His254 [NE2] 2.94 Thr228 [O] 
6 Trp232 [N] 2.96 Thr230 [O] 
7 Ile184 [O] 2.93 Gly190 [N] 
8 Thr186 [O] 2.86 Val188 [N] 
9 Val188 [O] 2.89 Thr186 [N] 
10 Gly190 [O] 2.83 His229 [NE2] 
11 Thr228 [O] 2.94 His254 [NE2] 
12 Thr230 [O] 2.96 Trp232 [N] 
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Table 5.3 C-JEVNS1 dimer interfacing residues reported with accessible (ASA) and 
buried surface area (BSA), solvation energy effect (ΔG) and conservation score. 
Number Residue ASA (Å2)1 BSA (Å2)2 ΔG (kcal/mol)3 Conservation4 
1 Gly181 23.56 6.81 0.03 3 
2 Ala182 91.29 45.68 0.30 1 
3 Ile184 22.47 16.36 -0.18 5 
4 Gly185 40.33 16.05 0.26 7 
5 Thr186 37.46 36.73 -0.22 7 
6 Ala187 63.58 21.49 0.34 9 
7 Val188 64.98 63.40 0.34 6 
8 Lys189 181.59 9.98 0.16 8 
9 Gly190 63.17 54.83 0.30 5 
10 His191 110.70 33.66 0.74 1 
11 Trp210 60.01 29.42 0.08 5 
12 Glu227 104.51 54.79 0.51 5 
13 Thr228 120.12 94.74 0.66 6 
14 His229 54.08 52.04 0.90 9 
15 Thr230 24.89 21.26 -0.20 9 
16 Leu231 48.09 48.09 0.77 8 
17 Trp232 95.68 59.18 0.38 5 
18 Gly233 39.95 30.60 -0.02 4 
19 Asp234 91.67 54.93 0.26 6 
20 Asp235 128.72 0.58 -0.01 1 
21 His254 13.56 10.75 0.73 8 
 
1 ASA= Accessible Surface Area 
2 BSA= Buried Surface Area 
3 ΔG= Solvation energy effect 
1,2,3 Assembly analysis in the program PISA. The values are taken from one monomer 
in a dimer. 
4Amino acid conservation scores are given by Consurf. (9 = conserved and 1 = 
variable)
 136 
 
Table 5.4 Residues forming hydrogen bond at dimer interface compared among 
existing flavivirus NS1 structures 
JEV 
ZIKV WNV DENV 
5k6k 5gs6 5iy3 4o6d 4o6c 4oie 4o6b 4oig 
 Asp1 His1  Asp1 Asp1    
 Val2 Val2  Thr2 Thr2  Ser2  
 Cys4 Cys4  Cys4 Cys4  Cys4  
 Ser5 Ser5       
 Val6 Val6  Ile6 Val6  Ile6  
 Phe8        
 Ser9        
    Arg10 Arg10    
 Lys11        
 Glu12   Glu12 Glu12    
    Leu13     
 Arg14 Arg14  Arg14 Arg14  Lys14  
 Thr17 Thr17  Ser17 Ser17  Ser17  
 Val19 Val19  Val19 Val19  Ile19  
 Phe20 Phe20  Phe20 Phe20    
 Ile21 Val21  Ile21 Ile21  Ile21  
 Tyr22 Tyr22       
 Asn23 Asn23  Asn23 Asn23  Asp23  
 Asp24 Asp24  Asp24 Asp24    
 Arg31   Arg31 Arg31    
 Tyr32   Tyr32 Tyr32    
 Asp157 Asp157       
       Tyr158  
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JEV 
ZIKV WNV DENV 
5k6k 5gs6 5iy3 4o6d 4o6c 4oie 4o6b 4oig 
    Phe160     
 Thr165   Thr165 Thr165    
    Ser181 Ser181    
    Lys182 Lys182   Arg182 
Ile184 Ile184 Ile184 Ile184      
        Ser185 
Thr186 Thr186 Thr186 Thr186 Thr186 Thr186 Thr186 Ala186 Ala186 
Val188 Val188 Val188 Val188 Val188 Val188 Val188 Ile188 Ile188 
 Lys189   Lys189 Lys189   Lys189 
Gly190 Gly190 Gly190 Gly190     Asp190 
  Lys191  Asn191 Asn191    
 192Glu Glu192       
 193Ala        
 Glu203   Glu203     
 Lys227 Lys227 Lys227      
Thr228 Ser228 Ser228 Ser228 Thr228 Thr228 Thr228 Ser228 Ser228 
His229 His229 His229 His229      
Thr230 Thr230 Thr230 Thr230 Thr230 Thr230 Thr230 Thr230 Thr230 
Trp232 Trp232 Trp232 Trp232 Trp232 Trp232 Trp232 Trp232 Trp232 
 Thr233 Thr233 Thr233    Ser233 Ser233 
 Asp234 Asp234 Asp234    Asn234 Asn234 
His254 His254 His254 His254 His254 His254 His254 His254 His254 
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Figure 5.6 Dimer interface of C-JEVNS1. 
(a, b) The surface of 21 residues from each monomer involved in dimer interface is 
coloured in lime green and the surface that form hydrogen bonds are coloured in 
dark green. Similarly, another monomer interfacing surface is in magenta and surface 
forming hydrogen bonds are in dark magenta. (c) Residues involved in hydrogen 
formation at the dimer interface are highlighted in lime green and magenta, 
respectively. Hydrogen bonds are indicated by dashed lines. 
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Table 5.5 Hydrogen bonds between C-JEVNS1’ dimer interfacing residues and the 
distance 
 
1 Assembly analysis in the program PISA. 
2See histidine atoms nomenclature in Appendix 5. 
 
Number Structure 1 Distance (Å)1 Structure 2 
1 Gly190 [N] 3.10 Ile184 [O] 
2 Val188 [N] 2.90 Thr186 [O] 
3 Thr186 [N] 2.96 Val188 [O] 
4 His229 [NE2]2 3.11 Gly190 [O] 
5 His254 [NE2] 3.00 Thr228 [O] 
6 Trp232 [N] 3.07 Thr230 [O] 
7 Ile184 [O] 3.10 Gly190 [N] 
8 Thr186 [O] 2.90 Val188 [N] 
9 Val188 [O] 2.96 Thr186 [N] 
10 Gly190 [O] 3.11 His229 [NE2] 
11 Thr228 [O] 3.00 His254 [NE2] 
12 Thr230 [O] 3.07 Trp232 [N] 
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Table 5.6 C-JEVNS1’ dimer interfacing residues reported with accessible (ASA) and 
buried surface area (BSA), solvation energy effect (ΔG) and conservation score. 
Number Residue ASA (Å2)1 BSA (Å2)2 ΔG (kcal/mol)3 Conservation4 
1 Gly181 23.27 3,57 -0.02 3 
2 Ala182 91.85 39.09 0.09 1 
3 Ile184 19.82 15.44 -0.16 5 
4 Gly185 39.39 16.40 0.26 7 
5 Thr186 37.67 36.77 -0.26 7 
6 Ala187 66.81 24.00 0.38 9 
7 Val188 64.00 62.27 0.38 6 
8 Lys189 183.40 10.95 0.18 8 
9 Gly190 68.07 56.39 0.31 5 
10 His191 114.57 9.46 0.15 1 
11 Trp210 59.38 28.61 0.08 5 
12 Glu227 85.91 55.86 0.30 5 
13 Thr228 120.24 98.04 0.75 6 
14 His229 53.99 44.78 0.76 9 
15 Thr230 20.31 20.28 -0.19 9 
16 Leu231 47.77 47.69 0.76 8 
17 Trp232 93.95 56.42 0.36 5 
18 Gly233 29.10 24.02 -0.04 4 
19 Asp234 96.17 56.52 0.33 6 
20 Asp235 128.64 1.02 -0.01 1 
21 His254 12.61 9.62 0.78 8 
1 ASA= Accessible Surface Area 
2 BSA= Buried Surface Area 
3 ΔG= Solvation energy effect 
1,2,3 Assembly analysis in the program PISA. The values are taken from one monomer 
in a dimer. 
4Amino acid conservation scores are given by Consurf. (9 = conserved and 1 = 
variable)  
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5.2.3 SAXS analysis of C-JEVNS1 and C-JEVNS1’ 
The dimeric state of the proteins was confirmed by SAXS. The first and second peak 
experimental profiles of C-JEVNS1 and C-JEVNS1’ were compared to its calculated 
monomer and dimer SAXS profiles (Figure 5.7, panel 1). For C-JEVNS1 first peak, C-
JEVNS1’ first and second peaks, the calculated profiles fit the experimental profiles 
with poor χ value (Table 5.7). Only the C-JEVNS1 second peak demonstrates a good 
match with χ of 4.02. Rg of all samples obtained from Guinier analysis is consistent 
with the value extracted from the pair distribution function (Table 5.7). The pair 
distribution function of all samples shows characteristics of a prolate ellipsoid 
particle. The maximum intra-particle distance (Dmax) of C-JEVNS1 first, C-JEVNS1 
second, C-JEVNS1’ first, and C-JEVNS1 second peaks are 122.36, 94.13, 106.20, and 
119.11 Å, respectively. Only C-JEVNS1 Dmax is similar to the widest point of C-JEVNS1 
dimer crystal structure (96.5 Å) (Figure 5.5c and Figure 5.7b.3). Molecular mass 
calculated from Porod volume is shown in Table 5.7, where C-JEVNS1 has the closest 
weight to the protein dimer, 45.5 kDa. The averaged ab initio models of all samples 
were generated at 30 Å resolution with good similarity agreement (Table 5.7) and 
were compared with C-JEVNS1 or C-JEVNS1’ dimer crystal structures (Figure 5.7b.4). 
The structures of the C-JEVNS1 second peak are well matched overall but there is an 
extra region of mass near the dimer interface in the SAXS model (labelled M in Figure 
5.7b.4). This feature is also seen in the SAXS model of WNV (Edeling et al., 2014) 
indicating that this is not an artefact. The rest of the samples showed different low 
resolution models. C-JEVNS1 first peak shows a symmetric SAXS model while C-
JEVNS1’ first and second peak models are not (Figure 5.7, panel 4). Asymmetric 
models are unexpected as the protein is a symmetric dimer. However, SAXS results 
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indicated that NS1 crystal structures may not fully represent the structure of the 
protein in solution.
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Figure 5.7 SAXS analysis of C-JEVNS1 and NS1’-C dimer. 
(a) SAXS analysis of C-JEVNS1 first peak, (b) C-JEVNS1 second peak, (c) C-JEVNS1’ first peak, and (d) C-JEVNS1’ second peak. Panel 1 is SAXS 
scattering curves. Experimental scattering curve is shown in black scattering. Scattering profile of monomer and dimer calculated with FoXS are 
shown. Panel 2 is Guinier plots. Panel 3 is pair distribution functions. Panel 4 Low-resolution model calculated from SAXS profiles docked with 
the crystal structure. An extra region of mass is labelled with M. 
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Table 5.7 SAXS analysis of C-JEVNS1 and C-JEVNS1’ first peak and second peak. 
 
Chi value (χ) Radius of gyration (Rg) 
Dmax Molecular mass (kDa) 
normal spatial discrepancy 
(NSD) monomer dimer 
Guinier 
analysis 
Pair distribution 
function 
C-NS1 1st 27.48 12.16 33.5 33.58 122.36 73.6 0.575±0.02 
C-NS1 2nd 14.11 4.02 27.02 27.08 94.13 45.46 0.513±0.016 
C-NS1’ 1st 38.62 24.53 38.06 38.06 106.20 105.73 0.698±0.026 
C-NS1’ 2nd 15.23 7.32 33.91 33.97 119.11 70.40 0.632±0.035 
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5.2.4 MD simulations of C-JEVNS1 
Examination of B-factors in the C-JEVNS1 structure shows that surface areas of loop 
218-272, especially sub-loop 235-237, have high conformational freedom within the 
crystal lattice (Figure 5.8a). A 40 ns all-atom molecular dynamics simulation (MD) of 
the C-JEVNS1 dimer at 37°C confirmed that movement of this loop is relatively 
unrestrained in both monomers (Figure 5.8). The obvious extra region of mass 
observed in the C-JEVNS1 and WNV SAXS envelope structures could be the result of 
loop 218-272 movement causing expansion of the particle’s volume. To more 
accurately model C-JEVNS1 behaviour in solution, a pool of possible structures with 
varying loop 218-272 conformations was created and compared with the SAXS data. 
Using this approach the model fitting to the experimental SAXS data was improved 
from χ of 4.02 to 1.48 (Figure 5.7 b.1).
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Figure 5.8 Flexible loop structure of C-JEVNS1 
(a) The root mean square fluctuation (RMSF) plot of the molecular dynamic simulation dimer structure at the flexible loop. RMSF values of each 
monomer were plot in grey and red. Average β-factor of each residue was plot in solid grey. (b) The best molecular dynamic simulation structure 
(red) was superimposed with the C-JEVNS1 crystal structure (blue). The flexible loop 218-272 was shown in yellow.
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5.2.5  C-JEVNS1 structure compared to other flavivirus C-NS1. 
C-JEVNS1 has the same fold as ZIKV, WNV, DENV, and superimposition gives Cα RMSD 
closest to WNV NS1 (1.16 Å for ZIKV, 0.96 Å for WNV, and 1.3 Å for DENV) (Figure 
5.5c). The N-terminus, C-terminus, and beta-turns show low positional conservation. 
The electrostatic surface potential map of known C-NS1: ZIKV, WNV, and DENV, were 
compared and show a symmetric pattern. On the β-ladder surface, all display neutral 
charge in the central regions flanked by negatively charged regions (Figure 5.9). This 
negatively charged region is small in DENV, larger in WNV, and is expanded diagonally 
from the top left to the bottom right pattern in JEV and ZIKV. Next to it toward the 
end are small positively charged pockets which are clearly seen only in JEV and ZIKV, 
and the tips of all C-NS1 have mixed charge. Loop surface is more variable than the 
ladder surface. DENV has a distinct positively charged central region, whereas JEV 
and WNV have negative charge in their central area. ZIKV is different, as the middle 
region displays both positive and negative charge. The adjacent area has positively 
charged pockets in all NS1 structures (Figure 5.9 and Table 5.8). Three pockets are 
found in WNV and DENV, whereas ZIKV has only pocket 1 and 2, and JEV has pocket 
1 and 3 (Figure 5.9). The residues building the positively charged pockets are 
conserved in pocket 1 and partially conserved in pocket 2, pocket 3, and front pocket 
on ladder surface (Figure 5.9 and Table 5.8). 
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Figure 5.9 Comparison of C-JEVNS1 with other flavivirus C-NS1 
(a) Electrostatic surface map of C-NS1 from JEV, ZIKV, WNV, and DENV. Surface is coloured 
by electrostatic potential from -5 kT/e (red) to 5 kT/e (blue). Positive potential pockets are 
depicted in dash circles. (b) Surface model colour-coded by conservation. The most 
conserved residues are represented in dark magenta and the most variable residues are 
represented in dark green. 
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Table 5.8 Residue forming positively charge pockets compared to existing C-NS1 
structures 
JEV ZIKV WNV DENV 
Conservation1 
 5iy3 4oie 4oig 
Pocket 1  
Gly259 Gly259 Gly259 Gly259 9 
Tyr260 Tyr260 Tyr260 Tyr260 9 
Lys261 Arg261 Lys261 Phe261 1 
   Ala265 1 
Ser292 Gly292 Gly292 Gly292 1 
Lys293 Thr293 His293 Asn293 1 
Arg294 Arg294 Arg294 Arg294 9 
Cys313    9 
Arg314 Arg314 Arg314 Arg314 9 
Ser315 Glu315 Ser315 Ser315 5 
Cys316 Cys316 Cys316 Cys316 9 
Glu334 Glu334 Glu334 Glu334 9 
Pocket 2  
 Thr262 Thr262 Thr262 6 
 Met264 Asn264 Thr264 1 
 Lys265   1 
 Gly295 Gly295 Gly295 9 
 Pro296 Pro296 Pro296 4 
  Gly332  6 
 Met333 Met333 Met333 9 
 Thr351 Asn351 Ser351 3 
Pocket 3  
Gly295    9 
Pro296    4 
Ser297  Ala297 Ser297 9 
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JEV ZIKV WNV DENV 
Conservation1 
 5iy3 4oie 4oig 
Val298  Thr298 Leu298 1 
Arg336  Arg336 Arg336 9 
Pro337  Pro337 Pro337 9 
Met339    3 
   Glu340 2 
  Glu342 Glu342 8 
Leu345  Leu345 Leu345 6 
Arg347  Gln347 Lys347 3 
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5.3 Discussion 
Flavivirus NS1 proteins have generated much interest and have been studied for 
more than 30 years. Since 2014, the structures of nine of the NS1 proteins have been 
solved (Brown et al., 2016, Akey et al., 2014, Xu et al., 2016, Song et al., 2016, Edeling 
et al., 2014). These proteins were expressed in bacterial or insect cell expression 
systems. In this study, we describe the structure of E. coli expressed JEV NS1 C-
terminus, which when compared to other NS1 structures, shows a high degree of 
structural conservation. Four conserved disulphide bonds are found in the same 
arrangement in crystal structures. Mass spectrometry analysis of reduced and non-
reduced DENV2 NS1 assigned different pair arrangement, C291-C313 and C312-C316 
(Edeling et al., 2014, Wallis et al., 2004), while the crystal structures show C291-C312 
and C313-C316 pairing. Conservation of the protein fold indicates that a bacterial 
expression system can produce stable NS1 comparable to that produced by an insect 
cell expression system, which is the virus natural vector. Moreover, C-JEVNS1 in this 
study was refolded from inclusion bodies which supports the view that NS1 protein 
has a very stable protein fold. The protein produced may be useful in categorizing 
NS1 protein-protein interactions. The key success of Edeling’s method over the in-
house method (Chapter 4) could be the ratio of the protein to the refolding buffer 
which was 1: 10 in in-house method and 1:100 in Edeling’s method. Moreover, 
differences in small details such as dilution with buffer at pH 5.2 prior the refolding 
step, addition of protease inhibitor, or ratio of oxidizing and reducing agents may also 
play a role in the success. 
Two populations of JEV NS1 were observed in both C-NS1 and C-NS1’, but it has never 
been observed before in WNV or DENV NS1 recombinant protein purification (Edeling 
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et al., 2014, Avirutnan et al., 2007). The NS1 first elution peak is suspected to be the 
higher order of C-JEVNS1 that the protein dimer is the building block. The oligomeric 
stage of the dimers might be easily broken, for example by reducing agent, because 
it did not show higher molecular weight than the dimeric form when analysed with 
non-heat treatment SDS-PAGE. The second peak protein only shift to from the first 
peak when the first peak exists in the environment. However, it is also possible that 
changing from peak 2 on its own to peak 1 takes a much longer time. The 
crystallization of C-JEVNS1 and C-JEVNS1’ were made from total protein which 
contains both peak 1 and 2. However, the higher order of NS1 has never been 
observed in crystal structures. This may due to the dimeric form protein, which is the 
majority of the purified protein, is enough to form crystals. However, SAXS analysis 
did not explain the higher order NS1 supposition because the extra mass shown in 
the models was not large enough to fit another NS1 monomer or dimer. 
Conformation shift may describe this dynamic observation, but more evidence is 
required. Otherwise, it could be the sample processing that generates 2 species of 
NS1 protein. 
All NS1 proteins are dimeric in crystallo, even though the recombinant protein 
contains only the C-terminal domain (Edeling et al., 2014, Xu et al., 2016). The 
molecular mass and low resolution model generated from SAXS data confirm the 
dimeric nature of the isolated C-terminal domain in solution. The availability of WNV, 
DENV, and ZIKV NS1 structures allowed us to assess both general and different 
characteristics of the protein which may be connected to their functional role. In 
contrast to previous work, which suggested that the β-roll domain is responsible for 
dimerization (Smith et al., 2015), this study proposes that 6 common residues which 
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form hydrogen bonds at the dimer interface of all NS1 structures mediate dimer 
formation (Smith et al., 2015). In principle, inhibition of dimer formation by 
interposing a ligand at this site could facilitate anti Flavivirus drug development. 
Both faces of the C-NS1 dimer display electrostatic surface charge diversity (Figure 
5.9). However, when considering the full length Flavivirus NS1 protein structure 
(Brown et al., 2016, Akey et al., 2014, Xu et al., 2016), the ladder face of the C-
terminal domain is positioned underneath the β-roll domain (Figure 1.9). The N-
terminus protects the central region of the ladder face from the environment. 
Besides that, the β-roll domain is contained by a hydrophobic region that is suspected 
to interact with the cell membrane making it harder for the ladder face to make an 
interaction. This conflicts with a hypothesis that the β-ladder may bind to the 
complement control protein domain (sushi domain) of complement proteins (Akey 
et al., 2015). On the other hand, the loop face is fully exposed with its diverse surface 
charge. Particularly, DENV has the most distinct positive central area while the rest 
are negatively charged. This may influence the protein-protein interactions. 
Positively charged pockets found on the loop face of the NS1 crystal structure could 
be responsible for an important anionic ligand binding because it is composed of 
conserved sequences and exists in all known NS1 structures especially pocket 1. The 
presence or absence of each pocket may relate to virus evolution and its ability to 
interact with specific target proteins. B-factor and MD analysis provide evidence 
suggesting that loop 218-272 is flexible. Although the B-factors are high in this region, 
the X-ray structure does not show disorder. This may be due to bias from cryocooling 
which accesses a low-energy conformation. Loop 218-272 links strands β4 and β5 and 
is the longest C-NS1 loop. It was suspected that the dynamic 218-272 loop may 
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harbour distinct protein-protein interaction functions. This phenomenon has been 
independently found in WNV (Edeling et al., 2014) thus all NS1 are likely to share this 
characteristic. Taken together, it is very probable that the NS1 protein orientates with 
the N-terminus facing the membrane and the loop facing outward (Brown et al., 
2016, Akey et al., 2014, Edeling et al., 2014) making an interacting interface. 
 
5.4 Conclusion 
This study presents a 2.1 Å resolution crystal structure of C-JEVNS1 and 2.6 Å 
resolution of C-JEVNS1’. C-JEVNS1 share a conserved fold of flavivirus NS1-C domains. 
The surface charge distribution of C-JEVNS1 is similar to WNV and ZIKV but is 
significantly different from DENV. This is likely to be important for their specificity 
and ability to interact with other proteins in the cell. Analysis of the JEV NS1 structure, 
in silico molecular dynamics simulations, and experimental solution small angle X-ray 
scattering indicate extensive loop flexibility on the exterior of the protein. Taken 
together with charge distribution on the exterior of the protein, the loop may govern 
protein-protein interaction function. 
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Chapter 6 Antibody, complement proteins and cell 
membrane interaction with C-JEVNS1 
 
Even though NS1 is known to be involved in viral replication and immune invasion, 
the molecular detail of its function is a mystery. From the structure, surface diversity 
gave a clue of the unique character of flavivirus NS1. It would be interesting therefore 
to investigate its functions further; however, NS1 is not known to have any enzymatic 
function. It is a challenge to develope the experiment to test the function of the 
protein. 
Antibodies against NS1 are known to have a protective effect in mice. In a WNV anti-
NS1 study, the 22NS1 antibody was notable as it had a strong protective effect 
specific to WNV (Chung et al., 2006b). The epitope was identified (Edeling et al., 2014) 
and quite conserved compared to JEV (Trp232, Ser239, Tyr260, Lys261, Thr262, 
Glu289, Arg294, Arg314, and Ser315). Cross reactivity of the antibody is investigated 
in this study. 
Unfortunately, JEV is not as widely studied as DENV, WNV, or ZIKV. Most information 
is inferred from other Flaviviruses. Immune molecules and cell membrane interaction 
were reported in DENV and WNV NS1. To prove that for JEV, complement proteins, 
liposome, and heparin interactions are examined in this study. Parts of the work 
reported in this chapter is now published (Poonsiri et al., 2018). 
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6.1 Materials and methods 
6.1.1 Recombinant proteins 
C-JEVNS1 with the histidine tag was generated from the full length template by PCR 
method for pulldown assay. Primer sequences are given in Table 3.4 in chapter 3. The 
truncated DNA fragment was cloned into pOPIN F vector at kpnI/HindIII cloning site 
to get the histidine tag at N-terminus. C-JEVNS1 and C-JEVNS1’ were produced using 
method described in chapter 4. All of the recombinant proteins were refolded and 
purified as mentioned in chapter 5. 
6.1.2 Protein complex formation 
Complex formation of the recombinant C-JEVNS1 and 22NS1 antibody was confirmed 
by Western blot. To detect C-JEVNS1, WNV 22NS1 monoclonal antibody was used as 
primary antibody and goat anti-mouse IgG was the secondary antibody. Purified C-
JEVNS1 and 22NS1 fragment antigen-binding (Fab) (prepared by Pierce™ Fab 
Preparation Kit, Thermo Fisher Scientific) were mixed at 2:1, 1:1, and 1:2 molar ratio 
of protein to antibody overnight at 4°C and purified by Bio-SEC3 4.6x300 mm HPLC 
column (Agilent Technologies) or Superdex 200 10x300 mm size exclusion 
chromatography column. 
6.1.3 Small angle X-ray scattering (SAXS) 
C-JEVNS1-22NS1 Fab complex at concentration of 3 mg/ml in TBS buffer (20 mM Tris-
HCl pH 7.4, 150 mM NaCl) were analysed with SEC-SAXS (SEC-3 4.6x300 mm HPLC 
column) at beamline SWING, Soleil synchrotron, France. The low resolution model 
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surface representation was created and docked with C-WNVNS1-22NS1 complex 
(PDB ID 4OII). 
6.1.4 Pulldown assay for complement proteins interaction study 
C-JEVNS1 with the histidine tag (bait) was produced for pull-down assay. The protein 
was expressed and purified by the same methods as C-JEVNS1. Small scale Ni-NTA 
column was set up by adding 50 µl of Super nickel-NTA agarose affinity resin 
(Generon) slurry into 1 ml pipette tip which was plugged by 20 µl tip’s filter. The 
column was operated with standard Ni-NTA protocol, except that 1000 µl pipette was 
used to dispense the buffer through the column. The binding buffer was 20 mM 
HEPES pH 7.4, 150 mM NaCl, 20 mM Imidazole and elution buffer was 20 mM HEPES 
pH 7.4, 150 mM NaCl, 500 mM Imidazole. Equilibration was done by adding 400 µl of 
binding buffer to the column. The steps were repeated 3 times. C-JEVNS1 (100-150 
µg) was added to the equilibrated column and incubated on a roller (both ends of the 
tip were wrapped with parafilm) for 30 minutes at 4°C. The bait flow-through was 
dispensed and the column was washed with 400 µl binding buffer 3 times and 400 µl 
of normal human serum (pray) (Sigma, H4522), which was 10 times diluted with 
binding buffer, was added. The column was incubated on a roller for 1 hour at 4°C 
and washed again with 400 µl binding buffer 3 times before eluted twice with 100 µl 
of elution buffer. Samples from each step: load, flow-through, wash, and elute, were 
analysed by SDS-PAGE and Coomassie staining. Bait protein alone and pray protein 
alone were applied to the column as the positive and negative control, respectively. 
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6.1.5 Lipid binding assay 
Liposomes were prepared from cholesterol (CHOL) (Sigma, C8667) and 1,2-
Dipalmitoyl-sn-glycero-3-phosphocholine (PC) (Sigma, P4329) at 1:9 CHOL to PC 
(Smith et al., 2015). CHOL and PC powder were dissolved in chloroform. To achieve 
total 400 nmol, 40 nmol of CHOL and 360 nmol of PC were mixed together in 2 ml 
tube and the lipid mixture was dried under nitrogen gas stream. The lipid films were 
kept in -20°C until use. To hydrate the lipid sheets, 50 µl of buffer (50 mM Bis-Tris pH 
5.5, 50 mM (NH4)2S04, 10 % glycerol or 150 mM KCl, 25 mM Tris-HCl pH 7.5, 1 mM 
DTT, 0.5 mM EDTA.) was added and incubated at room temperature on a shaker for 
30 min. Then the lipid was sonicated with an exponential probe at amplitude 4 for 30 
seconds with 30 seconds interval for 5 times in a warmed water bath to avoid 
overheat. The liposomes were kept at 4°C for 1-2 weeks or -20°C until use. Liposome 
binding reaction (50 µl) was set up at 400 nmol, 125 nmol and 25 nmol of total lipid 
and mixed with 5000 ng of C-JEVNS1 (5 µl of 1 mg/ml protein). The reactions were 
incubated at 37°C for 2 hours. After that, the reactions were centrifuged at 16000xg 
for 30 minutes at 22°C and the supernatant was harvested to a new tube. The lipid 
pellet was resuspended in 200 µl buffer and transferred to a new tube. Liposomes 
were pelleted again and the supernatant was discarded. Liposome pellet was 
resuspended in 30 µl of 1x SDS-PAGE sample buffer. Bovine cytochrome bc1 complex, 
membrane proteins provided by Kangsa Amporndanai, was used as positive control 
in 25mM phosphate buffer pH 7.5, 100mM NaCl, 3mM NaN3, 0.015% DDM buffer. 
The supernatant and pellet fractions were analysed by SDS-PAGE and Coomassie 
staining. 
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6.1.6 Heparin binding 
C-JEVNS1 was used in this assay. Small scale column was set up and operated as 
described in pull down assay by using heparin agarose beads (Affi-Gel heparin gel, 
BIO-RAD). The binding buffer was 20 mM HEPES pH 7.4, 150 mM NaCl and the elution 
buffer was 20 mM HEPES pH 7.4 supplemented with different concentrations of salt 
(1.5 M and 2 M NaCl). The column was equilibrated with 400 µl of binding buffer for 
3 times. C-JEVNS1 5000 ng was applied to the column and incubated on a roller for 
30 minutes at 4°C. The column was washed with 400 µl of binding buffer 3 times 
before eluted twice with 100 µl of 1.5 M and 2 M NaCl elution buffer, respectively. 
Samples from each step: load, flow-through, wash, and elute, were analysed by SDS-
PAGE and Coomassie staining. Superoxide dismutase 3 (SOD3) provided by Varunya 
Chantadul was used as positive control. 
6.1.7 Differential scanning fluorimetry (DSF).  
Polymers of heparan sulphate (average molecular weight 30,000), chondroitin 
sulphate (62% chondroitin 4-sulphate and 33% chondroitin 6-sulphate, average 
molecular weight 45,400), and dermatan sulphate (average molecular weight 41,000) 
from Iduron at final concentration of 100, 50, 25, 10, 5, 1, 0.5 µM were mixed with C-
JEVNS1 and Sypro Orange 5000X (Invitrogen) at final concentration of 10 µM and 10X, 
respectively. The reaction volume was 10 µM. The experiments were set in 96 well-
plates and perform using StepOnePlus™ Real-Time PCR Systems (software version 
2.3) (Applied Biosystems). The experiment was set to follow the Protein Thermal 
Shift™ Studies user guide. The heating cycle was a 2 minutes prewarming step at 25°C 
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and followed by a ramp to 95°C with a ramp rate of 1°C. The experiment type was set 
as Melt Curve, the reporter was ROX, and the quencher was None. 
  
 162 
 
6.2 Results 
6.2.1 NS1 protein and 22NS1 Fab interaction 
The interaction of WNV antibody with C-JEVNS1 and C-JEVNS1’ were confirmed by 
Western blot analysis (Figure 6.1, lower left inset) and size exclusion chromatography 
(Figure 6.1). C-JEVNS1 and 22NS1 Fab alone eluted at a retention volume of 3.16 and 
3.32 ml, respectively. C-JEVNS1 incubated with 22NS1 Fab eluted faster at a retention 
volume of 2.74 ml corresponding to complex formation with a small amount of free 
22NS1 Fab fragments left. The eluted fraction was analysed by SDS-PAGE and 2 peaks 
representing C-JEVNS1 and 22NS1 (~25 kDa) were identified. The incubation also 
generated a small peak at a retention volume of 2.44 ml which is believed to be a 
higher order oligomeric stage of C-JEVNS1 (front peak of C-JEVNS1 at a retention 
volume of ~3 ml) complexed with 22NS1. This confirmed that NS1 and 22NS1 
monoclonal antibody (mAb) interact in solution (Figure 6.1, lower right inset). The 
protein interaction was also analysed by SAXS. As the 22NS1 antibody, which binds 
to C-WNVNS1, was suspected to bind by the same epitope to JEVNS1 protein, it 
should have a similar structure for the complex. The JEV complex experimental profile 
was compared to calculated scattering profile of C-WNVNS1-22NS1 complex (PDB ID 
4OII) (Figure 6.2a, c). The complex (4OII) gave a poor fit to the experimental data with 
χ of 6.82. Guinier analysis gave the radius of gyration of 52.89 ± 0.34 Å which 
coincides with 52.50 Å extracted from the pair distribution function. The pair 
distribution function of the complex has multiple peaks which signify the multi-
domain geometric shape with Dmax of 154.9 Å (Figure 6.2b), similar to the C-
WNVNS1-22NS1 complex. The calculated molecular mass was 149.96 kDa. An 
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averaged ab initio model was generated at 30 Å resolution. The Fab part of WNV 
complex (4OII) structure did not fit into the SAXS envelope. The Fab part in SAXS 
structure moves away from the position in 4OII model indicating the flexibility of Fab 
epitope in solution, while the C-WNVNS1 dimer fits well (Figure 6.2c-e) into the 
envelope shape. I generated a pseudo-atomic model of the C-JEVNS1 antibody 
complex by replacing the C-WNVNS1 with C-JEVNS1 and optimizing the position of 
the Fab molecules. This model had better fit to the SAXS data which improved the fit 
parameter from χ of 6.82 to 3.09 (Figure 6.2a, c-e).
 
Figure 6.1 C-JEVNS1 in complex with 22NS1 Fab. 
C-JEVNS1 was detected by 22NS1 mAb (lower left inset). C-JEVNS1 was incubated 
with 22NS1 Fab at 1:1 molar ratio protein to Fab fragment and the complex formation 
was analysed on an Agilent BioSEC-3 4.6/300. The lower right panel show SDS-PAGE 
analysis of each elution fraction. 
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Figure 6.2 SAXS analysis of C-JEVNS1-22NS1 Fab complex. 
(a) SAXS scattering curve. Experimental scattering curve for C-JEVNS1-22NS1 Fab 
complex is shown in black scattering. Calculated scattering profile of C-WNVNS1-
22NS1 complex (4OII) is displayed in green and C-JEVNS1-22NS1 Fab complex 
manually fit model is shown in orange. (b) Pair distribution function shows 2 peaks 
signify the two-domain geometric shape. (c) C-WNVNS1-22NS1 complex (4OII). C-
WNVNS1 is coloured in blue. 22NS1 Fabs are coloured in pink. (d) C-WNVNS1-22NS1 
complex (4OII) fit the C-JEVNS1-22NS1 Fab complex ab initio model (upper). A 
pseudo-atomic model C-JEVNS1-22NS1 Fab complex are manually fit the ab initio 
model (lower). (e) C-JEVNS1-22NS1 Fab complex pseudo-atomic model.
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6.2.2 C-JEVNS1 and complement protein interaction 
The C-JEVNS1 with the histidine tag at N-terminus (bait) incubated with 10 times 
diluted normal human serum (pray) was isolated by Ni-NTA purification. Analysed by 
SDS-PAGE, no pray protein was eluted together with C-JEVNS1 (Figure 6.3) indicating 
the absence of interaction with complement protein. 
 
Figure 6.3 C-JEVNS1 pull down assay. 
The protein complex was isolated by Ni-NTA. First lane show protein loaded onto Ni-
NTA column. Second is the 10 times diluted human serum. Lane 3 and 4 are the 
control. The column was loaded with human serum alone and the elution fraction is 
shown in lane 3. Lane 4 is the elution of the column loaded only with C-JEVNS1. C-
JEVNS1 was loaded onto the column and mixed with human serum. Flow-through 
fraction (FT) is shown in lane 5. Wash fractions are in lane 6 and 7. Elution fractions 
are in lane 8 and 9. 
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6.2.3 C-JEVNS1 and cell membrane interaction via GAGs 
Sulphate molecules were found on the surface of C-JEVNS1 X-ray structure similar to 
ZIKV (PBD ID 5K6K), WNV (4O6C), and DENV (4OIG) (Figure 6.4 and Table 6.1). 
Moreover, they are distributed near the positively charged pockets. Hence, it is 
possible that this positively charged area might be the binding site of negatively 
charged ligands. Specifically, natural sulphate molecules like GAGs that are involved 
in membrane attachment may interact here (Avirutnan et al., 2007). 
 
 
  
Figure 6.4 Sulphate molecules bound to the loop surface of C-JEVNS1 
Sulphate molecules were found not only for JEVNS1, but also in DENV 4OIG, ZIKV 
5K6K, and WNV 4O6C. Thus, it is suspected to be an importance sulphate binding 
interface. 
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Table 6.1 Sulphate contact residues from assembly analysis in the program PISA 
Area C-JEV 
ZIKV WNV C-DENV 
5K6K 4O6C 4OIG 
Tip 
Arg347 Ser342  His309 
Gln349 Glu343  Glu310 
Thr302 Thr302  Lys339 
Ser304 Ser304   
Lys306 Arg306   
Thr343    
Thr344    
Positively charge pockets 
Arg294 Arg294   
Arg314 Arg261   
Central 
Asp235  Gly235 His181 
   Lys206 
   Thr210 
   Ser228 
   Trp232 
   Asn234 
   Gly235 
 
To prove that interaction with GAGs happens via sulphate binding sites at C-terminus, 
C-JEVNS1 binding to heparin agarose beads was analysed. The 20 kDa C-JEVNS1 was 
found only in flow-through and wash fractions (Figure 6.5a) indicating that C-JEVNS1 
could not interact with heparin. The interaction of heparan sulphate, chondroitin 
sulphate, and dermatan sulphate polymers with C-JEVNS1 was further investigated 
by protein thermal shift assay. No apparent of C-JEVNS1 stabilizing effect was 
observed for any of GAG polymers tested even at high concentration (100 µM) (Table 
6.2 and Appendix 6). No change of the unfolding temperature (∆ melting 
temperature) more than approximately 1°C was observed. No GAG binding was 
consistent with the pull-down experiments. These suggest that the interaction of NS1 
with GAGs does not happen at the C-terminal sulphate binding sites. 
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Interaction of C-JEVNS1 with the cell membrane was tested by liposome binding 
assay. Liposomes could not bind to C-JEVNS1 at either pH 7.5 or 5.5 (Figure 6.5b). 
While full length NS1 does bind liposomes (Akey et al., 2014, Smith et al., 2015), this 
study shows that the NS1 C-terminus is not responsible for membrane interaction. In 
contrast to this view, the hydrophobic residues of β-roll and wing domains were 
previously suggested to play a role in membrane binding (Xu et al., 2016, Brown et 
al., 2016, Akey et al., 2014). The C-JEVNS1 does not responsible for cell membrane 
interaction via GAGs. 
Figure 6.5 Cell membrane interaction determination.  
(a) Heparin binding determination. C-JEVNS1 was incubated with heparin agarose 
beads. Total C-JEVNS1 loaded to the column is shown in lane 1. Lane 2 is flow-through 
fraction. Lane 3-4 are wash fraction. The column was eluted with buffer 
supplemented with 1.5 M NaCl shown in lane 5. (b) Liposome binding assay. The 
experiments were conducted at pH 7.5 (upper) and pH 5.5 (lower). Supernatant and 
pellet fractions separated by centrifugation were analysed by SDS-PAGE. Lane 1, 2, 
and 3, were pellet of 400 nmol, 100 nmol, and 25 nmol reactions, respectively. Lane 
4, 5, and 6, were supernatant of 400 nmol, 100 nmol, and 25 nmol reactions, 
respectively. 
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Table 6.2 Mean values of melting temperatures calculated from experiments 
performed in duplicate and its ∆Tm. 
HS (µM) Mean Tm ±SD ∆Tm 
100 54.2 1.1 0.3 
50 54.6 1.2 -0.1 
25 54.8 0.9 -0.3 
10 54.8 0.9 -0.3 
5 54.8 0.9 -0.3 
1 54.7 1.1 -0.2 
0.5 54.6 1.3 -0.1 
0 54.3 1.3 0.2 
DS (µM) Mean Tm ±SD ∆Tm 
100 54.5 1.2 0.0 
50 54.7 0.7 -0.2 
25 55.2 1.1 -0.7 
10 55.0 0.8 -0.5 
5 54.7 0.4 -0.2 
1 54.8 0.6 -0.3 
0.5 55.2 1.4 -0.7 
0 54.8 1.2 -0.3 
CS (µM) Mean Tm ±SD ∆Tm 
100 53.2 1.3 1.3 
50 53.9 0.9 0.6 
25 54.2 0.8 0.3 
10 54.2 1.5 0.3 
5 54.1 1.9 0.4 
1 54.6 1.2 -0.1 
0.5 54.4 1.4 0.1 
0 54.5 1.4 0.0 
Note: The concentration of JEVNS1-C was kept constant at 10 µM. The average Tm of 
JEVNS1-C alone was 54.5°C. The experiments were performed in total 6 replicates (3 
replicates for each batch of protein purification). 
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6.3 Discussion 
A protective anti-WNV NS1 mAb, 22NS1, did not cross react with DENV-2 (Chung et 
al., 2006b). This study demonstrated that this mAb can cross-react with the more 
closely related C-JEVNS1 at the same epitope, but with some conformational 
flexibility. This finding agrees with our MD result (Chapter 5) showing elasticity in the 
epitope loop, which may affect the antibody-NS1 structure in solution. As 22NS1 may 
be able to interact with multiple viruses in the JE serocomplex, it could be useful in 
diagnostic testing and for passive antibody therapy development against related 
viruses (e.g., St. Louis encephalitis and Murray Valley encephalitis viruses). Moreover, 
the antibody may inhibit NS1 protein-protein interaction and limit viral activity. Even 
though the interaction partners of JEV NS1 are not fully defined, it is interesting to 
investigate further the inhibition of protein-protein interactions by the antibody. 
Even though the C-JEVNS1’ has the extra amino acids, the C-terminal tail does not 
obstruct the binding surface of the WNV 22NS1 mAb. JEV NS1’-C can interact with 
WNV 22NS1 mAb. The C-tail may then locate at the side flanking the dimer. The 
presence of NS1’ is a shared characteristic of JE serocomplex viruses. The protein may 
have specific protein interactions that consequently target the brain cells and lead to 
encephalitis in humans. Targeting NS1’ may prove useful for cross-protective 
vaccination against the JE serocomplex. 
Even though the flavivirus NS1 proteins have a conserved protein fold, these related 
proteins differ in their charge distribution so are capable of having unique 
interactions with host proteins. The fact that WNV 22NS1 mAb interacts positively 
with JEV NS1 is consistent with a close similarity of charge distribution of WNV and 
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JEV NS1. This similarity extends to ZIKV NS1 and may be a productive avenue for 
developing a common diagnostic and therapeutic strategy, which provide insight into 
the possible route for developing a strategy for diagnostic test and therapeutics for 
this group of Flavivirus. 
A pull-down assay failed to detect protein association between C-JEVNS1 and 
complement proteins in human serum. However, as interaction to complement 
proteins were reported in DENV and WNV (Avirutnan et al., 2010, Avirutnan et al., 
2011), JEV NS1 is still believed to bare an immune invasion function by interacting 
with complement proteins or other immune modulators. The interaction may occur 
via N-terminus or require full length protein. Moreover, it is possible that the 
interaction is weak and transient, so it is not accessible by pull down assay. Also, SDS-
PAGE may not be sensitive enough to detect a small amount of interaction (low 
percentage) complement proteins. Higher sensitivity method is suggested, for 
example, mass spectrometry. 
Sulphate molecules distributed on the NS1 surface agree with previous findings for 
DENV and ZIKV indicating its potential anionic ligand interaction, such as GAGs 
(Avirutnan et al., 2007). Although NS1 was thought to interact with uninfected cell 
membranes via these sulphate binding sites, our study shows that C-JEVNS1 cannot 
bind heparin, GAGs polymers, or liposomes. Thus, the sulphate binding sites are not 
GAG binding interfaces and could represent a crystallographic artifact. Our results 
suggest that cell membrane interactions via GAGs may occur at the β-roll and wing 
domains, as was suggested previously (Akey et al., 2014, Xu et al., 2016, Brown et al., 
2016). 
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6.4 Conclusion 
WNV 22NS1 antibody able to cross react to C-JEVNS1 by interacting at the flexible 
loop, the same epitope as WNV. No binding of C-JEVNS1 and complement proteins 
observed by Pull-down assay. C-JEVNS1 could not interact with either liposome, 
heparin, or GAGs polymers indicated no cell membrane association via GAGs. The 
study suggests a significant roles of the N-terminal domain for cell attachment and 
probably the complement proteins association. 
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Chapter 7 ZIKV NS1 and C terminal domain NS1 
protein expression and purification 
 
While the existence of ZIKV has been known for several decades it has not been at 
the forefront of public healthcare discussions until the recent outbreak in Brazil in 
2015. ZIKV quickly spread to Central and South American countries and has affected 
millions of people. Even though the majority of patients have mild symptoms, ZIKV 
has been proven to relate to Guillain-Barré syndrome and babies born with 
microcephaly in pregnant women. As little was known about this virus, many projects 
and funding on ZIKV have emerged to respond to the situation. Every aspect of ZIKV 
study such as protein structure, immunology, diagnosis, vaccine development, and 
therapeutic are growing fast. Even though ZIKV is new to flavivirus research field and 
it has distinct disease phenotype, it is closely related to DENV based on NS5 gene 
(Weaver et al., 2016) and it may share typical characters to other flaviviruses. 
Laboratory protocols develop for other flaviviruses may applicable for ZIKV. A 
structural study of NS1 protein could develop the knowledge of this virus especially 
the disease distinction. ZIKV NS1, which has about 50% sequence identity compared 
to other Flaviviruses and is suspected to have the same protein fold, was expressed 
and purified with the same protocol as C-JEVNS1 in this study. 
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7.1 Materials and methods 
7.1.1 Plasmid construction 
Synthetic ZIKVNS1 and C-ZIKVNS1 were constructed in the pET15b vector at NdeI/BlpI 
cloning site. The protein constructs contain N-terminus histidine tag, TEV cleavage 
site, and followed by ZIKV NS1 or NS1 C-terminus. 
7.1.2 Protein expression and purification 
ZIKVNS1 and C-ZIKVNS1 were produced and purified by using modified Edelling’s 
method previously described in chapter 3. 
7.1.3 Protein crystallization 
ZIKVNS1 was concentrated to ~4.4-4.6 mg/ml and screened by using SaltRx 1-2, 
PEGRx 1-2, and Natrix screens from Hampton research, and Structure, PACT premier, 
and JCSG screens from Molecular Dimension. 
Apart from robot screen, crystallization of ZIKVNS1 was seeded with C-JEVNS1 needle 
crystals (Figure 7.1). C-JEVNS1 needle crystals from 0.7 M Li2SO4, 0.05 M MES pH 6 
buffer condition were crashed into small pieces under a stereo microscope by fine tip 
glass rod made from heated Pasteur pipette and then vortex with some glass beads 
Figure 7.1 Crystal seeding for ZIKVNS1 crystallization 
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in a micro centrifuge tube for 10 cycles of 3 minutes vortex and 1 minute on ice 
interval. The seed stock was diluted to make 1:10, 1:100, and 1:1000 seed stocks. 
Crystal trays were set in hanging drop manner in 24-wells plates by using JCSG-plus 
Set 1 (formulation 1-24) and SaltRX Set 2 (formulation 1-24) commercial screens. On 
a cover slip of each well, 5 seed stock conditions were tested: no seed control, 
undiluted, 1:10, 1:100, and 1:1000, by mixing 1 µl of ZIKVNS1 protein, 0.7 µl of 
reservoir solution, and 0.3 µl of seed stock. Each well was filled with 500 µl of 
reservoir solution. 
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7.2 Results 
7.2.1 Protein expression and purification 
The protein inclusions were effectively refolded and 
purified as demonstrated by detection of protein in 
soluble fraction analysed by SDS-PAGE (Figure 7.2). 
From the protein sequences, the molecular weight of 
ZIKVNS1 and C-ZIKVNS1 is 40.1 kDa and 20.8 kDa, 
respectively. The SDS-PAGE appearance size of ZIKVNS1 
was ~40 kDa, while C-ZIKVNS1 showed 2 bands at >25 
and <22 kDa, which Western blot analysis against 
histidine tag confirmed that they all were the target 
proteins (Figure 7.3). By using SEC, I expected to see C-ZIKVNS1 eluted at the 
retention volume similar to C-JEVNS1 based on its similar MW and earlier in the case 
of NS1 full length. However, they all were eluted at a retention volume of ~16 ml, 
about the same retention volume as C-JEVNS1. ZIKVNS1 aggregated a lot during the 
refolding step and gave very low yield after SEC purification which might cause by 
buffer and pH that not appropriate to the protein (Figure 7.3a). Chromatogram of 
ZIKVNS1 showed similar profile to C-JEVNS1 with 3 elution peaks: void peak, middle 
peak, and end peak. SDS-PAGE analysis showed high protein purity of all 3 peak 
fractions (Figure7.3). Even the end peak had a high absorbance at UV 280 nm, a small 
amount of protein was shown in the SDS-PAGE gel. Moreover, the retention volume 
of peak 3 did not relate to protein size. Thus, only the middle peak was used for 
protein crystallization. C-ZIKVNS1 had less aggregation and also had 3 peak elution 
Figure 7.2 ZIKVNS1 and C-
ZIKVNS1 after refolding 
in lane 1 and 2, respectively 
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profile with a much better yield of the second peak (Figure 7.3b). Two bands 
observed in refolding step were purified together in the middle peak and were not 
affected by heat treatment, but appeared as a single band in non-reduced condition. 
In addition, dimer protein at the size approximately double of the monomer, 40-50 
kDa, was not observed (Figure 7.3b). 
 
Figure 7.3 ZIKV NS1 and NS1 C terminal domain purification. 
Elution profile of ZIKVNS1 (a) and C-ZIKVNS1 (b). Three peaks observed in 
chromatogram for each protein were analysed on SDS-PAGE in lane 1, 2, and 3, 
respectively. Bands at estimated size is indicated with red arrows. For C-ZIKVNS1 (b), 
band size at ~22 kDa was shown with another higher band at >25 kDa. The 2 bands 
were combined when run under non-reducing conditions. Western blot analysis 
against the histidine tag is shown in greyscale beneath or on the right on the gel. 
a 
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7.2.2 Protein crystallization 
None of the ZIKVNS1 crystal tray set by the robot gave crystal, so seeding method 
was used. By seeding with C-JEVNS1, positive results were obtained from 4 
formulations of SaltRX 2 and 2 formulations of JCSG-plus 1 (Figure 7.4, and Table 7.1). 
Conditions in figure a, b, d, g, and h looked like the solid phase of the protein. Crystals 
in figure c, e, and f were probed by a needle under a microscope which suggested 
that they were salt as the crystals were hard and not easy to break. The crystals were 
also tested at the in-house X-ray source, Barkla, University of Liverpool. In agreement 
with the previous tests, the crystals were salt as shown by sporadic mid high 
resolution. In the meantime, three crystal structures of ZIKA virus NS1 protein have 
appeared (Brown et al., 2016, Xu et al., 2016, Song et al., 2016). The solid phase 
conditions and C-ZIKVNS1 were not further investigated. 
Figure 7.4 ZIKVNS1 seeding. 
Positive results from SaltRX 2 screen (a-f) corresponding to buffer formulation 3, 4, 
6, 7, 9, and 10, respectively, and from JCSG-plus 1 screen (g, h) corresponding to 
buffer formulation 11 and 17, respectively. 
a b c d 
f e g h 
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Table 7.1 Buffer formulations and seed stock solutions that gave crystals 
Formulation 
Seed stock 
No 
seed 
undiluted 1:10 1:100 1:1000 
SaltRX 2: 0.1 M Tris pH 8.5, 1.5 M 
ammonium phosphate dibasic 
     
SaltRX 2: 0.1 M Tris pH 8.5, 2.4 M 
ammonium phosphate dibasic 
     
SaltRX 2: 1.0 M sodium phosphate 
monobasic monohydrate, 
 potassium phosphate dibasic pH 6.9 
     
SaltRX 2: 1.0 M sodium phosphate 
monobasic monohydrate, 
 potassium phosphate dibasic pH 8.2 
     
SaltRX 2: 1.8 M sodium phosphate 
monobasic monohydrate, 
 potassium phosphate dibasic pH 6.9 
     
SaltRX 2: 1.8 M sodium phosphate 
monobasic monohydrate, 
 potassium phosphate dibasic pH 8.2 
     
JCSG-plus 1: 0.2 M ammonium 
hydrogen phosphate, 0.1 M Tris pH 
8.5, 50% v/v MPD 
     
JCSG-plus : 0.1 M Sodium cacodylate 
pH 6.5, 40% v/v (+/-)-2-Methyl-2,4-
pentanediol (MPD) 
     
7.3 Discussion 
ZIKV NS1 both full length and C-terminal domain were successfully refolded by using 
the same protocol as JEV NS1, which had been adapted from the WNV NS1 protocol, 
indicating the similarity between the protein’s properties. However, there were some 
significant differences in details of the protein purification and refolding. The ZIKVNS1 
full length was more success to refold than JEVNS1. These may reflect that NS1 
proteins of flaviviruses share common features and also have distinct features at the 
same time, which the diversity of the protein surface charge and hydrophobicity may 
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be the cause of the differences. From NS1 X-ray structures, NS1 is dimerized by 
hydrogen bonds (Akey et al., 2014, Edeling et al., 2014, Song et al., 2016). The dimer 
is usually dissociated when heated as reported in DENV, TBEV, and JEV (Winkler et 
al., 1988, Flamand et al., 1992, Crooks et al., 1994). Two populations of C-ZIKVNS1 at 
the size of ~25 and ~22 kDa were observed which were not detected in C-JEVNS1 
expression or another C-ZIKVNS1 study (Song et al., 2016). The ~25 kDa band was not 
a protein dimer as it was detected even after the sample was boiled and the size was 
much smaller than the dimer (40-50 kDa on a gel). The upper band protein can form 
a complex with inter-molecular disulphide bonds as demonstrated by reduced size 
when analysed in non-reduced SDS-PAGE, while NS1 dimer normally intact when 
treated with a reducing agent (Winkler et al., 1988, Flamand et al., 1992). The ~22 
kDa band protein is suspected to be the C-ZIKVNS1 monomer because it is the similar 
size when the protein was denatured (any interaction was broke) and it was 
unchanged in non-reducing condition. Moreover, C-ZIKVNS1 was unable to form a 
dimer without non-heat treatment. In Song, et al. ZIKV NS1 structural study, refolded 
ZIKV NS1 C-terminus was proved to be able to dimerize and has the same protein fold 
as DENV (Akey et al., 2014), WNV (Edeling et al., 2014), and JEV NS1 (from this study). 
Thus, the protocol used in this study might not suit C-ZIKVNS1 and need some 
optimization. The results indicate that C-ZIKVNS1 produced in this study has unique 
protein assembly and might have wrong protein fold. This finding could be an 
experimental error during the purification or it might hint the uniqueness of ZIKV NS1 
protein. 
Indistinguishable elution time of ZIKVNS1 and C-ZIKVNS1 probably because size 
determination by SEC is good for globular protein. C-terminus NS1 has a rod shape as 
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determined from other flavivirus NS1, so SEC may not reveal its true molecular weight 
on the chromatogram. 
7.4 Conclusion 
ZIKVNS1 was successfully refolded but still needed some optimization in 
crystallization. C-ZIKVNS1 in this study formed a unique complex interacted by 
disulphide bonds and unable to form a dimer, in contrast to the feature of NS1 proved 
to be correct in another C-ZIKVNS1 study (Song et al., 2016). C-ZIKVNS1 in this study 
is believed to have the unusual protein fold. Then, I focused on ZIKVNS1 structure 
determination in order to compare to other flavivirus NS1. In the competitive field of 
ZIKV study, other research groups had accomplished the goal before us (Brown et al., 
2016, Xu et al., 2016, Song et al., 2016). ZIKVNS1 and C-ZIKVNS1 were not further 
investigated in this study. 
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Chapter 8 Structural study of JEV capsid protein 
 
The capsid protein forms the inner shell to enclose virus genome which happens in 
all viruses. The protein plays an important role in viral encapsidation (genome 
packaging) and dissociation to release the genome. Consequently, it involves viral 
particle assembly and propagation. Raising of many evidence shows that flavivirus 
capsid protein may relate to different functions in viral life cycle such as RNA 
replication, and interaction with different host proteins interfering cell functions (Byk 
and Gamarnik, 2016). The available X-ray structure of WNV capsid (Dokland et al., 
2004) and NMR structure of DENV capsid (Ma et al., 2004) have been solved but with 
poor resolution and statistics. In this study, the crystal structure of JEV capsid was 
obtained, which has never been visualized. Structure-function studies have the 
potential to increase our knowledge of a critical stage in viral transmission and 
provide information useful in its inhibition. Please note that the mass spectrometry 
analysis was done by Dr. Mark Wilkinson. 
8.1 Methods 
8.1.1 Plasmid construction 
JEV capsid DNA (nucleotide residue 1-315) lacking the hydrophobic C-terminal (Figure 
1. and Figure 8.1), which end at natural NS3 protease cleavage site 
(102QNKR↓GGNE109) (Shiryaev et al., 2007), was constructed in pET30a(+) vector at 
BamHI/XhoI cloning site. The protein construct is N-terminal histidine, S-tag, 
enterokinase cleavage site, and capsid protein (N-HIS-S tag-E-capsid) (Figure 8.2a). 
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Another capsid protein construct without S-tag was introduced into the same vector 
at NdeI/XhoI cloning site. 
8.1.2 Protein expression and purification 
Capsid protein was expressed in AIMTB at 30°C overnight in E. coli BL21(DE3). Lysis 
buffer screening was performed to identify the lysis buffer. Both first screen and salt 
solubility screen were tested. Finally, cells were lysed in high salt buffer (50 mM Tris 
pH 7.5, 1 M NaCl, 5 mM EDTA, 1 mg/ml lysozyme). Crude sample was purified by Ni-
NTA column and dialyzed against 25 mM Tris pH 7.6, 50 mM NaCl, 2 mM CaCl2 buffer 
overnight. The sample was then centrifuged at 16000xg for 20 minutes at 4°C to 
separate precipitation. S-tag was cleaved by enterokinase (New England Biolabs® 
inc., P8070) at 1:25, 1:50, and 1:100 ratio enzyme to capsid protein at 4°C overnight. 
The sample was purified by using Ni-NTA again to remove fusion tags. Flow through 
Figure 8.1 JEV capsid sequence hydrophobicity plot 
The plot was produced by ProtScale (McWilliam et al., 2013). The amino acid 
Kyte&Doolittle scale was used. The middle hydrophobic region (Arg44- Ala58) 
corresponding to the α helix 2 and C-terminal hydrophobic are demonstrated in grey. 
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fraction was subjected to superdex 75 10x300 mm column size-exclusion 
chromatography column (GE Healthcare Life Science). The peak at a retention volume 
of 13.5 ml (fraction A2-A4) was concentrated and used for crystallization. 
8.1.3 Tricine-SDS-PAGE 
Protein yield and purity were examined by Tricine-SDS-PAGE follow Schägger’s 
protocol (Schagger, 2006). Protein was separated by 4% (stacking gel) and 16% 
polyacrylamide gel (resolving gel) at 0.75 or 1.0 mm thickness. See gel recipes in Table 
8.1. Samples were mixed with 4x sample buffer (12% (w/v) SDS, 6% (v/v) 
mercaptoethanol, 30% (w/v) glycerol, 0.05% Coomassie blue G-250, 150 mM Tris HCl 
pH 7.0) at 3:1 sample to buffer ratio and heated at 95°C for 5 min. Electrophoresis 
was conducted at 200 volts constant in 1x anode buffer (100 mM Tris HCl pH 8.9) and 
cathode buffer (100 mM Tris pH~8.25, 100 mM Tricine, 0.1% SDS) by using Mini-
PROTEAN®3 Cell electrophoresis system (BIO-RAD). At the end of the run voltage was 
increased to 300 V. Gel was fixed in 50% methanol, 10% acetic acid, 100 mM 
ammonium acetate for 1 hour before stained in 0.025% Coomassie blue G-250 in 10% 
acetic acid for 20 minutes or until the gel was stained consistency blue and sample 
dye cannot be seen. Then gel was destained in 10% acetic acid solution until the 
background was clear. 
Table 8.1 Gel formulation (10 ml) 
16% Resolving gel  4% Stacking gel 
3x Gel buffer (3 M Tris HCl, pH 
8.45, 0.3% SDS) 
3.3 ml 3x Gel buffer (3 M Tris HCl, pH 
8.45, 0.3% SDS) 
3.3 ml 
Glycerol 1 ml - - 
Water - Water 4.85 ml 
30% Acrylamide/Bis 5.3 ml 30% Acrylamide/Bis 1.3 ml 
10% APS 50 µl 10% APS 50 µl 
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16% Resolving gel  4% Stacking gel 
TEMED 5 µl TEMED 5 µl 
8.1.4 Mass-spectrometry (MS) analysis 
Gel pieces of digested capsid and purified capsid (fraction A2-A4) from SDS-PAGE 
which was preserved in 20% ethanol were washed for 30 minutes twice with 50% 
acetonitrile, 0.2 M ammonium bicarbonate pH 8.9 and then dried in a rotary 
evaporator. The gel pieces were rehydrated in 2 M urea, 0.2 M ammonium 
bicarbonate pH 7.8 (RHB) containing 0.1 ug trypsin and incubated at 37°C overnight. 
Excess RHB was then removed to a new 1.5 ml microfuge tube and peptides were 
extracted from the gel pieces with 60% acetonitrile and 0.1% trifluoroacetic acid 
(TFA). The total peptide extract was then concentrated to 10 ul in a rotary evaporator 
and then desalted using C18 (200 Å pore size silica resin) ZipTips (Milipore) according 
to the manufacturer’s instructions. MS analysis was performed using a MALDI-Tof 
instrument (Waters-Micromass) using a saturated solution of alpha-cyano-4 
hydroxycinnaminic acid (CHCA) in 50% acetonitrile/0.1% trifluoroacetic acid. Samples 
were selected in the mass range of 850 – 2500 Da. 
8.1.5 Protein crystallization 
Capsid protein at the concentration of ~6mg/ml was screened by using commercial 
crystallization screens: the PEGRx screen from Hampton Research, the PACT premier 
and JCSG screens from Molecular Dimension. All the conditions that produce crystals 
are given in appendix 3. The 2 conditions: 10% v/v 2-propanol, 0.1 M BICINE pH 8.5, 
30% w/v polyethylene glycol 1,500 and 18% v/v 2-propanol, 0.1 M sodium citrate 
tribasic dihydrate pH 5.5, 30% w/v polyethylene glycol 4,000 were further optimized. 
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Needle crystals produced from 18% v/v 2-propanol, 0.1 M sodium citrate tribasic 
dihydrate pH 4.6, 5.6, and 6.2, 16 and 18% w/v polyethylene glycol 4,000 were used 
for diffraction experiment. The crystals were flash frozen in reservoir solution pH 5.6 
added with 25% ethylene glycol. 
8.1.6 Diffraction experiment, data processing, and model building 
X-ray data were collected at a cryogenic temperature at beamline PROXIMA 1 at 
Soleil synchrotron, France, I04 and I24 at Diamond Light Source, UK. Data were 
processed by HKL2000 (Otwinowski and Minor, 1997). Autoprocessing by Xia2 was 
used for processing of data collected at Diamond Light Source. The protein structure 
was determined by molecular replacement using the structure of WNV NS1 capsid 
protein (PDB ID 1SFK, 63% sequence identity) as a starting model. An automated 
model building was performed by Buccaneer. The structure was refined by REFMAC5 
and built in COOT in CCP4. The data were collected 3 times each from a single crystal. 
The first model was refined with weight term of 0.115 and the difference between R 
factor and R free was greater than 0.05. The second and third data were refined 
against the previously built model with weight term of 0.15. TLS 
(Translation/Libration/Screw) refinement was used once and tight NCS restraint was 
set on both chain A and B. Data collection and refinement statistics are shown in 
Table 8.2. The JEV capsid refinement statistics of Ramachandran plot are 100% 
favoured and 0% outliers. The MolProbity score is 1.03.
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Table 8.2 X-ray data collection and refinement statistics 
 1st (I24 Diamond) 2nd (Soleil) 3rd (I04 Diamond) 
Data collection    
Space group P212121 P212121 P212121 
Cell dimensions    
a, b, c (Å) 46.1, 49.14, 67.75 45.6, 49.32, 67.74 46.31, 49.78, 68.25 
α, β, γ () 90, 90, 90 90, 90, 90 90, 90, 90 
Resolution (Å) 
38.11-2.43(2.47-
2.43) 
39.82-2.3(2.38-
2.3) 
38.32-1.98(2.03-
1.98) 
Rmerge 
Rpim 
0.156(1.429) 
0.07(0.616) 
 
0.041(0.127) 
0.058(0.862) 
0.044(0.686) 
I / σI 
CC half 
7.8(1.6) 
0.995(0.656) 
16.06(4.49) 
0.999(0.918) 
12.1(1.4) 
0.999(0.551) 
Completeness (%) 
Redundancy 
100(99) 
6.1(6.4) 
91.1(66.5) 
5(3.3) 
99.6(99) 
4.5(4.3) 
    
Refinement    
Resolution (Å) 38.11-2.43 39.82-2.3 38.32-1.98 
No. reflections 5839 5936 10871 
Rwork / Rfree 0.194/0.255 0.185/0.266 0.188/0.237 
No. atoms 
  Protein 
  Water 
  Ethylene glycol 
  2-propanol 
  Citrate ion 
B-factors (Å) 
  Protein 
  Water 
  Ethylene glycol 
  2-propanol 
  Citrate ion 
1178 
1142 
36 
- 
- 
- 
 
54.981 
57.276 
- 
- 
- 
1203 
1147 
32 
16 
8 
- 
 
32.53 
35.25 
40.58 
50.94 
- 
1229 
1144 
56 
16 
- 
13 
 
42.77 
53.26 
52.91 
- 
66.22 
R.m.s. deviations    
Bond lengths (Å) 0.02 0.01 0.01 
Bond angles () 2.28 1.63 1.43 
*Values in parentheses are for highest-resolution shell.
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8.2 Results 
8.2.1 Protein expression and purification of JEV capsid protein 
JEV capsid without S-tag failed to express (data not shown). JEV capsid with S-tag was 
soluble in high salt lysis buffer (2 M NaCl) (Figure 8.2b). Later, the lower 
concentrations of salt were tested and JEV capsid protein was still soluble in 1 M NaCl 
buffer. The 20 kDa JEV capsid protein was successfully purified by Ni-NTA column 
with high protein yield and purity. Multiple bands were observed (~17 kDa and 15 
kDa) after the protein was stored at 4°C (Figure 8.2c, first lane). The S-tag was cleaved 
by enterokinase at the 1:25, 1:50, and 1:100 ratio enzyme unit to protein. There was 
no difference among the 3 ratios, so 1:100 ratio was used for large scale protein 
preparation. After cleavage, the protein’s apparent size reduced from 20 kDa to 15 
kDa (Figure 8.2c) and smaller bands size <15 kDa, 10 kDa, and ~8 kDa were observed 
in some batch of protein after digestion (Figure 8.2c). As the capsid protein had no 
tag after S-tag was cleaved, the protein band was identified by size. The strong band 
that showed a reduction in size was suspected to be the capsid protein. The band 
sometimes appears as hand shape (Figure 8.2d, first lane). However, after digestion, 
all 3 extra bands at <15 kDa, 10 kDa, and ~8 kDa were shown in Ni-NTA flow-through, 
wash, and elute fraction (Figure 8.2d), which makes it difficult to distinguish the 
target protein. The bands corresponding to proteins of 10 kDa and ~8 kDa size were 
not observed in the first digestion experiment (Figure 8.2c). Multiple bands observed 
during the process that usually occurs after storage most probably due to the 
instability and inclining to degrade of the capsid protein. The size exclusion 
chromatography elution demonstrated 2 peaks at UV 220 nm (Figure 8.3). The first 
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peak contained 15 kDa and <15 kDa size proteins, while the second peak had only ~8 
kDa size protein (Figure 8.2d). The first peak elution fractions A2 to A4 were 
concentrated together and appeared as the non-homogeneous band with the new 
size ~13 kDa (Figure 8.2d). Mass spectrometry confirmed that the 2 different size 
bands of the digested capsid and purified capsid (A2-A4) were the same protein, but 
N-terminus was lost after purification (Figure 8.5). The protein from fractions A2-A4 
was used for crystallization and it gave crystals in several conditions (Figure 8.4) (see 
Appendix 3). 
Figure 8.2 Capsid protein purification. 
(a) JEV capsid protein construct. EK indicates enterokinase cleavage site. (b) Lysis 
buffer screening demonstrated that capsid protein soluble in 2 M salt buffer. Four 
lysis buffers were the buffer added with the following additives: no additive (7.5N), 2 
M NaCl (2S), 0.5 M urea (0.5U), and 0.2% Triton X 100 (D). P indicates pellet fraction 
and S indicates suspension fraction. (c) Enterokinase digestion at 1:25, 1:50, and 
1:100 enzyme unit to protein. Different batch 1:50 enterokinase digestion is shown. 
(d) Ni-NTA purification after enterokinase digestion. Lane 1 is flow-through from the 
Ni-NTA column. Lane 2 and 3 are the wash and elute fraction, respectively. Size 
exclusion chromatography elution fractions are in lane 5-7. Enterokinase enzyme is 
shown as a faint band at ~30 kDa (indicated with arrow). 
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Figure 8.3 Capsid protein size exclusion chromatography profile. 
At UV 280, only one peak is observed at retention volume ~13 ml. At UV 220, there 
are 2 very high peaks at retention volume ~13 ml (fraction A2-A4) and ~17 ml (A5-
A7). 
Figure 8.4 Capsid protein crystallization. 
(a) Needle crystals were obtained from 10% v/v 2-propanol, 0.1 M BICINE pH 8.5, 30% 
w/v polyethylene glycol 1,500. (b) Thin rhomboid crystals were obtained from 18% 
v/v 2-propanol, 0.1 M sodium citrate tribasic dihydrate pH 5.5, 30% w/v polyethylene 
glycol 4,000. This condition can also give needle crystals. 
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Figure 8.5 Mass-spectrometry analysis of JEV capsid protein 
(a) MS analysis of digested and (b) purified capsid (fraction A2-A4). SDS-PAGE gels of 
the samples used for MS analysis are shown. Residue numbers are indicated next to 
the peaks. 
a 
b 
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8.2.2 Structure of JEV capsid protein 
Crystals of full length JEV capsid protein diffracted to 1.98 Å resolution. Data 
collection and refinement statistics are shown in Table 8.2. The first 25 residues at N-
terminus are not visible. Same as DENV and WNV, the crystal structure reveals a 
dimer in the asymmetric unit. Each monomer is composed of 4 helices: α1 (amino 
acid 30-38), α2 (44-57), α3 (63-71), and the longest α4 (74-94), connected by short 
loops (Figure 8.6a-b). The dimer is created by the anti-parallel pairing of the α1-α1’, 
α2-α2’, and α4-α4’ connected with hydrogen bonds and salt bridges (Table 8.3, Table 
8.4, and Figure 8.7). The hydrogen bonds also hold the α2 and α 4 together. From the 
side view, there are 3 layers of protein and flanking by the α3 and α3’ (Figure 8.7c-
d). Almost half of the protein are dimer interfacing residues, 43 residues out of 105 
(Table 8.5) and the surface is quite hydrophobic (Figure 8.8b, c). However, it is 
concealed after protein dimerization and the rest of the surface is hydrophilic (Figure 
8.8a). At neutral pH, the dimer net charge is +19 and the electrostatic surface map 
indicates total positive surface charge (Figure 8.9). The higher-order structure is not 
observed. Structural homolog searching was performed by using Dalilite v.3 (Holm 
and Rosenstrom, 2010). Except for the flavivirus itself, JEV capsid resemblance to the 
transcription factor II B (TFIIB) subunit of yeast polymerase II transcription initiation 
complex (PDB code 5FYW; Z= 4.5, RMSD = 2.9) and the human CCR4-NOT 
transcription complex subunit 1 (CNOT1) (4CQO; Z = 4.4, RMSD = 3.0). They are both 
gene regulatory proteins that involved in nucleic acid interactions. Only a monomer 
of JEV capsid (α1- α4) could align to Asn124-Lys217 of the TFIIB which is the DNA 
interacting subunit with the α4 closest to the DNA fragment (Figure 8.10a). CNOT1 
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directly interacts with mRNA. However, the RNA binding site of CNOT1 has not 
revealed yet. The monomer of JEV capsid (α2- α4) aligns to N-terminal of CNOT1 at 
Tyr1842-Pro1921 (Figure 8.10b). 
  
Figure 8.6 Structure of JEV capsid. 
(a) Ribbon model of JEV capsid monomer coloured by the 1-4 α helices in pink, blue, 
green, and sandy brown, respectively. Another subunit is in grey. (b) Topology 
diagram of JEV capsid dimer. The α helices of one subunit are indicated with 
apostrophe symbol. (c, d) Side view of JEV capsid dimer with the dimension of 39x36 
Å. 
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Figure 8.8 Hydrophobic surface coloured by Kyte&Doolittle scale. 
(a) Hydrophobic surface of the dimer. (b, c) Hydrophobic surface of the dimer with 
one subunit in ribbon model. Surface colour ranging from dodger blue for the most 
hydrophilic to white for neutral and orange red for the most hydrophobic. 
Figure 8.7 Hydrogen bonds at JEV capsid dimer interface. 
Hydrogen bonds at the α1-α1’, α2-α2’, and α3-α3’ are shown with dashed lines in 
figure (a), (b), and (c), respectively. One monomer is in orange. Another is in green. 
a b c 
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Figure 8.10 Superimposition of structural homologs 
(a) JEV capsid in pink colour superimposed to TFIIB subunit of transcription initiation 
complex (PDB 5FYW) and (b) human CNOT1 (PDB 4CQO). 
Figure 8.9 Coulombic surface colouring of the capsid dimer. 
Electrostatics potential was calculated according to Coulomb’s law with thresholds ± 
10 kcal/mol*e. 
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Table 8.3 Hydrogen bonds between JEV capsid dimer interfacing residues and the 
distance 
1 Assembly analysis in the program PISA. 
2See lysine, aspartic acid, and arginine atoms nomenclature in Appendix 5. 
  
Number Structure 1 Distance (Å)1 Structure 2 
1 Lys 31 [NZ]2 2.64 Asp 39 [OD1]2 
2 Arg 45 [NE]2 3.11 Phe 56 [O] 
3 Arg 45 [NH2] 3.13 Phe 56 [O] 
4 Arg 98 [NH2] 3.36 Trp 69 [O] 
5 Arg 98 [NH1} 2.94 Val 72 [O] 
6 Lys 85 [NZ] 3.87 Lys 85 [O] 
7 Lys 55 [NZ} 3.03 Glu 87 [O} 
8 Lys 74 [NZ] 2.77 Arg 98 [O] 
9 Asp 39 [OD1] 2.69 Lys 31 [NZ] 
10 Phe 56 [O] 3.16 Arg 45 [NH2] 
11 Phe 56 [O] 3.07 Arg 45 [NE] 
12 Glu 87 [O] 3.00 Lys 55 [NZ] 
13 Arg 98 [O] 2.98 Lys 74 [NZ] 
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Table 8.4 Salt bridges between JEV capsid dimer interfacing residues and the 
distance 
1 Assembly analysis in the program PISA. 
2See lysine, aspartic acid, and arginine atoms nomenclature in Appendix 5. 
 
Table 8.5 JEV capsid dimer interfacing residues reported with accessible (ASA) and 
buried surface area (BSA), solvation energy effect (ΔG) and conservation score. 
(The values are reported from one monomer) 
Number Residue ASA (Å2) BSA (Å2) ΔG (kcal/mol) Conservation 
1 Leu27 84.03 20.42 0.33 1 
2 Val30 118.46 92.59 1.48 2* 
3 Lys31 141.43 88.01 0.13 8 
4 Val33 68.52 17.91 0.29 3* 
5 Val34 63.66 54.72 0.93 6* 
6 Met35 103.38 55.26 1.33 1 
7 Leu37 11.11 10.11 0.16 5* 
8 Leu38 49.81 39.11 0.61 3* 
9 Asp39 71.47 20.51 -0.37 2* 
10 Arg45 83.50 17.61 -1.16 6* 
11 Phe46 94.02 43.47 0.68 2* 
12 Ala49 41.64 41.64 0.57 7 
13 Leu50 24.48 24.48 0.39 2* 
14 Ile51 18.69 7.03 0.11 5* 
Num15ber Structure 1 Distance (Å)1 Structure 2 
1 Lys 31 [NZ] 2.64 Asp 39 [OD1] 
2 Lys 31 [NZ] 3.92 Asp 39 [OD2] 
3 Lys 74 [NZ] 2.77 Arg 98 [O] 
3 Asp 39 [OD1] 2.69 Lys 31 [NZ] 
4 Asp 39 [OD2] 4.00 Lys 31 [NZ] 
5 Arg 98 [O] 2.98 Lys 74 [NZ] 
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Number Residue ASA (Å2) BSA (Å2) ΔG (kcal/mol) Conservation 
15 Thr52 28.35 28.11 0.17 5* 
16 Phe53 94.72 94.08 1.51 7* 
17 Phe54 22.93 16.25 0.26 5* 
18 Lys55 164.08 90.08 -1.12 7* 
19 Phe56 144.14 141.80 1.46 6* 
20 Thr57 62.62 45.02 0.44 6* 
21 Leu59 102.61 51.41 0.82 7* 
22 Ala60 89.91 20.19 -0.12 5* 
23 Thr62 52.55 26.77 0.43 8 
24 Trp69 89.96 32.30 0.52 8 
25 Lys74 157.5 81.09 -0.41 6* 
26 Ala77 17.07 11.38 0.18 9 
27 Met78 106.84 41.91 1.07 7* 
28 Leu81 58.55 58.55 0.81 8 
29 Thr82 69.27 21.75 0.35 2* 
30 Phe84 36.05 36.05 0.51 7* 
31 Lys85 157.40 87.05 -0.32 7 
32 Glu87 97.04 48.21 0.17 6* 
33 Leu88 79.65 79.65 1.24 7 
34 Gly89 30.26 14.10 0.20 5* 
35 Thr90 92.33 10.55 0.17 4* 
36 Leu91 109.62 92.39 1.46 7 
37 Ile92 91.20 74.11 1.18 6* 
38 Val95 70.00 67.32 0.92 4* 
39 Asn96 116.67 40.08 -0.45 8 
40 Lys97 167.41 0.31 0.00 3* 
41 Arg98 241.04 124.28 -0.98 9 
*Below the confidence cut-off - The calculations for this site were performed on less 
than 6 non-gaped homologue sequences, or the confidence interval for the estimated 
score is equal to- or larger than- 4 colour grades. 
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8.2.3 Structure of JEV capsid protein compared to WNV and DENV 
Compare to DENV capsid NMR structure and WNV X-ray structure, the flavivirus 
capsid protein fold is conserved with Cα RMSD of 2.1 Å and 1.4 Å, respectively, except 
for the helices 1 which is oriented in the different position (Figure 8.11). The α1- α1’ 
of JEV and WNV are on top of the α2- α2’ covering the hydrophobic surface of the 
α2- α2’, whereas in DENV the α1 is not paired with α1’ and move aside 
perpendicularly to the helices 4 when looking from the top view (Figure 8.11b, c). 
This movement allows the hydrophobic patch at the α2- α2’ surface to expose Figure 
8.11d, e). 
Figure 8.11 JEV capsid superimposing to WNV and DENV capsid proteins. 
(a) Superimposition of of WNV capsid (PDB 1SFK) in gold and DENV capsid (1R6R) in 
blue to JEV capsid in pink. (b) superposition of the α1-α1’ of WNV, DENV, and JEV 
from the side view and (c) top view in the same color scheme. Please note that the 
helix 1 in chain B of WNV capsid is missing. (d) Hydrophobic surface of JEV capsid 
from the top view showing closed position and (e) DENV capsid from the top view 
showing opened position. Surface colour ranging from dodger blue for the most 
hydrophilic to white for neutral and orange red for the most hydrophobic. 
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8.3 Discussion 
Other flavivirus capsid structures have been solved by different research groups using 
both NMR (Ma et al., 2004) and X-ray crystallography (Dokland et al., 2004). One 
common feature of the protein is the unstable N-terminus. The first 20 residues of 
DENV capsid (PDB 1R6R) are conformational labile and WNV capsid (1SFK) is stable 
from residue 23. The helix 1 of JEV capsid may well be longer than we observed as 
the first 25 residues from N-terminal are not visible. It is consistent with the 
expression profile and mass spectra that the protein is degraded from N-terminus. 
Moreover, it is possible that the protein degradation happened during the JEV capsid 
protein purification creating a non-uniform N-terminus which gave poor density in 
this region leading to a non-structure of the first 4 residues. Compared to WNV 
capsid, the helix 1 of WNV capsid from residue 24 is well defined (Dokland et al., 
2004). It maybe because the WNV capsid was trypsinized to generate stable 
fragments before crystallization. 
With a large interfacing surface, there are only 9 hydrogen bonds between the dimer. 
However, the dimer is packed by inclusive hydrophobic interaction. The fact that 
capsid monomer bears a large hydrophobic patch which later not expose after 
dimerization leads to the conclusion that the capsid protein may preferable in dimeric 
form because the monomer protein might not be able to solubilize. Furthermore, in 
our study, JEV capsid was isolated from bacteria cells only in high salt buffer (1-2 M 
NaCl) similar to what have found in TBEV capsid (Kiermayr et al., 2004). High 
concentration of salt may facilitate the capsids to interact with each other and form 
a stable dimer. Even after buffer exchange to low salt buffer (50 mM NaCl), the dimer 
still intact. Importantly, dimeric stage of flavivirus capsid is confirmed by structural 
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studies of DENV and WNV (Dokland et al., 2004, Ma et al., 2004). This supports the 
notion that capsid dimer is probably the building block of the nucleocapsid 
(Mukhopadhyay et al., 2005, Kiermayr et al., 2004). 
RNA binding site of flavivirus capsid was mapped to N-terminal and C-terminal of 
WNV (Khromykh and Westaway, 1996) but was mapped to the middle hydrophobic 
region of JEV (Tseng et al., 2007). In our study, the homolog search matched the C 
terminus of the JEV capsid monomer to the TFIIB subunit of transcription complex, in 
partial agreement with the WNV study. Besides this, the 3D structure revealed that 
the middle hydrophobic region or the helix 2 is obscured under the α1-α1’ making it 
more difficult to access. In addition, Cryo-EM structures of flavivirus virions suggest 
the capsid protein is poorly ordered, which may reflect random interactions between 
capsid and RNA (Zhang et al., 2003, Mukhopadhyay et al., 2005). These observations 
might explain the difference in RNA binding site mapping (Khromykh and Westaway, 
1996). Other positive-stranded RNA viruses typically exhibit RNA binding as a function 
of the N-terminus of the protein, which binds in a non-icosahedral manner (Zhang et 
al., 2003). The flavivirus capsid is very small and the whole protein might function as 
RNA-binding similar to N-terminal of other positive stranded RNA viruses (Zhang et 
al., 2003, Mukhopadhyay et al., 2005). 
Two conformations of the α helix 1 were detected; close conformation in JEV and 
WNV capsid crystal structures, and open conformation in DENV NMR structure. The 
open conformation of capsid protein allows more access to the α2-α2’ hydrophobic 
patch, but it is likely to make hydrophobic interaction to, for example, cell membrane 
rather than interaction with a negatively charged molecule such as RNA. NMR 
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structure might allow more flexibility than crystal structure, but it does not explain 
the protein disorder in WNV capsid structure (helix 1 of chain B is missing). Thus, 
flexibility is an inherent characteristic of the N-terminus itself. The buffer pH did not 
affect the conformation as 3 of capsid crystals used in this study were in buffer pH 
4.6, 5.6 and 6.2 gave the same fold of the protein. DENV capsid was in pH 6 buffer, 
while WNV capsid was in pH 10.5 buffer. The factor that triggers conformational 
changing of capsid protein is unclear, but the flexibility of helix 1 indicates that it may 
bear functionally importance roles such as lipid bilayer and LDs association and higher 
order structure assembly. 
Capsid protein is known to form a spherical core enclosing viral genome. However, 
cryo-EM structural studies showed that the maximum height of nucleocapsid density 
was low (~25-50%) compared with the envelope (Zhang et al., 2003, Kuhn et al., 
2002). This, together with the missing of an oligomeric stage of DENV NMR structure 
and in our study, suggests that flavivirus nucleocapsid is disordered (Kuhn et al., 2002, 
Zhang et al., 2003, Wang et al., 2017, Zhang et al., 2013). It is also possible that lacking 
higher order structure is due to the conformation of the protein. Protein assembly 
probably occurs after conformational changing obtain by certain stimulation. 
Moreover, as virus assembly is a complex process and occurs with coordinating 
factors, an in vitro experiment that contains only capsid protein might not generate 
the core protein assembly process. Addition of interacting molecules is possibly 
required; for example, capsid-like particles were successfully produced from dimeric 
capsid isolated from TBEV virions incubated with viral RNA (Kiermayr et al., 2004). 
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8.4 Conclusion 
JEV capsid protein has an unstable N-terminus and also has conserved protein folds 
compared with DENV and WNV. The N-terminus corresponding to α helix 1 in the 3D 
structure is flexible which might be functionally important. However, the factors 
governing the conformational change are unclear. A change in conformation of α 
helix 1, might in turn expose the α2-α2’ hydrophobic in order to allow interactions 
with lipid bilayers or LDs. JEV capsid protein C-terminus, which corresponds to helix 
4, may interact with RNA as suggested by the RNA binding study of WNV capsid and 
homolog protein search in this study. Capsid oligomerization to form nucleocapsid 
was not observed but may consist of capsid dimers as a building block. 
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Chapter 9 General Discussion 
 
Proteins are the machinery of all organisms including viruses. Understanding of 
protein is the key to understand the building block of life. In most of the studies, for 
example, this work, even though the target proteins were selected for the potential 
to be drug targets, this fundamental knowledge is also applicable to several topics 
covering disease aetiology, vaccine, treatment and diagnosis development. 
The target proteins in this work, NS1 and capsid protein, were chosen for their 
multifunctional character involved in crucial roles in the viral life cycle and also to 
complete JEV structural proteomics study. The two are potential targets for drug 
development. 
Flavivirus capsid proteins are not very conserved in sequence, but structurally 
conserved. This study presented the first JEV and the third flavivirus capsid protein 
structure available. Despite the lack of functional study, evidence provided here 
demonstrated important capsid protein properties such as the dimer building block 
of the nucleocapsid and α-helix 1 conformation. 
Nine structures of flavivirus NS1 proteins have been described before this study 
started. The first structures were DENV and WNV NS1 full length proteins published 
in 2014. Even only NS1 and NS1’ C-terminal domain are presented in this study, it is 
useful as no JEV NS1 protein structure has been revealed before. This protein 
truncation helps to link protein region to its functions, for example, cell membrane 
and GAG binding may locate to its N-terminal. In addition, even C-JEVNS1 protein 
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structure is almost identical to WNV, DENV, and ZIKV which described previously, 
several differences are pointed out in this study including protein surface charge, 
loop flexibility, and WNV antibody cross-interaction. 
What we have learned here may be just the tip of the iceberg. The NS1 protein may 
not be amenable as a drug target as the DENV whole-genome sequencing research 
suggested. As the result of error-prone NS5 (viral RNA polymerase), the viral genome 
is diverse from the single-nucleotide variants (SNVs) which accumulated on prM, E 
and NS1 gene on viral genome derived from human cases (Sim et al., 2015). The study 
suggested that drug-resistance mutations are more probable in these areas. 
However, this field of study is emergent and there is still some controversy over the 
data (Wash and Soria, 2015). 
With the fast development of instruments and understanding of structural studies 
(both X-ray crystallography and cryo-EM) and protein production, the breakthrough 
of difficult to obtain protein structures like membrane proteins or large protein 
complex structures has become true. Virus replication complex or assembled capsid 
structures are very probable in the near future. These will provide us the information 
of protein-protein interaction from the actual working part. 
Nowadays, there are still some boundaries of flavivirus endemic areas. For example, 
JEV has not established yet in the Australian mainland or America. JEV genotype 4 
and 5 are restricted in the Malaysia-Indonesia area (no human case outside this 
region). WNV is majorly present in the western hemisphere. However, migration of 
birds (reservoir hosts), globalization, changing agricultural practices, and climate 
change may influence the introduction of viruses to the naïve regions. Although the 
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establishment of exotic viruses depends on many factors such as vectors, reservoir 
hosts, and climate, we have seen ZIKV that successfully adapted and caused 
outbreaks in many countries in a short time. While JEV is preventable by vaccination 
and a DENV vaccine has been recently introduced, there is no vaccine for WNV and 
ZIKV. Moreover, immune cross-reactivity between endemic virus infection, which 
people in the endemic region are usually pre-exposed or vaccinated, and the viruses 
that have not been circulated in the area before, is not well understood. It could be 
a cross-protection or adverse effect between the two as has been observed in 
different serotypes of dengue virus. Besides that, if the viruses co-circulate in the 
same region, the specific and sensitive diagnosis will be required due to the high 
serological cross-reactivity of flaviviruses. Currently, a combination of more than one 
enzyme-linked immunosorbent assays is needed to be able to specifically distinguish 
JEV from WNV (Latif et al., 2015) or ZIKV from previous DENV infection (Tsai et al., 
2017). 
Therefore, not only JEV but flaviviruses are a critical concern to global public health. 
Although the findings of this study cannot clearly describe the full protein function, 
we are building up knowledge, which will lead us to a greater understanding of virus 
biology, especially at the molecular level which will facilitate the next-generation of 
diagnostic, vaccine, and treatment development. 
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Appendix 2 Chromatogram of C-JEVNS1, C-JEVNS1’, and JEVNS1, respectively, purified 
by Superose 6 10x300 mm column. 
 
 
Appendix 3 Crystallization screen formulation that gave crystals. 
No. Screens Formulations 
Protein 
concentration 
1 
SaltRx 
1.5 M Ammonium sulphate, 0.1 M Sodium 
acetate trihydrate pH 4.6 C-JEVNS1 
4 mg/ml 
2 
2.4 M Ammonium phosphate dibasic, 0.1 M Tris 
pH 8.5 
3 
PEGRx 
18% (v/v) 2-propanol, 0.1 M Sodium citrate 
tribasic dihydrate pH 5.5, 20% (w/v) PEG 4000 
 
C-JEVNS1 
6 mg/ml 
 
 
4 
15% (v/v) 2-propanol, 0.1 M Sodium citrate 
tribasic dihydrate pH 5.0, 10% (w/v) PEG 10000 
5 Natrix 
0.02 M Magnesium sulphate hydrate, 0.002 M 
Cobalt(II) chloride hexahydrate, 0.05 M Sodium 
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No. Screens Formulations 
Protein 
concentration 
 
 
 
 
Natrix 
cacodylate trihydrate pH 6, 25% (v/v) (+/-)-2-
Methyl-2,4-pentanediol, 0.0005 M Spermine 
 
 
 
C-JEVNS1 
6 mg/ml 
 
6 
0.08 M Sodium chloride, 0.02 M Barium 
chloride dihydrate, 0.04 M Sodium cacodylate 
trihydrate pH 7, 40% (v/v) (+/-)-2-Methyl-2,4-
pentanediol, 0.012 M Spermine 
tetrahydrochloride 
7 
0.08 M Strontium chloride hexahydrate, 0.02 M 
Magnesium chloride hexahydrate, 0.04 M 
Sodium cacodylate trihydrate pH 7, 20% (v/v) 
(+/-)-2-Methyl-2,4-pentanediol, 0.012 M 
Spermine tetrahydrochloride 
8 Structure 
1.0 M Ammonium phosphate monobasic, 0.1 M 
Sodium citrate pH 5.6 
9 
JCSG 
0.02 M Calcium chloride dihydrate, 0.1 M 
Sodium acetate pH 4.6, 30% (v/v) (+/-)-2-
Methyl-2,4-pentanediol 
10 
0.1 M Sodium cacodylate pH 6.5, 40% (v/v) (+/-
)-2-Methyl-2,4-pentanediol, 5% (w/v) PEG 8000 
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No. Screens Formulations 
Protein 
concentration 
11 
 
 
Structure 
 
 
 
 
 
 
 
 
Structure 
0.1 M Sodium citrate pH 5.6, 20 % (w/v) PEG 
4000, 20% (v/v) 2-propanol 
 
 
C-JEVNS1’ 
7 mg/ml 
 
 
 
 
 
 
 
 
 
 
C-JEVNS1’ 
7 mg/ml 
12 
0.2 M Magnesium acetate tetrahydrate, 0.1 M 
Sodium cacodylate pH 6.5, 20% (w/v) PEG 8000 
13 
1.5 M Litium sulphate, 0.1 M Sodium HEPES pH 
7.5 
14 
2.0 M Ammonium sulphate, 0.1 M Sodium 
HEPES pH 7.5, 2% (v/v) PEG 400 
15 
0.1 M Sodium HEPES pH 7.5, 20% (v/v) PEG 400, 
10% 2-Propanol 
16 0.05 M Potassium phosphat monobasic 
17 30% (w/v) PEG 1500 
18 
1.5 M Ammonium sulphate, 0.1 M Tris pH 8.5, 
12% (v/v) Glycerol 
19 0.1 M Sodium HEPES pH 7.5, 70% (v/v) MDP 
20 
1.6 M Ammonium sulphate, 0.1 M MES pH 6.5, 
10% (v/v) 1,4-Dioxane 
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No. Screens Formulations 
Protein 
concentration 
21 
0.1 M Sodium HEPES pH 7.5, 20% (w/v) PEG 
10000 
22 
2.0 M Ammonium sulphate, 0.2 M Potassium 
sodium tartrate tetrahydrate, 0.1 M Sodium 
citrate pH 5.6 
23 2.0 M Sodium chloride, 10% (w/v) PEG 6000 
24 2.0 M Ammonium sulphate, 5% (v/v) propanol 
25 
 
PEGRx 
 
 
PEGRx 
10% (v/v) 2-Propanol, 0.1 M BICINE pH 8.5, 30% 
PEG 1500  
JEV capsid 6 
mg/ml 
 
 
 
 
 
 
26 
0.1% (w/v) n-Octyl-β-D-glucoside, 0.1 M Sodium 
citrate tribasic dehydrate pH 5.5, 22% (w/v) 
PEG 3350 
27 
18% 2-Propanol, 0.1 M Sodium citrate tribasic 
dehydrate pH 5.5, 20% (w/v) PEG 4000 
29 
PACT 
premier 
0.1 M SPG buffer pH 6, 25% (w/v) PEG 1500 
30 0.1 M SPG buffer pH 7, 25% (w/v) PEG 1500 
31 0.1 M SPG buffer pH 8, 25% (w/v) PEG 1500 
32 0.1 M SPG buffer pH 9, 25% (w/v) PEG 1500 
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No. Screens Formulations 
Protein 
concentration 
33 0.1 M PCTP buffer pH 8, 25% (w/v) PEG 1500 JEV capsid 6 
mg/ml 
 
 
34 
JCSG-
plus 
0.2 M Ammonium citrate dibasic, 20% (w/v) 
PEG 3350 
35 
0.1 M BICINE pH 9, 10% (w/v) PEG 20000, 2% 
(v/v) 1,4-Dioxane 
36 
0.1 M HEPES pH 7.5, 20% (v/v) Jeffamine® M-
600 
37 
0.1 M Potassium thiocyanate, 30% (w/v) PEG 
2000 MME 
Note: The formulation used for data collections are shaded in grey. 
SPG = Succinic acid, Sodium phosphate monobasic monohydrate 
 PCTP = Sodium propionate, Sodium cacodylate trihydrate, Bis-Tris propane 
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Appendix 4 Homologous sequences of NS1 C-terminus submitted to Consurf program 
 
 
 
Appendix 5 Arginine, aspartic acid, histidine, and lysine atoms nomenclature 
Amino acid Molecular formula 
Atoms nomenclature (Elodie 
Foulquier, 2017) 
Arginine 
 
 
No. Homologous sequence No. Homologous sequence 
1 P06935 POLG_WNV_965_1139 12 P29991 POLG_DEV27_954_1127 
2 Q32ZE1 POLG_ZIKV_968_1142 13 Q04538 POLG_POWVL_954_1128 
3 Q89277 POLG_YEFVF_956_1130 14 P14335 POLG_KUNJM_969_1143 
4 5IY3 15 Q1X880 POLG_YEFVU_956_1130 
5 4OIE 16 JEV M55506 
6 Q9WDA6 POLG_DEV2Q_954_1127 17 P05769 POLG_MVEV5_971_1145 
7 4OIG 18 P07720 POLG_TBEVS_954_1128 
8 P22338 POLG_LIV_954_1128 19 Q2YHF2 POLG_DEN4H_953_1126 
9 P29837 POLG_LANVT_954_1128 20 Q6YMS4 POLG_DEN3S_952_1125 
10 Q01299 POLG_TBEVH_954_1128 21 P33478 POLG_DEN1S_953_1126 
11 P09732 POLG_STEVM_967_1141   
 245 
 
Amino acid Molecular formula 
Atoms nomenclature (Elodie 
Foulquier, 2017) 
Aspartic acid 
 
 
Histidine 
 
 
Lysine 
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Appendix 6 Mean values of melting temperatures calculated from experiments performed in duplicate and its ∆Tm. 
HS (µM) Tm1 Tm2 Tm3 Tm4 Tm5 Tm6 Mean Tm ±SD ∆Tm 
100 55.3 54.5 55.5 53.3 53.7 52.7 54.2 1.1 0.3 
50 55.5 55.8 55.6 54.2 53.6 53 54.6 1.2 -0.1 
25 55.4 55.6 55.8 54 54 53.8 54.8 0.9 -0.3 
10 55.5 55.7 55.6 54.1 54.1 53.6 54.8 0.9 -0.3 
5 55.6 55.5 55.5 54.2 54 53.8 54.8 0.9 -0.3 
1 55.9 55.6 55.6 53.6 53.6 53.8 54.7 1.1 -0.2 
0.5 56.2 55.5 55.6 53.3 53.7 53.3 54.6 1.3 -0.1 
0 55.2 55.4 55.8 53.2 52.7 53.6 54.3 1.3 0.2 
DS (µM) Tm1 Tm2 Tm3 Tm4 Tm5 Tm6 Mean Tm ±SD ∆Tm 
100 56.3 53.9 55.4 53.3 54.3 53.5 54.5 1.2 0.0 
50 55.2 55.6 55.2 54.1 54.1 53.9 54.7 0.7 -0.2 
25 56.6 55.8 56 54.2 54.5 54.1 55.2 1.1 -0.7 
10 55.5 55.9 55.7 54.3 54.6 54.1 55.0 0.8 -0.5 
5 54.8 55.4 54.8 54.4 54.6 54.1 54.7 0.4 -0.2 
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DS (µM) Tm1 Tm2 Tm3 Tm4 Tm5 Tm6 Mean Tm ±SD ∆Tm 
1 54.8 55.6 55.4 54.5 54.4 54.1 54.8 0.6 -0.3 
0.5 56.7 56.6 55.9 54.5 53.6 53.6 55.2 1.4 -0.7 
0 55.9 55.7 55.7 54.6 53.6 53.2 54.8 1.2 -0.3 
CS (µM) Tm1 Tm2 Tm3 Tm4 Tm5 Tm6 Mean Tm ±SD ∆Tm 
100 53.7 53.7 55.2 52.7 51.5 52.4 53.2 1.3 1.3 
50 54.5 54.5 54.9 53 52.8 53.5 53.9 0.9 0.6 
25 55 54.7 55.1 53.3 53.5 53.8 54.2 0.8 0.3 
10 55.2 55.6 55.7 53.5 52.1 53.2 54.2 1.5 0.3 
5 55.3 55.8 56 51.8 52.3 53.2 54.1 1.9 0.4 
1 55.6 55.6 55.6 53.9 53.1 53.5 54.6 1.2 -0.1 
0.5 55.5 55.7 55.7 53.3 52.6 53.4 54.4 1.4 0.1 
0 55.5 55.7 55.7 54 53.5 52.5 54.5 1.4 0.0 
Note: The concentration of JEVNS1-C was kept constant at 10 µM. The average Tm of JEVNS1-C alone was 54.5°C. 
 The experiments were performed in total 6 replicates (3 replicates for each batch of protein purification). 
 
